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R ARTICLE 
Current and Future Issues in the Development of Spinal Agents for the 
Management of Pain 
 
Tony L. Yaksh
*
, Casey J. Fisher, Tyler M. Hockman and Ashley J. Wiese 
University of California, San Diego, Anesthesia Research Lab 0818, 9500 Gilman Dr. LaJolla, CA 92093, USA 
Abstract: Targeting analgesic drugs for spinal delivery reflects the fact that while the conscious 
experience of pain is mediated supraspinally, input initiated by high intensity stimuli, tissue injury and/or 
nerve injury is encoded at the level of the spinal dorsal horn and this output informs the brain as to the 
peripheral environment. This encoding process is subject to strong upregulation resulting in hyperesthetic 
states and downregulation reducing the ongoing processing of nociceptive stimuli reversing the 
hyperesthesia and pain processing. The present review addresses the biology of spinal nociceptive 
processing as relevant to the effects of intrathecally-delivered drugs in altering pain processing following 
acute stimulation, tissue inflammation/injury and nerve injury. The review covers i) the major classes of 
spinal agents currently employed as intrathecal analgesics (opioid agonists, alpha 2 agonists; sodium 
channel blockers; calcium channel blockers; NMDA blockers; GABA A/B agonists; COX inhibitors; ii) 
ongoing developments in the pharmacology of spinal therapeutics focusing on less studied agents/targets 
(cholinesterase inhibition; Adenosine agonists; iii) novel intrathecal targeting methodologies including 
gene-based approaches (viral vectors, plasmids, interfering RNAs); antisense, and toxins (botulinum 
toxins; resniferatoxin, substance P Saporin); and iv) issues relevant to intrathecal drug delivery (neuraxial 
drug distribution), infusate delivery profile, drug dosing, formulation and principals involved in the 
preclinical evaluation of intrathecal drug safety. 
Keywords: Adenovirus transfection, dorsal horn, neurotoxins, pain pathways, spinal drug delivery, spinal analgesics, toxicity.  
RATIONALE 
 Targeting analgesic drugs for direct spinal delivery 
reflects the fact that while the conscious experience of pain 
is mediated supraspinally, input initiated by high intensity 
stimuli, tissue injury and/or nerve injury is encoded at 
the level of the spinal dorsal horn. Thus, high intensity 
(e.g., nociceptive) stimulation activates populations of 
small primary afferents, generating an intensity-dependent 
increase in activity of second order dorsal horn projection 
neurons. This excitation is transmitted through spinofugal 
projection pathways to higher centers, such as the 
somatosensory thalamus – somatosensory cortex, and to the 
medial thalamus - limbic cortices that are respectively 
believed to underlie the sensory-discriminative and affective-
motivational components of the pain experience [1-3]. The 
dorsal horn encoding process reflects a remarkable plasticity 
wherein the input-output function of the spinal dorsal horn is 
subject to pronounced regulation by local neuronal and non-
neuronal circuits as well as supraspinal (bulbospinal) input. 
Thus, following tissue or nerve injury there is an enhanced 
neuronal response to moderate or low intensity stimuli, e.g., 
 
 
*Address correspondence to this author at the University of California,  
San Diego, Anesthesia Research Lab 0818, 9500 Gilman Dr. LaJolla, CA 
92093, USA; Tel: 619-543-3597; Fax: 619-543-6070;  
E-mail: tyaksh@ucsd.edu 
a right shift in the stimulus intensity-neuronal response 
curve. Accordingly, the spinal outflow generated by a given 
stimulus of moderate or low intensity following tissue and 
nerve injury generates an enhanced activation of supraspinal 
systems [4-6] and an enhanced pain state, e.g., hyperalgesia 
and allodynia [7], respectively. Accordingly, regulation of 
the spinal input-output function can alter the supraspinally 
organized pain experience. The organization of the input-
output function of the spinal dorsal horn and its associated 
pharmacology has been the subject of extensive investigation 
and review [8, 9]. The associated pharmacology of this 
processing as defined by studies of spinal physiology and 
behavior after spinal drug delivery has permitted targeting 
drugs at specific components to alter the content of the 
spinofugal transmission. While many analgesic drugs may be 
given systemically to exert their spinal action, the specific 
use of the intrathecal or epidural route for analgesic drug 
delivery may be employed for three reasons: i) the drug 
target lies at the spinal level (opiates, baclofen); ii) the agent 
does not penetrate the blood brain barrier (antisense, toxins); 
and/or iii) the agent penetrates the blood brain barrier but 
does so at systemic doses that produce undesirable side 
effects, so spinal delivery increases the therapeutic index 
(e.g., baclofen and opiates). 
 The efficacy of spinal drugs administered for the 
management of pain syndromes is dependent on the 
pharmacology of the underlying mechanisms that mediate 
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the particular pain state. Pain states can be broadly 
categorized as those initiated by an acute noninjurious 
stimulus, those arising from tissue injury and inflammation 
and those secondary to nerve injury. Although the source of 
the pain state may be distinguishable, many clinical pain 
states likely reflect a combination of mechanisms; and, 
increasing evidence has pointed to overlapping components 
at the level of the primary afferent and spinal dorsal horn. 
These mechanisms and their associated pharmacology and 
biology have been extensively reviewed elsewhere [10, 11]. 
In this discussion we will focus on the lumbar intrathecal 
route of drug delivery and consider: i) ongoing developments 
in the pharmacology of spinal therapeutics focusing on 
agents/targets that have been employed and shown to a 
varying degree to have efficacy in humans, ii) novel 
targeting methodologies and iii) several issues relevant to 
intrathecal drug delivery. 
SPINAL THERAPEUTIC TARGETS 
 Spinal analgesic agents may target the primary afferent, 
the second order neurons, bulbospinal projections and non-
neuronal components. From a practical standpoint, many of 
these pharmacologic targets lie within the parenchyma of the 
dorsal horn and emphasize that after intrathecal delivery, the 
topically delivered agents (such as opiates, alpha2 agonists, 
targeted toxins, and transfection agents targeting 2
nd
 order 
neurons) must penetrate from the CSF through the pia and 
then up to several hundred microns in the parenchyma or 
more to reach these dorsal horn sites to exert their action. 
These issues will be discussed further below. In other cases, 
the agent may target the dorsal root ganglion cell (e.g., 
antisense, viral vectors). This target lies distal to the dural 
cuff formed by the meninges [12, 13] and is consistent with 
the fact that the DRG lies outside the blood brain barrier as 
evidenced by movement of large molecules into the DRG 
from the blood [14] and by the sympathetic innervation of 
the DRG vasculature [15]. The necessity to move from the 
CSF to the DRG for a drug to reach its effect site represents 
a barrier for spinally administered drugs. 
CURRENT SPINAL AGENTS 
 In this section, we will review families of agents that 
have been employed in humans for the management of 
spinal nociceptive processing. In each case we will consider 
the preclinical and clinical work with intrathecal delivery, 
mechanisms, typical molecules, adverse events with an 
emphasis on the work considering local drug toxicity and 
finally future areas of target and drug development. 
Opioids 
Spinal Opioids 
 Intrathecal delivery of opioids in amphibia and in 
mammals (from mouse to primate) [16, 17] reliably attenuate 
the response to noxious somatic and visceral stimuli that 
otherwise evoke an organized escape behavior with minimal 
effects upon light touch or proprioception [18]. 
Mechanisms of Action 
 Agonist action at the mu opioid receptor leads to 
hyperpolarization of neuronal membranes through activation 
of inwardly rectifying K+ channels and depression of 
excitatory neurotransmitter release from the presynaptic 
nerve terminal by blocking the opening of voltage sensitive 
Ca++ channels (VSCC), both of which serve to inhibit 
nociceptor neuronal activation [19]. Receptor autoradio- 
graphy and histochemistry has shown that mu binding and 
protein are limited to the substantia gelatinosa, the region in 
which small afferents show their principal termination, and 
to small, TRPPV1 (+) dorsal root ganglion cells [20, 21]. 
The presynaptic action blocking the opening of VSCCs leads 
to an inhibition of transmitter release from the nociceptive 
afferents and suppression of excitability in the second order 
neurons [17, 18]. Local delivery of opiates (delivered 
systemically in spinal transected animals, or by intrathecal, 
topical or iontophoretic methods) in the spinal cord 
selectively depresses discharge of spinal dorsal horn neurons 
activated by small (C high threshold) but not large (Aß low 
threshold) afferents [22-25] and blocks release of substance 
P from C polymodal nociceptors [26, 27]. At the spinal level µ 
opioids depress the bladder reflex arc, accounting for urinary 
retention [28]. Other effects such as sedation or depression 
of the CO2 response curve accounting for respiratory 
depression are mediated by a supraspinal action [29, 30]. 
Chronic spinal infusion of opiates in animal models shows 
clear loss of effect with continued exposure (e.g., tolerance) 
[31, 32], although the magnitude of this tolerance effect with 
continuous spinal infusion in man has been debated [33-36]. 
Drug Molecules 
 While morphine is the only FDA-approved drug for 
intrathecal administration, other opioids have been used for 
chronic intrathecal infusion including hydromorphone, 
methadone, and fentanyl/sufentanil [37]. With respect to 
neuraxial administration, the hydrophilic nature of morphine 
makes it a particularly useful drug for this route of 
administration as systemic uptake and thus potential side 
effects are delayed. As a comparison for these opioids, 
octanol/water partition co-efficients(cLogP) are morphine: 
0.9,hydromorphone: 1.6; Fentanyl: 3.8; Methadone; 4.0; 
Sufentanil: 4.2. In general higher cLogP values result in 
more rapid clearance from the intrathecal space (by 
meningeal and vascular uptake) and correspondingly shorter 
durations of action [38-40]. The hydrophilic nature of 
morphine accounts in part for its long residence time in the 
spinal space and for a comparatively long duration of action 
thereby making bolus drug delivery a useful means for 
intrathecal delivery. 
Adverse Events 
 Following intrathecal opiates, clinically significant 
sedation, altered mental status, nausea/vomiting, respiratory 
depression [41, 42] and these end points are considered to 
represent supraspinal mu opioid receptor activation [43]. 
Urinary retention is mediated by a spinal effect upon sacral 
mu receptors (e.g., produce by mu opiates and reversed by 
naloxone) of the bladder–spinal bladder reflex secondary to a 
suppression of small afferent input and increased external 
sphincter tone [44-46]. Pruritus can be mediated by a 
peripheral, nonopioid receptor mediated effect on mast cells 
degranulation (e.g., not naloxone reversible and with a 
minimal effect of agents such as fentanyl and sufentanil in 
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contrast to morphine and hydromorphone [47] and by an 
action upon mu receptors in a hypothesized brain stem site 
[48]. From a toxicological perspective, preclinical large 
animal safety studies have shown no significant effect upon 
spinal morphology, but has revealed the formation of 
intrathecal granulomas (e.g., an aseptic space-occupying 
mass proximal to the catheter tip composed of inflammatory 
cells that have migrated from the meninges) to be associated 
with the intrathecal infusion of high concentrations of 
morphine, hydromorphone and methadone, but not alfentanil 
or fentanyl) [49-55] but see [56]. Preclinical work has shown 
that in accord with the lack of an opiate structure activity 
relationship (e.g., granuloma inducing potency: morphine > 
fentanyl), the granuloma formation was not prevented by 
concurrent opiate receptor antagonism [54]. Preclinical work 
has pointed to the potential role of meningeal mast cell 
degranulation in granuloma formation [54]. In humans, 
comparable intrathecal masses have been observed after 
continuous infusion of high concentrations of most opioids 
including morphine and hydromorphone, but less so with 
fentanyl [53, 57]. 
Future Directions for Spinal Opiates 
 The pharmacodynamics of mu receptors has proven to be 
complex and suggest several promising avenues for future 
development: i) Mu opioid receptors occur as splice variants. 
Efforts have been made to develop ligands targeted at these 
splice variants [58, 59]. ii) Mu receptors couple through Gi/o 
protein in a ß arrestin dependent fashion such that ligand 
occupancy yields receptor internalization and desensitization 
of G protein signaling [60, 61]. Activation of mu receptors 
can be achieved separately from ß arrestin signaling. Such 
“G protein biased” ligands are believed to yield increased 
analgesic efficacy compared to other G protein-coupled 
receptors [62]. iv) Current work suggests that many G 
protein coupled receptors may form homo- and heterodimers 
[63]. Bivalent ligands interacting with these hetero-dimers, 
such as mu and delta receptors, have demonstrated enhanced 
cellular responses [64]. Thus, a mu agonist and a delta 
antagonist ligand display enhanced efficacy and a reduced 
propensity for tolerance [65]. Heterodimers constructed from 
opioid and nonopioid binding sites, such as bivalent Mu - 
CB1 (cannabinoid) [66] or µ-mGluR5 (metabotrophic 
glutamate receptors) [67, 68], have potent antihyperalgesic 
effects in avariety of models. v) Agents with delta opioid 
preference (e.g., the effects of which are antagonized by 
naloxone and naltrendole) have been shown to have a spinal 
analgesic action in preclinical models when given 
intrathecally as a bolus [69-74]; or an infusion [75, 76]. This 
work is consistent with the presence of delta opioid receptors 
presynaptic on subpopulations of small primary afferents 
which regulate the activity of thermal and/or mechanical 
nociceptor [77-79] and block of release of small spinal 
afferent peptides [26, 69, 80-82]. One agent administered 
intrathecally, DADL (d-ala2-d-leu5 enkephalin), was shown 
to have efficacy in humans [83, 84]. These agents have been 
shown to not display cross-tolerance to mu opiates [75, 76]. 
vi) As noted above, one current hypothesis regarding 
granuloma formation is that it may relate to a concentration 
dependent degranulation of mast cells that is not mediated by 
an opiate receptor [54]. This dissociation suggests the 
possibility that agents that do not result in mast cell 
degranulation at concentration necessary for opiate receptor 
activation and have intrathecal kinetics similar to morphine 
might provide an alternative approach to defining an 
alternative to the currently available opiates. Potential 
molecules might for example be potent mu or delta opioid 
peptides [85, 86]. 
Alpha 2 Agonists 
Spinal Alpha 2 Agonists 
 Alpha 2(α2) agonists administered intrathecally have 
been shown to have efficacy in a variety of animal pain 
models including those associated with acute tissue injury 
and neuropathic pain states [87, 88]. 
Mechanisms of Action 
 Three relevant subclasses of α 2agonists, α 2A, α 2B, α 2C, 
have been shown [89]. In situ studies have shown that 
subtype messages are present in sensory neurons: α2C, > α2A, 
>> α2B, whereas in spinal dorsal horn the message levels are: 
α2B> α 2c> α 2A [90]. Interestingly, discrepancies are noted 
between the α2 subtypes as defined by message and immuno- 
histochemistry (see [91]). Spinal α2adrenergic receptors display 
several characteristics: i) binding is present presynaptically 
on C-fibers and postsynaptically on spinal neurons; ii) 
agonists are believed to alter spinal nociceptive processing 
by preventing opening of voltage-sensitive Ca channels 
(blocking release) [92, 93] and increasing potassium conductance 
leading to hyperpolarization of dorsal horn neurons through 
increased pK conductance [87, 88, 94, 95]. Consistent with 
their pharmacology, the analgesic activity is reversed by 
α2antagonists such as atipamezole [96-98]. At the spinal 
level, α 2 agonists reduce preganglionic sympathetic outflow, 
accounting in part for their hypotensive actions, while 
sedation is mediated supraspinally [99]. A similar mechanism 
of action to opioids is noted, albeit through distinctly 
different receptors that are often co-localized. Tolerance with 
repeated exposure has been reported, but cross-tolerance 
with mu opioids does not occur [100, 101]. 
Drug Molecules 
 Dexmedetomidine, clonidine, and xylazine are α2 
agonists used systemically in human and veterinary clinical 
practice, however, clonidine is the only α 2agonistwith FDA 
approval for spinal (epidural) delivery in humans. Perhaps 
not surprisingly, the addition of clonidine to neuraxial 
morphine enhances analgesic efficacy [102, 103]. 
Adverse Events 
 The use of α2 agonists such as clonidine is largely limited 
by sedation, systemic hypotension, and bradycardia that are 
likely produced by a central sympatholytic effect and 
activation of α2A in the medulla. Chronic epidural [104] and 
limited intrathecal large animal [49] preclinical safety work 
has shown no evidenceof spinal toxicity. 
Future Directions for Spinal Alpha 2 Agonist 
 While some work has suggested that analgesia and 
sedation may be separable if different sub-classes of α 2 
receptors can be targeted [98, 105, 106], such differentiation 
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is not supported by studies in gene-altered mice [107], and 
the work has not led to definitively distinguishable agents. 
The cLogP of clonidine (2.6) and dexmedetomidine (3.0) 
reflect upon the short duration of action and rapid systemic 
exposure that occurs with these spinal agents suggesting that 
a more polar α2agonist might have virtue. 
Spinal Sodium Channel Blockers 
Spinal Antagonists 
 The original drugs employed for spinally directed therapy 
were cocaine and derivatives [108, 109]. Those incredibly 
insightful studies performed over 100 years ago defined the 
potent anesthetic and motor block produced by intrathecal 
cocaine and the residual presence of analgesia to pain and 
temperature [110]. Preclinical studies have typically shown 
minimal effects upon acute nociception at sub-motor 
impairing doses of conventional sodium channel blockers 
given intrathecally. However, they are reported to reliably 
result in a remarkable analgesic synergy with intrathecal 
agents such as opiates or alpha 2 agonists with minimal 
attendant effects upon motor function in animal models 
[111-114] and in humans [115-117]. There is a clinical 
literature that suggests that neuraxial local anesthetics may 
display a tachyphylaxis with chronic exposure that may 
respond to different local anesthetics [118]. However, 
systematic clinical evidence of this impression is 
controversial (see [119]. Nerve block studies do not display 
such changes, suggesting that if tachyphylaxis does occur it 
reflects some system level change [120]. 
Mechanisms of Action 
 The common mechanism of all clinically employed 
“local anesthetics” is to block the voltage-gated sodium 
channel (Nav). Navs consist of an α -subunit complex that 
forms the transmembrane spanning pore and auxiliary β -
subunits [121]. The channel expresses molecular components 
mediating the voltage sensing and gating elements that result 
in the voltage-dependent opening and voltage-independent 
closing of the channel. Importantly, the typical anesthetic 
with pKa >7.4 is unionized at extracellular physiological 
pHs, penetrates the membrane, reionizes in the more acidic 
intracellular environment and in the ionized (protonated) 
state blocks the channel from the intracellular side. Several 
general properties of the block are appreciated. The 
differential block of motor axons and low vs. high threshold 
sensory afferents reflect the greater sensitivity of small vs. 
large afferents to block of the conducted action potential. As 
local anesthetics bind to sodium channels in an activated 
state, the initiation of blockade is facilitated in neurons 
discharging at a high frequency (e.g. a state-dependent block 
[122-124]. Previous speculations [112] have pointed to the 
role of impedance mismatching at the extensive afferent 
branch points within the dorsal horn. This would lead to an 
increased probability of conduction failure in the small (C-
fiber) afferents [125] and an increased susceptibility of the 
terminal depolarization to be blocked by low concentrations 
of local anesthetics. 
 Nine isoforms have been identified with distinguishable 
activation properties and tissue distributions [126]. Of  
 
particular note, Nav1.4 and Nav1.5 are present in skeletal and 
cardiac myocytes. Nav1.7, Nav1.8, and Nav1.9 are 
predominantly expressed in small sensory DRGs/afferents, 
while NaV 1.1 and 1.6 are found more highly expressed in 
large DRG/axons [127]. Clinically employed local 
anesthetics (amide and ester) are essentially non-selective in 
their blocking of different sodium channels (see [124]). 
Several sodium channel isoforms are sensitive to the puffer 
fish toxin, tetrodotoxin (TTX) (Nav1.1, Nav1.2, Nav1.3, 
Nav1.4, Nav1.6, and Nav1.7), while others (Nav1.5, Nav1.8, 
and Nav1.9) are resistant to TTX [124, 128]. Importantly, 
following chronic inflammation and peripheral nerve injury, 
prominent increases in the expression of small afferent Navs 
has been noted and such increases appear to be associated 
with the initiation of ongoing (ectopic) afferent traffic [129]. 
The use of antisense, siRNA and murine mutations  
have indicated that impairment of Nav1.3, 1.7,1.8 and 1.9 
expression has varying antihyperpathic effects in models of 
inflammatory and neuropathic pain states [127, 130, 131]. 
Specific gain and loss of function mutations in the Nav1.7 
channels have been identified in humans wherein there is an 
increased and decreased pain state, respectively [132, 133]. 
Drug Molecules 
 Avariety of local anesthetics are employed with two 
common structural motifs: Hydrophobic (aromatic residue) 
and hydrophilic (tertiary or secondary amines) domains 
separated by an ester procaine, 2-chlorprocaine, tetracaine) 
or amide (lidocaine, bupivacaine, ropivacaine) linkage. The 
principal differences between drugs being use dependency, 
effective concentrations and duration of action. Though 
differences in relative potency with respect to blocking 
different Nav subtypes have been reported, such selectivity 
remains controversial and in part reflect variation in on and 
off rates of binding and channel opening and inactivation 
properties rather than a specific difference in Nav affinity 
[123, 124]. The properties of local anesthetic actions at the 
channel have been extensively reviewed elsewhere [134, 
135]. 
Adverse Events 
 Adverse events such as motor weakness and anesthesia 
after intrathecal delivery of currently employed local 
anesthetics reflect side effects related to the block of the 
several voltage-gated channels associated with large sensory 
and motor axons and spread of the block to higher centers 
(e.g. “total spinals”) and to non-neuraxial tissues such as 
cardiac myocytes. As noted, the large axons are relatively 
resistant to conduction block. Neurological signs secondary 
to intrathecal local anesthetics have been identified in 
patients with uncomplicated spinal anesthesia wherein distal 
lower extremity pain was reported. Transient neurologic 
symptoms were reported with relative risk being higher for 
lidocaine compared to bupivacaine, prilocaine, procaine and 
mepivacaine [136]. Preclinical safety evaluations with 
intrathecal local anesthetics such as lidocaine, bupivacaine 
and ropivacaine have been marked initially by mitochondrial 
vacuolization, mild focal edema, with evidence of change in 
the lamellar structure of fibers and Schwann cells in rat and 
dog models [137, 138]. The molecular mechanisms of the  
 
236    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
local anesthetic toxicity are not understood. Work with 
intrathecal TTX has shown that long-lasting sodium channel 
block itself is not associated with a specific toxicity [139]. 
Small local anesthetic molecules can have effects on lipid 
membrane components, which reflect the detergent nature of 
these amphiphillic molecules [140]. Though the mechanisms 
are not understood, the afferent toxicity does appear to be 
associated with increased intracellular calcium in the DRG 
[141]. 
Future Directions for Spinal Sodium Channel Blockers 
 The current advances in our understanding of the Nav 
subtypes and their differential distribution in the body and 
particularly in the neuraxis, as well as the upregulation in 
their expression after injury leading to ectopic activity and 
increased neuronal excitability, offers evident opportunities 
for creating drugs that target those elements that might be 
most altered by the pain states. Several strategies have been 
employed. As reviewed elsewhere, there has been a great 
deal of effort to define structures that prefer one channel 
over another [142, 143]. Preclinical work with intrathecally-
delivered molecules targeted at Nav1.7 [144] and 1.8 [145] 
has shown preclinical efficacy. While much attention has 
been paid to the TTX-resistant sodium channels in sensory 
neurons (e.g., Nav1.8 and 1.9) an important role for TTX 
sensitive channels cannot be excluded. Intrathecal TTX has 
been reported to have mild effects upon acute and 
inflammatory nociceptive end points [146]. Nav1.3 and 1.7 
produce TTX-sensitive sodium currents and have been 
shown to contribute to ectopic firing in injured neurons. As 
noted above, Nav1.3 expression increases with nerve injury. 
Intrathecal knockdown of these channels with antisense 
reduced their upregulation in nerve injury and reduced the 
behaviorally defined tactile allodynia [147-149]. The use of 
intrathecally-delivered siRNA and antisense targeting these 
structures clearly offers a direct approach to targeting these 
membrane proteins [127, 130, 131]. An alternate strategy for 
selective targeting has been the use of non-selective blockers 
that are restricted in terms of the cells to which they have 
access. The quaternary lidocaine molecule (QX314) cannot 
readily penetrate the cell. However, activating membrane 
channels such as the TRV1 channel has been reported to 
allow QX314 entry into the neurons and to block the Nav 
channel from the interior and result in a selective block of 
the TRPV1 expressing primary afferent [150]. Intrathecal 
QX316 has been reported to produce significant pain 
behavior after intrathecal delivery in rodent models and this 
may reflect upon its ability to concurrently activate the 
TRPV1 channel [151]. It should be noted that while this 
section considers the role of sodium channel blockage in 
reducing axon excitability, it has been shown that conditions 
leading to an enhanced expression of sodium channels often 
lead to a reduction in the expression of potassium channels 
which further contributes to membrane excitability [152]. 
Increasing potassium conductance with potassium channel 
agonists or increasing the expression of potassium channels 
can serve to move the membrane towards a hyperpolarized 
state and normalize (reduce) otherwise enhanced axon, DRG 
and terminal excitability, an action associated with an 
antihyperalgesic action [153, 154]. 
Spinal Calcium Channel Blockers 
Spinal Antagonists 
 Ziconotide (Prialt), discovered in the venom of fish-
killing marine snails [155], was demonstrated to be a potent 
antihyperpathic agent in rodents and humans after intrathecal 
delivery as a bolus or an infusion [156-159]. Ziconotide was 
observed to be a highly selective ligand blocking the N-type 
voltage-sensitive calcium channel (VSCC) [160]. 
Mechanisms of Action 
 VSCCs facilitate neurochemical cell signaling through 
mobilization of presynaptic vesicles for neurotransmitter 
release. The N-type calcium channel is most important for 
neurotransmission in sensory neurons. This calcium channel 
subtype is densely expressed in presynaptic nerve terminals 
in the spinal cord superficial dorsal horn and dorsal root 
ganglia. In the presence of nerve injury these channels are 
upregulated [161] and blocking these channels has shown to 
produce antinociceptive effects [162] that do not show 
tachyphylaxis (tolerance) [163]. 
Drug Molecules 
 Ziconotide, an ω-conotoxin derived from the cone snail, 
is a calcium channel blocker that binds with high affinity and 
physically blocks the N-type calcium channel. It is a stable, 
water soluble, large 25 amino acid, polybasic peptide 
containing three disulfide bridges with a molecular weight of 
2639 Da. Ziconotide is FDA approved for intrathecal use for 
chronic, severe pain. 
Adverse Events 
 In animals, ziconotide produces dose-dependent body 
shaking and ataxia [157, 164, 165]. A narrow therapeutic 
index reflecting nonspinally mediated side effects such as 
dizziness, nausea and somnolence has limited the human 
clinical utility of ziconotide. Extensive large animal 
preclinical safety evaluations have emphasized the lack of 
tissue toxicity of this molecule at clinically useful 
concentrations [166]. 
Future Directions for Spinal Calcium Channel Blockers 
 i) Currently the only N type channel blocker approved as 
a therapeutic is Ziconotide. Considerable work has focused 
on the development of other conopeptides as well as small 
molecules [160, 167]. Alternatively, there is considerable 
interest in altering N-type VSCC function by impeding its 
membrane trafficking and such strategies have been shown 
to alter nociceptive processing [168]; ii) VSCCs are broadly 
divided into two types: high-voltage-activated (HVA) and 
low-voltage-activated (LVA) channels. HVA channels are 
further divided into L-, P/Q-, N- and R-type channels. LVA 
channel include the T-type channel. Each channel locates in 
a distinct area in the peripheral nerve and CNS and 
contributes in different ways to nociceptive transmission (see 
[169]). Spinal blockade of R- and T-type but not L and P/Q 
type VSCCs attenuated formalin-induced pain behavior 
[170-172]. In other work, intrathecal PQ-preferring toxins 
displayed efficacy in neuropathic pain models [173]. 
Intrathecal delivery of T-type calcium channel blockers  
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(ethosuximide and mibefradil)produce analgesia in rodents 
[171, 174]. iii) An alternate therapeutic target thought to 
involve regulation of VSCCs is the α2 delta calcium channel 
auxiliary subunit. This subunit is the binding site for 
gabapentinoid drugs in the dorsal horn. In preclinical 
models, gabapentin and pregabelin have been shown to have 
potent effect in a variety ofhyperalgesic pain [175-178] 
Preclinical results indicate adequate spinal pK with a very 
hydrophilic cLogP (-1.13). In a recent study, however, it was 
unexpectedly reported that intrathecal infusion of gabapentin 
failed to alter pain assessments in human patients suffering 
from a variety of neuropathic and non-neuropathic pain 
states [179]. 
NMDA Ionophores 
Spinal NMDA Antagonists 
 A wide variety of NMDA ionophore antagonists given 
intrathecally have been reliably shown to have potent 
attenuating effects upon the hyperpathia resulting from a 
variety of tissue [99, 180] and nerve injury [181] facilitated 
pain states in animals and, though not approved, in humans 
[182]. 
Mechanisms of Action 
 The NMDA receptors are heteromeric protein complexes 
assembled from three families of NMDA receptor subunits 
(NR1, NR2 and NR3) each with multiple distinct subunits 
[181]. When activated it allows the influx of sodium, 
potassium and calcium. Glutamate, released from afferents 
and interneurons in response to high threshold noxious input 
from C fibers, binds target sites on the NMDA receptor. 
These receptors are densely expressed in spinal cord dorsal 
horn on the terminals of the primary afferent, on second order 
neurons as well as in non-neural cells such as astrocytes and 
oligodendroglia. Activation of the channel requires the 
presence of occupied binding sites on the ionophore for 
glycine and polyamines [183]. At resting membrane potentials 
a Mg++ ion provides a block in the channel that effectively 
prevents calcium flux through the channel. In the face of 
repetitive activation, the membrane displays progressive 
depolarization, relieves the Mg++ block and allows calcium 
flux [183], leading to a cascade initially described electro- 
physiologically, as wind-up [184]. Blocking NMDARs inhibits 
the wind-up phenomenon of spinal dorsal horn neurons [185, 
186]. This increased excitability further results in activation 
of a variety of protein kinases (Mitogen activated kinases 
and PKA and PKC) which, respectively, increases protein 
synthesis, phosphorylates channel and enzymes that lower 
their thresholds for activation and enhances their ion 
permeability leading to hyperalgesic states [187-190]. 
Drug Molecules 
 Numerous NMDA antagonists have been employed for 
preclinical work showing the antihyperpathic effects of 
intrathecal NMDA antagonists [191-194]. These include 
channel blockers such as ketamine (cLogP: 3.1), MK-801 
(cLogP: 2.7) and memantine (cLogP 2.0), and competitive 
antagonists such as 2 amino 5 phosphonovalorate (cLogP=-2.32), 
glycine site blockers such as 7 Chlorothiokynurenic acid 
(cLogP: 2.7). No NMDA antagonists have been approved for 
human neuraxial use. 
Adverse Events 
 Single intrathecal injections of ketamine did not produce 
histological alterations in the dog [195] but resulted in spinal 
cell death in the neonatal rat [196]. After repeated intrathecal 
delivery in rabbits [197] or continuous infusion in dogs 
[198], Ketamine and a number of other NMDA channel-
blocking antagonists including MK-801, dextrorphan, 
dextromethorphan and memantine and the nonopiate agent 
D-methadone, and to a lesser degree the glutamate antagonist 
2AP5,resulted in prominent spinal pathology reflecting 
parenchymal necrosis in dogs and/or sheep [198, 199]. These 
spinal effects, where examined, appear to be concentration-
dependent and, with the exception of the neonatal model, the 
therapeutic ratio (e.g., therapeutic dose/minimum toxicity 
dose-concentration) has not been defined. It should be noted 
that a weakness of these studies is that there was no 
corresponding assessment of the efficacy of the intrathecal 
infusion was assessed relative to the dose required to 
produce pathology in these animals models (but see [196]). 
Future Directions for Spinal NMDA Antagonists 
 i) Preclinical work and anecdotal clinical data clearly 
indicate the efficacy of spinal NMDA antagonism. However, 
in light of the controversy related to the intrathecal toxicity 
of NMDA antagonists (see above), characterization of the 
intrathecal therapeutic ratio for the NMDA antagonist is 
necessary to define the relative safety of these agents. While 
their ability to produce untoward histopathology is evident, it 
is not clear how close the toxicity is in the adult, 
continuously infused animal to the dose-producing beneficial 
consequences. ii) The NMDA ionophore is constituted of a 
variety of subunits. Ionophores constituted of different 
subunits have different binding profiles and are differentially 
distributed [200, 201]. One such subtype is the NR2B 
subunit. Specific antagonists such as Ifenprodil [202], Ro 25-
6981 [202, 203] and Conantokin G [204] has antihyperpathic 
effects in models of spinal injury and facilitated processing. 
Other NMDA ionophore-associated targets for which ligands 
have been shown to produce analgesia include the glycine 
binding site and the polyamine binding site [201, 205]; iii) 
Magnesium sulphate is a noncompetitive antagonist of the N-
methyl-d-aspartate (NMDA) receptor and thus can modify 
nociceptive modulation [206-207]. Limited preclinical safety 
studies have been performed examine the effects of bolus 
delivery in several species. At least one preclinical paper has 
reported evidence of neurotoxicity after intrathecal delivery 
[208]. Chronic spinal exposures have not been examined. A 
variety of reports have noted activity in humans after 
intrathecal and epidural delivery [209]. iv) Agmatine is an 
endogenous neuromodulator present in the brain and spinal 
cord that has both NMDA receptor antagonist and nitric 
oxide synthase inhibitor activities. It has been reported to 
have antihyperalgesic properties after systemic and 
intrathecal delivery [210]. v) The primary focus of glutamate 
ionotrophic receptors has been on the NMDA. However, the 
AMPA receptor plays a prominent role in acute dorsal horn 
evoked excitation as a sodium selective ionophore [211].  
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Agents such as Tezampanil (LY-293558, NGX-424) given 
spinally in preclinical studies has effect upon postoperative 
pain and spasticity [212, 213] and its action were associated 
with changes in motor function, a fact consistent with the 
prominent role of AMPA in motor neuron excitation. In 
humans oral dosing has indicated some effects upon afferent 
evoked hyperalgesia [214]. vi) The AMPA receptor is 
composed of GluR1-GluR4 subunits. In the face of injury, 
there is a change in subunit trafficking and ionophore 
composition such that the ionophore becomes calcium 
permeable. Intrathecal antagonists selective for the calcium 
permeable AMPA site, such as joro spider toxin, reduces the 
development of secondary mechanical allodynia evoked in 
tissue injury models [215-216]. 
GABA-A 
Spinal GABA-A Activation 
 Preclinically, intrathecal GABA-A agonists such as 
muscimol or isoguavacine have been reported to display 
efficacy in neuropathic pain models [217-221]. Intrathecal 
benzodiazepines and neurosteroids have been shown 
precliincally in rodent models to attenuate tissue and nerve 
injury hyperpathic states [218, 222-226]. In dogs, intrathecal 
benzodiazepines have been shown to depress nociceptive 
reflexes [227]. In humans, bolus intrathecal Midazolam was 
reported to display efficacy after bolus deliveryin 
postoperative, low back and labor pain [228-231]. 
Mechanisms of Action 
 The GABA-A receptor is a GABA gated chloride 
ionophore composed of five subunits, each with four 
transmembrane spanning domains. With multiple subunits, 
not surprisingly, several different pharmacological and 
functional phenotypes of the receptor have been identified 
[232]. GABA binds at an α and a β subunit [233] to activate 
the Cl conductance. Importantly, numerous agents interact 
with specific sites on the GABA-A ionophore to serve as 
positive allosteric modulators. Thus, benzodiazepines (e.g., 
midazolam, diazepam) bind to specific populations of 
GABA-A ionophores that possess both an α and a γ subunit. 
This binding forces a conformation where GABA displays a 
higher affinity increasing the frequency of opening of the ion 
channel [234]. Similarly, several neurosteroids such as 
allopregnanolone will bind to the GABA-A ionophore and 
force conformational changes enhancing GABA effects 
[235, 236]. Immunohistochemical studies have shown dense 
staining in spinal Rexed laminae for several alpha, beta and 
gamma subunits likely corresponding to primary afferents 
[237, 238] presumably localized on primary afferent 
terminals. Electrophysiological studies have indeed shown 
GABA-A receptors to be present on both large and small 
afferents [239] and such studies have emphasized the potent 
regulation by benzodiazepines of the excitability of small, 
nociceptive, primary afferents through their associated 
GABA-A receptors [240]. There is not enough space here to 
review the differential distribution of functionally distinct 
GABA-A receptor phenotypes, but electrophysiological and 
knockout studies have shown considerable phenotype 
diversity in the neuraxis [241, 242]. 
 
Drug Molecules 
 As noted above, the common agonists employed in 
pharmacological studies of the GABA-A receptor are muscimol 
(cLogP = -0.7). Agents serving as allosteric modulators 
include benzodiazepines (midazolam; cLogP = 3.16) and 
neurosteroids (allopregnanolone; cLogP= 3.7). 
Adverse Events 
 Activation of nonspinal GABA-A ionophores has 
prominent sedative, anxiolytic and amnestic effects. At the 
spinal level enhanced GABA-Aactivity has been shown to 
have effects upon motor function [243]. The use of 
intrathecal midazolam in man has been reported as noted 
above. However, there has been concern about the potential 
for spinal toxicity [243, 244]. While several systematic 
assessments of toxicity have shown distinct deleterious 
reactions [245, 246], others have failed to observed toxicity 
[56]. The origin of the preclinical toxicity is not known, but 
the acidic pH required by the formulation of midazolam may 
be a contributing issue (see for review [244]. In our opinion, 
concern over its potential for toxicity remains. Barbiturates 
act through the GABA A ionophore, but their spinal action 
may be associated with a cauda equine syndrome. Such has 
been the case after inadvertent intrathecal injection of 
sodium thiopental [247]. 
Future Directions for Spinal GABA-A Agonists 
 As noted above, a high degree of heterogeneity of the 
GABA-A receptor structure/subtype has been observed, 
which raises the possibility of defining specific structures 
targeting these subtypes [242, 248-250]. Activation of spinal 
GABA-A ionophores either directly through agonist 
activation or by positive allosteric modulators has significant 
preclinical support for further development as reviewed 
above with benzodiazepines and neurosteroids. Interestingly 
agent such as Etifoxine may act by stimulating 
allopregnanolone synthesis in the spinal cord [251]. Current 
work has shown that subtype specificity may be achieved 
and that they may have different effects upon neuronal 
inhibition in different systems [252]. 
GABA-B Receptors 
Spinal GABA-B Agonists 
 Baclofen, the clinically approved GABA-B agonist, has 
potent stereospecific suppressive effects upon motor tone 
[253] and is widely used clinically to regulate motor tone in 
the case of spasticity [254-256]; but it has also been 
implicated in having suppressive effects upon nociceptive 
processing after intrathecal delivery in preclinical models of 
facilitated processing [217] and hyperpathia in mono and 
polyneuropathies and spinal injury [220-221, 257-259] and 
in humans [260, 261]. 
Mechanisms of Action 
 The GABA-B receptor is a metabotrophic receptor 
coupled to intracellular signaling through Gi and Go proteins 
that, when stimulated, activate K+ and inhibit Ca2+ channels 
via the βγ complex, with the α subunit regulating adenylate  
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cyclase [262]. They are dense in laminae I and II in the 
dorsal horn on small afferent terminals and on 2
nd
 order 
neurons [263]. DRG neurons of various diameters also 
express GABA-B immunoreactivity. At the electron 
microscopic level, the immunoreactivity is present on 
myelinated and unmyelinated fibers and on the dendrites of 
dorsal horn neurons. Electrophysiological studies show that 
GABA-B agonists initiate hyperpolarization through an 
increase in K conductance through G protein coupling and 
attenuation of evoked primary afferent transmitter release 
through block of opening of voltage gated Ca channels. 
GABA-B receptors are present on motor neurons and serve 
to reduce their excitability leading to flaccidity at doses that 
are similar to those yielding antinociception. 
Drug Molecules 
 The common GABA-B agonist is baclofen (cLogP = 1.3), 
which exerts its effects in a stereospecific fashion [253, 264]. 
GABA-B selective antagonists, such as saclofen [265], block 
the effects of these agents. 
Adverse Events 
 Intrathecal baclofen produces a prominent dose-
dependent motor weakness in animal models and humans 
[253]. In humans, this effect has a particular therapeutic 
benefit in managing clinically relevant spasticity (see [256]). 
Intrathecal baclofen has undergone one published systematic 
toxicology evaluation in dogs involving a 28-day continuous 
infusion without evidence of toxicity [55, 266]. Intrathecal 
baclofen has been reported to result in intrathecal space-
occupying masses, but this has proven to be controversial 
[267, 268]. 
Future Directions for GABA-B Receptor Targeting 
 Other GABA-B agonists have been identified and include 
agents such asCGP35024 and the more potent CGP 44532, 
which were reported to induce antinociceptive responses at 
doses below those that cause sedation [257, 269]. It has 
become clear that regulation of GABA-B activity is 
associated with a role for positive allosteric modulators to 
potentially reduce unwanted drug effects. These agents 
interact with discrete domains of the GABA-B receptor 
stabilizing it in the active state involved in G-protein 
coupling. Such agents have been found to modulate the 
GABA-B receptor analgesic activity [270]. 
Spinal Cholinesterase Inhibitors 
Spinal Cholinesterase Inhibitors 
 Neostigmine is a cholinesterase inhibitor that yields 
antinociceptive effects in a variety of preclinical models 
[106, 271-275] in several species such as rodents and sheep 
[276]. Bolus intrathecal delivery of neostigmine has been 
reported in humans to have significant effects upon 
postoperative pain [277-279]. 
Mechanisms 
 Intrathecal cholinesterase inhibitors are considered to 
increase the local extracellular levels of acetylcholine. Spinal 
delivery of a variety of cholinergic antagonists has indicated 
the importance of muscarinic receptors and in particular 
several M subtypes in mediating these antinociceptive 
actions [280]. These findings are consistent with the 
antinociceptive effects of intrathecal muscarinic agonists 
[281]. Spinal muscarinic receptors in the spinal cord are 
strongly expressed in the superficial dorsal horn [282].There 
are five subtypes (M1-5) [283, 284] divided into two broad 
groups: M1/M3/M5 coupled to Gq/11 proteins, activating 
phospholipase C - IP3—diacylglycerol (DAG) cascade 
yielding increased Ca
2+ 
and activation of protein kinase C 
and mitogen-activated protein kinases. M2 and M4 receptors 
(M2-class) coupling to Gi/o proteins and inhibiting opening 
of voltage-gated calcium channels [284]. M1/3/5 receptors 
induce membrane depolarization by enhancing cation 
currents and inhibiting potassium channels [285, 286], while 
M2 and M4 channels activate potassium channels and inhibit 
some voltage-gated Ca channels (especially Cav2.2), leading 
to hyperpolarization and block of transmitter release [287]. 
M2 and M4 knockout animals show a robust attenuation of 
the analgesic effects produced by muscarinic agonists [165, 
288, 289] Interestingly, stimulation of M2 and M4 receptors 
inhibit spinal glycinergic function which might lead to a 
paradoxical hyperpathia, whereas stimulation of the M3 
activation potentiates synaptic glycine release [290]. The 
events underlying the effects upon spinal nociceptive 
processing have been proposed to reflect several 
mechanisms.1) effect of muscarinic receptor subtypes in 
reducing afferent terminal excitability (reducing glutamate 
release) [289]; and, 2) activation of muscarinic receptors on 
glycinergic and GABAergic interneurons enhancing dorsal 
horn inhibitory amino acid release through muscarinic 
subtypes, such as the M2 and M4 receptors [290, 291]. 
Adverse Events 
 The safety of intrathecal neostigmine has been examined 
systematically in rats after multiple bolus deliveries and after 
chronic infusion in the dog [292] and no apparent tissue 
toxicity was noted. In humans, intrathecal neostigmine has 
been shown to provoke nausea and vomiting [277]. 
Future Directions 
 Considerable work has focused on the development of 
novel muscarinic agonists and cholinesterase inhibitors 
[293]. As noted above, there is considerable evidence that 
subtypes of muscarinic receptors may be involved in the 
spinal antinociceptive actions and anticholinesterase targeted 
agents. 
Adenosine 
Intrathecal Adenosine 
 Delivery of adenosine and associated ligands can have 
potent antihyperalgesic effects in models of acute nociceptive 
processing [294], neuropathy [294-298] and inflammatory 
pain [299]. In humans, intrathecal adenosine has been shown 
to reduce allodynia in experimental pain models [300, 301] 
and in patients with neuropathic pain [302,303]. Negative 
results with intrathecal adenosine have also been reported 
[304]. 
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Mechanisms 
 Adenosine can activate four G-protein-coupled receptors: 
A1, A2A, A2B, A3 [305]. A1receptors are expressed on small-
to-medium-diameter neurons of the DRG and on dorsal horn 
neurons [306-309] and serve to inhibit synaptic transmission 
through presynaptic inhibition of neurotransmitter release 
and on postsynaptic inhibition of excitatory transmission 
[309, 310]. 
Adverse Events 
 In preclinical studies, A1, agonists and A2A antagonists 
reversibly depressed the volume-evoked micturition reflex 
[311, 312] and produced motor weakness. An unexpected 
observation was that chronic exposure of spinal systems to 
A1agonists led to a hyperalgesic state [313]. The safety of 
intrathecal adenosine has been examined systematically in 
rats after multiple bolus deliveries and after chronic infusion 
in the dog [300, 314] with no adverse signs or 
histopathology. Studies with intrathecal delivery of the A1 
agonistR-phenylisopropyl adenosine (R-PIA) also failed to 
show histopathology [315]. 
Future Directions 
 It has been reported that A2Areceptor agonists may 
produce a long-term reversal of allodynia in mononeuro- 
pathies [316]. It has been proposed that the mechanisms of 
this long-term effect may reflect the effects ofA2Aagonists as 
potential glial inhibitors. The complexity of this possible 
drug effect is also reflected by the observation that 
A2Areceptors may serve to stimulate glutamate release and 
that A2Aantagonists may have protective effects by reducing 
that excitatory effect [317]. 
Cyclooxygenase Inhibitors 
Cyclooxygenase Inhibitors 
 Considerable work has shown that in the face of 
persistent small afferent input there is an increase in the 
release of cyclooxygenase products such as PGE2 [318-320]. 
This increase results from activity in constitutively 
expressedCOX-2 in spinal dorsal horn neurons and glia 
[321]. The role of these PGs in the development of a 
sensitized dorsal horn state of processing is mediated by 
several mechanisms including enhanced opening of voltage-
gated calcium channels [322] and the loss of intrinsic 
inhibition by an inhibitory effect upon dorsal horn glycine 
receptor function [323]. Intrathecal delivery of COX-1/2 or 
COX-2 selective inhibitors has been shown to have 
antihyperalgesic effects in a variety of models producing 
central sensitization [318, 324-326]. Spinal COX-1 inhibition 
has attenuating effects upon postoperative pain [327] and 
Ketorolac is a mixed COX-1/2 inhibitor. Preclinical work 
has shown no evidence of toxicity in repeated bolus 
injections in the rat and continuous intrathecal infusion in the 
dog [328, 329] and was well tolerated in humans [330]. In 
human studies, intrathecal ketorolac delivered as a bolus had 
modest effects in human experimental pain models [331], 
enhanced morphine analgesia after total knee replacement 
[332], but had no effects on postoperative pain [333] or hip 
arthroplasty [334]. 
Other Potential Pharmacological Spinal Targets 
 In this section, we will briefly consider the role of several 
pharmacological targets that have been shown to play a role 
in spinal nociceptive processing. It should be stressed that 
virtually all of the mechanistic studies defining pain 
processing have shown the importance of spinal systems. 
Accordingly, future pharmaceutical targets may likely arise 
from one or more of systems that have been shown to have 
actions on the behaviorally defined pain end point after 
intrathecal delivery in one of more preclinical models (see 
[10-11]). Several of these will be summarized below. 
Importantly, most of these agents and their associated targets 
have not undergone any systematic assessments of toxicity 
and may carry with them unexpected/off-target membrane 
effects. 
Metabotrophic Glutamate Receptors (mGluR) 
 Eight mGluRs (mGluR1-8) have been identified and 
these are divided into three groups [335]: Group I (mGluR1 
and mGluR5) stimulates phospholipase C (PLC); Group II 
(mGluR2 and mGluR3) and Group III (mGluR4 - mGluR8) 
inhibit adenylate cyclase [335, 336]. In the brain and spinal 
cord, nGluRs have been identified on primary afferents, 
neurons and glia [337, 338]. Group I is localized 
postsynaptically, whereas Group II and Group III are present 
largely on the presynaptic terminal [339]. Activation of 
Group I mGluRs have been implicated in the processes of 
central sensitization and persistent nociception, whereas 
activation of Group II mGluRs has been shown to suppress 
facilitated states [340]. Accordingly, antagonists of Group I 
mGluRs and agonists of Groups II and III mGluRs have 
shown analgesic activity in neuropathic or inflammatory 
pain states [341-348] and accordingly represent a promising 
target for the development of future spinally-targeted agents 
[349, 350].  
Toll Receptors 
 Toll-like receptors (TLRs) are a family of pattern 
recognition receptors that recognize a variety of injury-
associated molecular structures. They are located on 
neuronal and non-neuronal cells in the spinal cord and signal 
through downstream pathways that often lead to anelaboration 
of a variety of proalgesic/inflammatory cytokines(DRG) 
[351, 352]. Intrathecal delivery of TLR4 antagonists has 
been shown to have ameliorating effects upon inflammatory 
and neuropathic pain states [353] and has been implicated in 
the phenomena of opiate-induced hyperalgesia [354]. Novel 
structures for blocking TLR activation through an interaction 
with the TLR4 ligand or targeting downstream signaling 
have been of therapeutic interest [355-357]. 
Cannabinoids 
 Cannabinoid receptors (CB1r and CB2r) are 7 trans- 
membrane, G-protein- coupled receptors that negatively 
couple through Gi/o proteins [358]. Spinally, CB1 receptors 
are expressed in neurons while CB2 receptors are expressed 
on microglia, where the CB1 agonists reduce excitatory 
transmitter release and CB2 receptors attenuate microglial 
activation [359, 360]. Intrathecal delivery of both CB1 and 
CB2 preferring ligands reduced facilitated states such as the 
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formalin model, hyperpathia in neuropathy models and in 
tumor bone pain in rodents [361-363]. As many of these 
ligands have very high cLogPs, appropriate formulation in 
spinally compatible vehicles is an important consideration in 
their development for spinal use. 
Purine Agonist/Antagonists 
 Adenosine triphosphate is widely released in the nervous 
system [364] and has been shown to interact with the P2 
receptor family, which is divided into P2X ligand-gated 
ionotropic receptors (further divided into 7 subtypes) and 
P2Y\G-protein-coupled receptors divided into 8 subtypes). 
The P2Y receptors may couple through either Gq/G11 to 
activate the phospholipase C/inositol triphosphate (InsP3) 
endoplasmic reticulum Ca
2+
-release pathway (the P2Y1, 
P2Y2, P2Y4, P2Y6, and P2Y11 receptors) or through to Gi/o, 
which inhibits adenylyl cyclase and serves to modulate ion 
channel function [365]. Both P2X and P2Y receptors are 
widely distributed in spinal dorsal root ganglia and in spinal 
neurons and glia [366]. A large persuasive literature has 
implicated these receptors as primary activators of glia, 
particularly microglia, leading to the spinal release of a 
plethora of proinflammatory proteins and cytokines relevant 
to initiating facilitated pain states [367-371]. Intrathecal 
delivery of a variety of P2X and P2Y inhibitors results in a 
temporary reversal of hyperpathia after nerve injury [372-
375]. Studies with a variety of approaches have strongly 
implicated the P2X4 subtype in spinal facilitation initiated 
by tissue and nerve injury [376]. Intrathecal administration 
of a P2X4R antisense oligodeoxynucleotide prevented the 
increase in P2X4R protein expression and suppressed the 
development of mechanical allodynia [372]. 
Anti-Inflammatory Cytokines (IL-10) 
 Activation of a variety of glial signaling cascades will 
lead to the release of a variety of cytokines including 
activation of NF-B and results in the production of 
proinflammatory mediators such as TNF, IL-6, and IL-1β 
that activate pro-algesic cascades [377]. Conversely, these 
cascades can lead to the release of so-called anti-inflammatory 
products that may bind the soluble product (IL-1ra) and 
cytokines such as, IL-4, IL-6, IL-10, IL-11, IL-13, TGF-β, and 
various soluble cytokine receptors [378], which can regulate 
the inflammatory cascade [379]. As an example, intrathecal 
delivery of IL-10 has been shown in animal models to have 
therapeutic efficacy in a variety of pain models [380]. 
Future Targeting 
 An exciting component of pain modulation has been the 
implementation of several novel approaches to modify the 
function of systems that process nociceptive information. A 
brief note on these approaches will be given below. 
Targeted Toxins 
 This approach takes advantage of toxin delivery to 
specific cell systems. Several examples can be considered. 
TRPV1 Receptors 
 These TRPV1 channels are present on the terminals of 
small high threshold primary afferents and when activated by 
ligands such as capsaicin [381] and analogues [382] will 
yield activation, desensitization and loss of terminals 
expressing the channel after spinal delivery [383]. Intrathecal 
resiniferatoxin, a potent TRPV1 agonist, has been shown to 
have a potent antihyperalgesic effect in canine persistent 
pain models [384] and is currently in human clinical trials 
(http://clinicaltrials.gov/show/NCT00804154). A further modality 
for targeting TRPV1- bearing neurons takes advantage of the 
fact that when activated TRPV1 forms a pore that is able to 
pass large charged molecules. Protonated local anesthetics 
(e.g., QX314), which cannot normally enter the axon, can 
pass through TRPV1 channels that have been opened by 
TRPV1 agonists such as capsaicin and produce a selective 
block of sodium channel function in the TRPV1 (+) afferent 
axon [385]. 
Toxins Coupled to Agonists for G-Protein-Coupled 
Receptors 
 G-protein-coupled receptors when occupied by their 
agonists will undergo internalization [386]. Composite 
molecules composed of the ligand and a toxin will bind to 
the respective GPCR. Such binding leads to an 
internalization of the agonists and the coupled toxin into the 
cell expressing the particular receptors [387]. Such GPCRs 
thus far intensely studied include those for the neurokinin 1 
for sP. These receptors are present on cells within the spinal 
pain pathway. The spinal neurokinin 1 receptor is located on 
postsynaptic second order neurons [388]. The majority of 
work at present has focused on the NK1-r. However, other 
G-protein receptors that are likely ligands are the mu 
receptors. As reviewed above, mu opiate receptors located in 
the spinal cord are primarily located in Laminae I and II on 
the nerve terminals of primary afferent C-fibers and 
interneurons in Lamina II. Agonist binding to these receptors 
leads to their internalization [19].  
 i) Saporin, a protein derived from the plant Saponaria 
officinalis, has been coupled to a variety of ligands including 
dermorphin, a ligand for the mu opiate receptor, and sP, the 
ligand for the neurokinin 1 receptor. The internalized saporin 
is cleaved in endosomes within the cell and serves to block 
ribosylation thereby preventing protein synthesis and leading 
to death of the targeted cells. Intrathecal sP-saporin has been 
shown to lead to a robust change in a variety of pain states in 
several species including the rodent [389] and dog [261]. 
Large animal safety studies have shown target engagement 
after intrathecal delivery showing local knockdown of spinal 
NK1-r protein and message [390]. Importantly, at high 
concentrations motor dysfunction was observed that 
reflected upon the presence of NK1-r in motor neurons in the 
dog. Intrathecal sP-Saporin is currently in human clinical 
trials (http://clinicaltrials.gov/show/NCT02036281). 
 ii) Botulinum toxin. Botulinum toxin is constructed of a 
heavy chain (HC) and a light chain (LC). The HC enables 
the uptake of the complex into the cell. Once in the cell, the 
complex is cleaved freeing the LC, which is the active 
enzyme cleaving SNARES [391]. SNAREs play an 
important role in mobilizing vesicles for transmitter release 
and in enabling movement of certain proteins to the 
membrane, such as the GLUA1 AMPA receptor subunits 
[392]. By cleaving SNAREs, transmitter release is blocked 
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and intracellular trafficking may be diminished. Intrathecal 
BoNTs have been shown to produce antihyperalgesic effects 
in a number of preclinical models of inflammatory and 
neuropathic hyperpathia [393-396]. The BoNT uptake is 
considered to be ubiquitous and the potent effects upon 
transmitter release may include inhibitory interneurons and 
motor neurons [397, 398]. A single human experience has 
emphasized the potential of producing an enhanced pain 
state, perhaps through block of inhibitory amino acid release 
[399]. An approach to achieving specificity has employed 
the GPCR coupling motif described above. Here sP coupled 
to the LC may be delivered IT and the coupled molecule 
uptake is restricted to cells that express the NK1 receptor 
[400]. Such an approach is reversible and may find utility in 
long-lasting but non-terminal pathophysiological pain states. 
Gene-Based Approaches 
 Targeting specific proteins that play a role in nociceptive 
processing has been accomplished with several methodologies 
including intrathecally-delivered antisense and viral and 
nonviral transfection [401-403]. 
 i) Intrathecal antisense has been employed to reduce 
expression of a variety of proalgesic mediators, including 
growth factor cellular matrix proteins (thrombospondin) 
[404] and receptors relevant to nociceptive processing, 
including the NK1 receptor for substance P [405], purines 
[372]; GFRα1, receptor for GDNF [406], NMDA receptors 
[407]; glutamate metabotrophic receptors [408-410], P2X3 
[411, 412], TrpV1 receptors [413], TrpV1 receptors [413], 
CCR2 (canonical receptor for MCP-1) [414], synaptic 
scaffolding proteins [415], a variety of kinases such as P38 
MAPK [416, 417], phospholipases [418], and a variety of 
channels including sodium (Nav1.8: [419, 420] and calcium 
channels (T-type: [421, 422]). Inactivating transcription 
factors by employing an oligonucleotide decoy protein 
represents an alternate approach to prevent activation 
otherwise initiated by a pain state [423]. 
 ii) Transfection by intrathecal delivery of viral vectors 
encoding a given protein or the use of nonviral methods  
such as nanoparticles or permeabilizing systems [403] can 
enhance the targeted protein expression in vivo. Several 
examples may be noted. i) Dorsal root ganglion neurons 
virally transduced with a vector coding for glutamic acid 
decarboxylase (QHGAD67) increase the release of spinal 
GABA to produce an analgesic effect [424-425]. ii) Animals 
displayed increased expression of endomorphin-2, an opioid 
peptide [426], or the preprohormone for enkephalin [427] or 
ß endorphin [428] after intrathecal vector transfection 
elevated thresholds. iii) The use of intrathecal viral vectors 
or plasmid delivery to increase appropriate antihyperalgesic 
targets has been shown to have utility. Thus, increased spinal 
expression of IL-10 (anti-inflammatory cytokine)or plasmid 
delivery was anti-hyperalgesic [424, 429-431]. Increasing 
MAPK (Mitogen activated protein kinase) phosphatase-1 
reduces activation of P38 MAPKs and this resulted in 
reduced nerve injury-evoked increases in inflammatory 
cytokines and chemokines and hyperalgesia [432]. Increased 
expression of the Ca
2+
 channel-binding domain 3 (CBD3) 
peptide blocks function of Ntype calcium channels and block 
nerve injury-induced hyperpathia [433]. Increased expression 
of the potassium channel Kv1.2 reduced nerve injury-
induced hyperpathia [434]. Transfecting small interfering 
RNAs can be used to reduce Nav1.7RNA and protein in 
DRG and reduce hyperpathia in diabetic rats [435]. An 
important issue is the ability of various viral vectors to 
transefect dorsal root ganglion cells vs.spinal parencyhma. 
After intrathecal delivery, DRG neurons are readily 
transfected wheras the transfection of spinal neurons appears 
restricted at best [436]. Issues related to the ability of viral 
particles to move into the parechnyma have been consideredas 
well as the use of direct intraparenchymal injections [437]. 
Here the potential role of the pia mater in establishing such a 
barrier to particulates and larger molecules in the CSF has 
been noted in humans and dogs [438-440]. Techniques to 
increasethat movement have been proposed,including the use 
of hypertonic solutions [441]. 
Future Issues of Intrathecal Delivery 
Intrathecal Drug Distribution 
 The effect of intrathecal local anesthetics upon sensory 
input reflects their interaction with sodium channels on the 
sensory root (or upon superficial long tracts). Other agents 
exerting their action at specific receptors or certain channels, 
such as those for the mu opiate, GABA-B agonist, the N-
type calcium channel, or agents such as substance P saporin 
targeting NK1 receptor-bearing cell bodies, must reach the 
appropriate sites to regulate the input from the root 
innervating a given dermatome. This required targeting 
poses several issues. 1) As reviewed above, these targeted 
sites lie largely on the terminal of the primary afferent and/or 
upon cells postsynaptic to the afferent input. Accordingly, at 
the least, we can appreciate that if these agents remain in the 
intrathecal sac, they, unlike local anesthetics, have an action 
upon coupled receptors that are present on the terminals of 
the axon or postsynaptic neurons. 2) Pain arising from a 
specific dermatome, myotome or sclerotome reflects afferent 
input from defined dorsal root ganglion cells. Importantly, 
after entry into the dorsal horn, the sensory afferent axon 
sends collaterals rostrally and caudally as far as 4-6 spinal 
segments [442, 443]. Thus, current thinking is that the input 
arising from any given dermatome represents an excitatory 
drive that is mediated in the dorsal horn not just at the spinal 
segment of entry, but also at levels up to several spinal 
segments in distance.3) Terminals of small sensory axons lie 
within the parenchyma (substantia gelatinosa) at depths 
ranging from 10-20µ (mouse and rat) to 200-300 mu in the 
dog and 500 mu in humans. Intrathecal (superficially 
applied) agents must diffuse into the parenchyma to reach 
these target sites. As diffusion from the surface to the 
presumed site of action is a time-dependent process that is 
proportional to distance, it is interesting to note that all 
things being equal for a given drug such as morphine, the 
time of onset is fastest in the mouse (2-3min) [444] and 
proportionally more delayed in larger animals (30 min in cat 
and dog) [445-447] to >1 hr in humans [448, 449]. 
Importantly, several variables define the ability of a drug to 
diffuse into tissue. Further, movement through lipid rich 
tissues is delayed for agents with low logP than for those 
with higher values. Thus, recording from deep dorsal horn 
(Lamina V) neurons in cat spinal dorsal horn, it was 
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demonstrated that time to onset of suppression of cell 
activity was greatest from morphine and least for fentanyl 
[450, 451], a finding that corresponds to the behavioral time 
course effects of these agents in preclinical models [446, 
447] and clinical experience [452]. A second variable 
reflects on the pathways for extracellular drug movement, 
referred to as tortuosity and based on diffusional studies. 
Large molecules typically display a more restricted 
movement than small molecules [453, 454]. 
 Accordingly, it is believed that for these membrane-
targeted agents to produce a change in spinal nociceptive 
processing generated by a peripheral stimulus or spasticity, 
the intrathecally infused drug must move rostrally and 
caudally a distance of several segments and must then 
diffuse into the parenchyma to reach the membrane targets. 
Modeling of the CSF space has emphasized that spinal CSF 
does not undergo major flow [455, 456] and, thus, intrathecal 
agents delivered at a low rate, such as 10-20 µL/hr (as 
required by implanted pumps of limited reservoir volumes), 
undergo limited redistribution. This limited redistribution of 
low volume infusions has been emphasized in large animal 
models [38, 457-459] and to some degree inhumans [460]. 
Drug Dosing 
 A consequence of the intrinsically poor intrathecal 
redistribution of low volume injectates is the need to 
increase drug concentration to drive rostrocaudal movement. 
This use of high concentrations in human pumps has led to 
local toxicity. For opiates, the manifestation of this toxicity 
is the intrathecal granuloma [37, 116, 461-463]. Our group 
showed that the primary determinant for intrathecal opiate 
granulomas is the local concentration to which the tissue 
adjacent to the catheter tip is exposed [49, 51, 52]. Even 
baclofen, which has no strong evidence of granuloma 
formation in humans, may have limitations in that regard  
if concentrations higher than the currently available 
formulation (2mg/mL) is employed ([464] but see [267]). 
Formulation 
 An important issue characteristic for neuraxial delivery 
are the formulation requirements. Typically, neuraxial 
formulations are water-based products with a pH between  
5-7 and osmolarity in the range of 300 mOsM with minimal 
adjuvants (e.g., surfactants, antioxidants or antimicrobial 
constituents) (see: [465, 466]). Few are generally regarded as 
safe vehicles. Surfactant/detergents (Tween, polyethylene glycol) 
or common solubilizing agents such as dimethylformamide 
or dimethylsulfoxide cannot be routinely considered as 
“safe” and evaluation of the safety of a spinal therapeutic 
employing such products must consider the potential  
direct tissue effects of the formulation at the specific 
concentrations being employed. It should also be appreciated 
that DMSO and other solvents can interact and solubilize 
various plastic-based hardware (e.g. catheters, syringes, 
tubing and plastics) used to administer the drug. The family 
of cyclodextrins has been widely employed preclinically  
for producing increased solubility and altered distribution  
of otherwise water insoluble agents [467-470]. Other 
formulation strategies, including liposome, microsphere and  
 
nanoparticle compounds, to enhance the duration of action 
and reduce peak concentrations of intrathecally-delivered 
agents have been proposed to permit single long-lasting drug 
delivery paradigms. Such systems have been described in ex 
vivo and in vivo work for baclofen [471, 472] (see [466] for 
review). 
Infusate Delivery Profile 
 Enhancement of redistribution may minimize the risk of 
local intrathecal drug concentration-based toxicity. Strategies 
for enhancing redistribution and, accordingly, reducing the 
concentration at the catheter tip can been proposed. A 
solution to this issue by changing delivery of the total daily 
infused to multiple bolus dosing may enhance the efficacy 
and reduce the potential toxicity associated with intrathecal 
therapeutics. In previous work in the dog, continuous 
delivery of a given dose of morphine at a high concentration 
yielded granulomas. Continuous infusion of the same dose at 
a lower concentration did not result in a granuloma [51]. 
Daily bolus delivery of the same total dose of morphine had 
no effect [49, 447]. Other strategies that may possess at least 
theoretical interest is the use of repetitive microboluses 
instead of a truly continuous infusion and the use of 
multiport small orifice catheters that would evenly distribute 
injectate over the length of the catheter rather than from a 
single port at the catheter tip. 
Device Compatibility 
 Implantable pumps require appropriate solution stability 
for the 4-6 weeks the pump is delivering. Stability of the 
solutions at body temperature and in the pump reservoir 
must be defined in the course of drug development. Further, 
formulations for continuous infusion require delivery by 
existing pump systems. High concentration solutions, extreme 
pH (e.g.,<3) and formulations or drug combinations may 
exert effects upon pumping mechanisms. Each manufacturer 
may have compatibility protocols that require consideration 
for drugs to be delivered by such devices and literature exists 
for some agents and agent combinations (see, for example: 
[473, 474]. Given the different mechanics of each pump 
(e.g., valved vs. peristaltic), compatibility in one pumping 
system dose not guarantee compatibility in another. 
Preclinical Assessments in Spinal Analgesic Drug 
Development 
 The rodent models have been useful in defining the 
pharmacology of spinal nociceptive processing. As noted 
above, however, the use of neuraxial drug delivery poses 
issues related to scaling of the volumes and kinetics of the 
intrathecal space. The issue of whether an intrathecal 
molecule can make its way to the target site in the 
parenchyma of humans is not readily defined in the much 
smaller rodent cords. This raises the need to define effects 
upon behavior and target engagement in a large spinal cord. 
Further, the FDA requirements for a drug progressing to 
approval mandates safety to be demonstrated in a large 
animal preclinical model in addition to small animal (rodent) 
models. Particularly with regard to pharmacokinetic profiles, 
large animal models such as dogs, sheep, and primates  
offer similar metabolic functions [458, 475]. Experimental  
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threshold models have been described for these species (see, 
for example, in dog [476-478] and in sheep [479, 480]. Such 
models, while useful, may not capture the complexities of 
the inflammatory/nerve injury pain states. Models of 
experimental injury such as joint injury in models of 
osteoarthritis are well described [481-485]. Of particular 
interest has been the growing implementation of clinical 
studies in companion animals and sheep suffering from 
natural pathologic processes accompanied by a pain 
condition. Such conditions in dogs include fore and hind 
limb osteosarcoma and osteoarthritis [486] and osteosarcoma 
[487]. Numerous scoring systems and scales are available for 
assessment of pain in animals, which range from simple 
descriptive scales, visual analogue scales, subjective verbal 
scales, numeric rating scale, and composite pain scales. 
Owner-completed questionnaires have been validated to 
assess the severity and impact of chronic pain syndromes in 
dogs with bone cancer and osteoarthritis [488]. Such 
inventories have been shown to be useful in defining the 
efficacy of a variety of spinal and [261, 384] systemic [489] 
therapies (see [490]. Strengths of such tools include its 
incorporation of animal behavior over a period of time as 
opposed to assessment once under the influence of an 
abnormal environment. Appropriate study design is essential 
in preclinical therapeutic assessment to ensure studies are 
carried out in a humane fashion with the effort to minimize 
the severity and duration of pain to that which is necessary 
for the information sought. Appropriate rescue therapeutics 
are incorporated into the study design as in human clinical 
trials to provide pre-emptive analgesia when at all possible, 
analgesia once the study endpoint is met or to provide rescue 
analgesia if pain is beyond the acceptable severity as 
determined by the study guidelines when pain is sustained in 
a study.   
Intrathecal Drug Safety Evaluation 
 A final issue to consider in developing a spinal agent is 
the need for specific preclinical safety evaluations 
employing this route of delivery. Issues of such safety 
evaluations have been extensively discussed [243, 244, 462, 
491]. Several specific guidelines will be outlined here. 
 i) At a minimum, drugs for neuraxial delivery must 
undergo preclinical safety assessments for the appropriate 
route (epidural/intrathecal) with the delivery motif proposed 
(e.g., bolus vs. continuous infusion) in functionally relevant 
large animal models (dog, sheep, primate), which have been 
shown to display drug responses in previous work. The use 
of large animals vs. small animals (e.g., rodent) reflects upon 
the issue of scaling of intrathecal volumes and kinetics 
across species particularly at the extremes. 
 ii) Study design must incorporate drug concentrations 
that meet or exceed those to be developed for human use and 
employ the respective formulation proposed for approval. 
Where feasible, the drug dosing should be shown to have 
appropriate target engagement (e.g., behavioral endpoints, 
CSF concentrations, and knock-out of target marker (e.g., 
receptor or enzyme protein). The development of such data 
is important not only because it demonstrates confirmatory 
effects in another species, it has the practical benefit of being 
able to show the safety data studies to be constructed so as to 
define safety as multiples of a therapeutically effective dose 
in a large spinal cord (see, for example [390]). 
 iii) In the development of chronically delivered agents, 
the minimum length of exposure profiles should be 1-3 
months to ensure that long-term safety is demonstrated. 
 iv) Systemic safety must also be demonstrated for drugs 
or compounds administered spinally. Neuraxially delivered 
drugs undergo local distribution into the CSF. Flow patterns 
are largely influenced by respiratory and cardiovascular 
cycles (respirations and pulsations, respectively) with drug 
uptake into spinal cord tissue or into the meninges ultimately 
occurring. Elimination of spinally-administered drugs 
eventually occurs through the systemic circulation, thus 
systemic effects and plasma concentrations must be 
measured to demonstrate systemic safety. 
 v) The principle characteristic separating pharmacological 
investigation from one defining safety study is the 
implementation of systematic histopathology of the target 
tissues (see [492]). An important implication of the above 
commentary is that because of the peculiar nature of the 
intrathecal space as regards local and persistent exposure is 
that changes in drug delivery profile (bolus vs. infusion), 
volume or rate of drug delivery and most certainly formulation 
(pH/osmolarity/ionic or additive content) and most certainly 
concentration must be considered as defining variables for 
the characterization of potential toxicity. Our experience 
with alterations in these variables for intrathecally delivered 
drugs (e.g., opiates and local anesthetics) emphasizes that 
such changes can have clear impacts upon the assertion of 
safety of the formulation. 
 vi) Adult versus neonate. Finally, it has long been 
appreciated that neuraxial anesthesia and pain management 
therapies are relevant to the neonatal and pediatric population. 
The current concerns over the effects of general anesthetics 
on neural development in the young population has increased 
the focus on the neuraxial route. Yet, there has been a 
paucity of data to indicate the relative safety of neuraxial 
anesthetics in the same population (see [196, 493-496]. Given 
issues of pathway development and synaptic connectivity, 
assessment of the effects of neuraxial agents on concurrent 
and future spinal function must be considered in further 
application of analgesics and analgesic agents to this space 
[491]. 
SUMMARY 
 In summary, the spinal delivery of therapeutic  
agents reflects upon the role played by the spinal cord in a 
number of sensory and motor functions and the diverse 
pharmacological components that are associated with these 
systems. The initial demonstration of spinal catheterization 
in the rodent provided a robust model to assess the effects of 
drugs with an action limited to the spinal cord on behavioral 
function [497, 498]. The robust and selective effects of 
spinal opiates on pain behavior first shown in this rodent 
model (and the growing understanding of the complex 
algorithms that encode the input-output relationships in the 
spinal dorsal horn has resulted in exciting advances in the 
management of these adverse sensations, which, upon arrival 
at higher centers, initiate the pain experience. 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    245 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no 
conflict of interest. 
ACKNOWLEDGEMENTS 
 Declared none. 
REFERENCES 
[1] Price, D.D. Psychological and neural mechanisms of the affective 
dimension of pain. Science, 2000, 288(5472), 1769-1772. [http:// 
dx.doi.org/10.1126/science.288.5472.1769] [PMID: 10846154] 
[2] Tracey, I.; Mantyh, P.W. The cerebral signature for pain perception 
and its modulation. Neuron, 2007, 55(3), 377-391. [http://dx.doi. 
org/10.1016/j.neuron.2007.07.012] [PMID: 17678852] 
[3] Vierck, C.J.; Whitsel, B.L.; Favorov, O.V.; Brown, A.W.; 
Tommerdahl, M. Role of primary somatosensory cortex in the 
coding of pain. Pain, 2013, 154(3), 334-344. [http://dx.doi.org/ 
10.1016/j.pain.2012.10.021] [PMID: 23245864] 
[4] Peyron, R.; Laurent, B.; Garcia-Larrea, L. Functional imaging of 
brain responses to pain. A review and meta-analysis. Clin. 
Neurophysiol., 2000, 30(5), 263-288. [http://dx.doi.org/10.1016/ 
S0987-7053(00)00227-6] 
[5] Asghar, M.S.; Pereira, M.P.; Werner, M.U.; Mårtensson, J.; 
Larsson, H.B.; Dahl, J.B. Correction: Secondary Hyperalgesia 
Phenotypes Exhibit Differences in Brain Activation during 
Noxious Stimulation. PLoS One, 2015, 10(5), e0128640. [http://dx. 
doi.org/10.1371/journal.pone.0128640] [PMID: 25978430] 
[6] Benson, S.; Rebernik, L.; Wegner, A.; Kleine-Borgmann, J.; Engler, 
H.; Schlamann, M.; Forsting, M.; Schedlowski, M.; Elsenbruch, S. 
Neural circuitry mediating inflammation-induced central pain 
amplification in human experimental endotoxemia. Brain Behav. 
Immun., 2015, 48, 222-231. [http://dx.doi.org/10.1016/j.bbi.2015. 
03.017] [PMID: 25882910] 
[7] Treede, R.D.; Meyer, R.A.; Raja, S.N.; Campbell, J.N. Peripheral 
and central mechanisms of cutaneous hyperalgesia. Prog. Neurobiol., 
1992, 38(4), 397-421. [http://dx.doi.org/10.1016/0301-0082(92) 
90027-C] [PMID: 1574584] 
[8] Kuner, R. Central mechanisms of pathological pain. Nat. Med., 
2010, 16(11), 1258-1266. [http://dx.doi.org/10.1038/nm.2231] [PMID: 
20948531] 
[9] West, S.J.; Bannister, K.; Dickenson, A.H.; Bennett, D.L. Circuitry 
and plasticity of the dorsal horntoward a better understanding of 
neuropathic pain. Neuroscience, 2015, 300, 254-275. [http://dx.doi. 
org/10.1016/j.neuroscience.2015.05.020] [PMID: 25987204] 
[10] Yaksh, T.L.; Woller, S.A.; Ramachandran, R.; Sorkin, L.S. The search 
for novel analgesics: targets and mechanisms. F1000Prime Rep., 
2015, 7, 56. [http://dx.doi.org/10.12703/P7-56] [PMID: 26097729] 
[11] Ji, R.R.; Xu, Z.Z.; Gao, Y.J. Emerging targets in neuro- 
inflammation-driven chronic pain. Nat. Rev. Drug Discov., 2014, 
13(7), 533-548. [http://dx.doi.org/10.1038/nrd4334] [PMID: 24948120] 
[12] Reina, M.A.; Villanueva, M.C.; Machés, F.; Carrera, A.; López, A.; 
De Andrés, J.A. The ultrastructure of the human spinal nerve root 
cuff in the lumbar spine. Anesth. Analg., 2008, 106(1), 339-344. 
[table of contents.]. [http://dx.doi.org/10.1213/01.ane.0000295803. 
31074.dc] [PMID: 18165601] 
[13] Pollay, M. The function and structure of the cerebrospinal fluid 
outflow system. Cerebrospinal Fluid Res., 2010, 7, 9. 
[http://dx.doi.org/10.1186/1743-8454-7-9] [PMID: 20565964] 
[14] Tonra, J.R.; Mendell, L.M. Rabbit IgG distribution in skin, spinal 
cord and DRG following systemic injection in rat. J. Neuroimmunol., 
1997, 80(1-2), 97-105. [http://dx.doi.org/10.1016/S0165-5728(97) 
00140-9] [PMID: 9413264] 
[15] McLachlan, E.M.; Jänig, W.; Devor, M.; Michaelis, M. Peripheral 
nerve injury triggers noradrenergic sprouting within dorsal root 
ganglia. Nature, 1993, 363(6429), 543-546. [http://dx.doi.org/ 
10.1038/363543a0] [PMID: 8505981] 
[16] Stevens, C.W. Opioid research in amphibians: an alternative pain 
model yielding insights on the evolution of opioid receptors. Brain 
Res. Brain Res. Rev., 2004, 46(2), 204-215. [http://dx.doi.org/ 
10.1016/j.brainresrev.2004.07.003] [PMID: 15464208] 
[17] Yaksh, T.L. Pharmacology and mechanisms of opioid analgesic 
activity. Acta Anaesthesiol. Scand., 1997, 41(1 Pt 2), 94-111. [http:// 
dx.doi.org/10.1111/j.1399-6576.1997.tb04623.x] [PMID: 9061092] 
[18] Yaksh, T.L. Spinal opiate analgesia: characteristics and principles 
of action. Pain, 1981, 11(3), 293-346. [http://dx.doi.org/10.1016/ 
0304-3959(81)90633-3] [PMID: 6276842] 
[19] Williams, J.T.; Ingram, S.L.; Henderson, G.; Chavkin, C.; von 
Zastrow, M.; Schulz, S.; Koch, T.; Evans, C.J.; Christie, M.J. 
Regulation of μ-opioid receptors: desensitization, phosphorylation, 
internalization, and tolerance. Pharmacol. Rev., 2013, 65(1), 223-
254. [http://dx.doi.org/10.1124/pr.112.005942] [PMID: 23321159] 
[20] Laduron, P.M. Axonal transport of opiate receptors in capsaicin-
sensitive neurones. Brain Res., 1984, 294(1), 157-160. [http://dx. 
doi.org/10.1016/0006-8993(84)91322-2] [PMID: 6199089] 
[21] Zhang, Q.; Schäffer, M.; Elde, R.; Stein, C. Effects of neurotoxins 
and hindpaw inflammation on opioid receptor immunoreactivities 
in dorsal root ganglia. Neuroscience, 1998, 85(1), 281-291. [http:// 
dx.doi.org/10.1016/S0306-4522(97)00647-7] [PMID: 9607719] 
[22] Le Bars, D.; Menétrey, D.; Conseiller, C.; Besson, J.M. Depressive 
effects of morphine upon lamina V cells activities in the dorsal horn 
of the spinal cat. Brain Res., 1975, 98(2), 261-277. [http://dx.doi. 
org/10.1016/0006-8993(75)90005-0] [PMID: 171029] 
[23] Duggan, A.W.; Hall, J.G.; Headley, P.M. Suppression of trans- 
mission of nociceptive impulses by morphine: selective effects of 
morphine administered in the region of the substantia gelatinosa. 
Br. J. Pharmacol., 1977, 61(1), 65-76. [http://dx.doi.org/10.1111/ 
j.1476-5381.1977.tb09740.x] [PMID: 199311] 
[24] Yaksh, T.L. Inhibition by etorphine of the discharge of dorsal horn 
neurons: effects on the neuronal response to both high- and low-
threshold sensory input in the decerebrate spinal cat. Exp. Neurol., 
1978, 60(1), 23-40. [http://dx.doi.org/10.1016/0014-4886(78)90166-
8] [PMID: 658193] 
[25] Dickenson, A.H.; Sullivan, A.F. Electrophysiological studies on the 
effects of intrathecal morphine on nociceptive neurones in the rat 
dorsal horn. Pain, 1986, 24(2), 211-222. [http://dx.doi.org/10.1016/ 
0304-3959(86)90044-8] [PMID: 3754322] 
[26] Kondo, I.; Marvizon, J.C.; Song, B.; Salgado, F.; Codeluppi, S.; 
Hua, X.Y.; Yaksh, T.L. Inhibition by spinal mu- and delta-opioid 
agonists of afferent-evoked substance P release. J. Neurosci., 2005, 
25(14), 3651-3660. [http://dx.doi.org/10.1523/JNEUROSCI.0252-
05.2005] [PMID: 15814796] 
[27] Yaksh, T.L.; Jessell, T.M.; Gamse, R.; Mudge, A.W.; Leeman, S.E. 
Intrathecal morphine inhibits substance P release from mammalian 
spinal cord in vivo. Nature, 1980, 286(5769), 155-157. [http://dx. 
doi.org/10.1038/286155a0] [PMID: 6157098] 
[28] McQuay, H.J.; Moore, R.A. Urinary retention following spinal 
opiates. Anesthesiology, 1988, 69(3), 441-442. [http://dx.doi.org/ 
10.1097/00000542-198809000-00042] [PMID: 2901241] 
[29] Atchison, S.R.; Durant, P.A.; Yaksh, T.L. Cardiorespiratory effects 
and kinetics of intrathecally injected D-Ala2-D-Leu5-enkephalin 
and morphine in unanesthetized dogs. Anesthesiology, 1986, 65(6), 
609-616. [http://dx.doi.org/10.1097/00000542-198612000-00008] 
[PMID: 3098139] 
[30] Sultan, P.; Gutierrez, M.C.; Carvalho, B. Neuraxial morphine and 
respiratory depression: finding the right balance. Drugs, 2011, 
71(14), 1807-1819. [http://dx.doi.org/10.2165/11596250-000000000-
00000] [PMID: 21942973] 
[31] Stevens, C.W.; Yaksh, T.L. Time course characteristics of tolerance 
development to continuously infused antinociceptive agents in rat 
spinal cord. J. Pharmacol. Exp. Ther., 1989, 251(1), 216-223. 
[PMID: 2795458] 
[32] Gu, G.; Kondo, I.; Hua, X.Y.; Yaksh, T.L. Resting and evoked 
spinal substance P release during chronic intrathecal morphine 
infusion: parallels with tolerance and dependence. J. Pharmacol. 
Exp. Ther., 2005, 314(3), 1362-1369. [http://dx.doi.org/10.1124/ 
jpet.105.087718] [PMID: 15908510] 
[33] Yaksh, T.L.; Onofrio, B.M. Retrospective consideration of the 
doses of morphine given intrathecally by chronic infusion in 163 
patients by 19 physicians. Pain, 1987, 31(2), 211-223. [http://dx. 
doi.org/10.1016/0304-3959(87)90037-6] [PMID: 3431881] 
[34] Anderson, V.C.; Burchiel, K.J. A prospective study of long-term 
intrathecal morphine in the management of chronic nonmalignant 
pain. Neurosurgery, 1999, 44(2), 289-300. [http://dx.doi.org/ 
10.1097/00006123-199902000-00026] [PMID: 9932882] 
246    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
[35] Shaladi, A.; Saltari, M.R.; Piva, B.; Crestani, F.; Tartari, S.; Pinato, 
P.; Micheletto, G.; DallAra, R. Continuous intrathecal morphine 
infusion in patients with vertebral fractures due to osteoporosis. 
Clin. J. Pain, 2007, 23(6), 511-517. [http://dx.doi.org/10.1097/AJP. 
0b013e31806a23d4] [PMID: 17575491] 
[36] Duarte, R.V.; Raphael, J.H.; Haque, M.S.; Southall, J.L.; Ashford, 
R.L. A predictive model for intrathecal opioid dose escalation for 
chronic non-cancer pain. Pain Phys., 2012, 15(5), 363-369. [PMID: 
22996848] 
[37] Prager, J.; Deer, T.; Levy, R.; Bruel, B.; Buchser, E.; Caraway, D.; 
Cousins, M.; Jacobs, M.; McGlothlen, G.; Rauck, R.; Staats, P.; 
Stearns, L. Best practices for intrathecal drug delivery for  
pain. Neuromodulation, 2014, 17(4), 354-372. 
[38] Ummenhofer, W.C.; Arends, R.H.; Shen, D.D.; Bernards, C.M. 
Comparative spinal distribution and clearance kinetics of intra- 
thecally administered morphine, fentanyl, alfentanil, and sufentanil. 
Anesthesiology, 2000, 92(3), 739-753. [http://dx.doi.org/10.1097/ 
00000542-200003000-00018] [PMID: 10719953] 
[39] Bernards, C.M. Understanding the physiology and pharmacology of 
epidural and intrathecal opioids. Best Pract. Res. Clin. Anaesthesiol., 
2002, 16(4), 489-505. [http://dx.doi.org/10.1053/bean.2002.0255] 
[PMID: 12516887] 
[40] Bernards, C.M. Recent insights into the pharmacokinetics of spinal 
opioids and the relevance to opioid selection. Curr. Opin. 
Anaesthesiol., 2004, 17(5), 441-447. [http://dx.doi.org/10.1097/ 
00001503-200410000-00015] [PMID: 17023903] 
[41] Ruan, X. Drug-related side effects of long-term intrathecal 
morphine therapy. Pain Phys., 2007, 10(2), 357-366. [PMID: 
17387357] 
[42] Deer, T. R.; Levy, R.; Prager, J.; Buchser, E.; Burton, A.; Caraway, 
D.; Cousins, M.; De Andres, J.; Diwan, S.; Erdek, M.; Grigsby, E.; 
Huntoon, M.; Jacobs, M. S.; Kim, P.; Kumar, K.; Leong, M.; Liem, 
L.; McDowell, G. C., 2nd; Panchal, S.; Rauck, R.; Saulino, M.; 
Sitzman, B. T.; Staats, P.; Stanton-Hicks, M.; Stearns, L.; Wallace, 
M.; Willis, K. D.; Witt, W.; Yaksh, T.; Mekhail, N. Polyanalgesic 
Consensus Conference--2012: recommendations to reduce 
morbidity and mortality in intrathecal drug delivery in the 
treatment of chronic pain. Neuromodulation, 2012, 15(5), 467-482. 
[43] Yaksh, T.; Wallace, M.S. Opioids, analgesia, and pain 
management. In: Goodman & Gilman’s The Pharmacological 
Basis of Therapeutics; Brunton, L.; Chabner, B.; Knollman, B., 
Eds.; McGraw -Hill Medical: New York, 2011; pp. 481-526. 
[44] de Groat, W.C. Anatomy of the central neural pathways controlling 
the lower urinary tract. Eur. Urol., 1998, 34(Suppl. 1), 2-5. [http:// 
dx.doi.org/10.1159/000052265] [PMID: 9705544] 
[45] Durant, P.A.; Yaksh, T.L. Drug effects on urinary bladder tone 
during spinal morphine-induced inhibition of the micturition reflex 
in unanesthetized rats. Anesthesiology, 1988, 68(3), 325-334. [http:// 
dx.doi.org/10.1097/00000542-198803000-00002] [PMID: 3344988] 
[46] Herman, R.M.; Wainberg, M.C.; delGiudice, P.F.; Willscher, M.K. 
The effect of a low dose of intrathecal morphine on impaired 
micturition reflexes in human subjects with spinal cord lesions. 
Anesthesiology, 1988, 69(3), 313-318. [http://dx.doi.org/10.1097/ 
00000542-198809000-00005] [PMID: 3415012] 
[47] Levy, J.H.; Brister, N.W.; Shearin, A.; Ziegler, J.; Hug, C.C., Jr; 
Adelson, D.M.; Walker, B.F. Wheal and flare responses to opioids 
in humans. Anesthesiology, 1989, 70(5), 756-760. [http://dx.doi. 
org/10.1097/00000542-198905000-00008] [PMID: 2470272] 
[48] Kumar, K.; Singh, S.I. Neuraxial opioid-induced pruritus: An 
update. J. Anaesthesiol. Clin. Pharmacol., 2013, 29(3), 303-307. 
[http://dx.doi.org/10.4103/0970-9185.117045] [PMID: 24106351] 
[49] Yaksh, T.L.; Horais, K.A.; Tozier, N.A.; Allen, J.W.; Rathbun, M.; 
Rossi, S.S.; Sommer, C.; Meschter, C.; Richter, P.J.; Hildebrand, 
K.R. Chronically infused intrathecal morphine in dogs. 
Anesthesiology, 2003, 99(1), 174-187. [http://dx.doi.org/10.1097/ 
00000542-200307000-00028] [PMID: 12826858] 
[50] Gradert, T.L.; Baze, W.B.; Satterfield, W.C.; Hildebrand, K.R.; 
Johansen, M.J.; Hassenbusch, S.J. Safety of chronic intrathecal 
morphine infusion in a sheep model. Anesthesiology, 2003, 99(1), 
188-198. [http://dx.doi.org/10.1097/00000542-200307000-00029] 
[PMID: 12826859] 
[51] Allen, J.W.; Horais, K.A.; Tozier, N.A.; Wegner, K.; Corbeil, J.A.; 
Mattrey, R.F.; Rossi, S.S.; Yaksh, T.L. Time course and role of 
morphine dose and concentration in intrathecal granuloma 
formation in dogs: a combined magnetic resonance imaging and 
histopathology investigation. Anesthesiology, 2006, 105(3), 581-
589. [http://dx.doi.org/10.1097/00000542-200609000-00024] [PMID: 
16931993] 
[52] Allen, J.W.; Horais, K.A.; Tozier, N.A.; Yaksh, T.L. Opiate 
pharmacology of intrathecal granulomas. Anesthesiology, 2006, 
105(3), 590-598. [http://dx.doi.org/10.1097/00000542-200609000-
00025] [PMID: 16931994] 
[53] Yaksh, T. L.; Steinauer, J. J.; Veesart, S. L.; Malkmus, S. A. 
Alfentanil: Correlations Between Absence of Effect Upon 
Subcutaneous Mast Cells and Absence of Granuloma Formation 
After Intrathecal Infusion in the Dog. Neuromodulation, 2013, 
16(5), 459-466. 
[54] Yaksh, T.L.; Allen, J.W.; Veesart, S.L.; Horais, K.A.; Malkmus, 
S.A.; Scadeng, M.; Steinauer, J.J.; Rossi, S.S. Role of meningeal 
mast cells in intrathecal morphine-evoked granuloma formation. 
Anesthesiology, 2013, 118(3), 664-678. [http://dx.doi.org/10.1097/ 
ALN.0b013e31828351aa] [PMID: 23426209] 
[55] Michael, A.; Buffen, E.; Rauck, R.; Anderson, W.; McGirt, M.; 
Mendenhall, H.V. An in vivo canine study to assess granulomatous 
responses in the MedStream Programmable Infusion System (TM) 
and the SynchroMed II Infusion System®. Pain Med., 2012, 13(2), 
175-184. [http://dx.doi.org/10.1111/j.1526-4637.2011.01308.x] 
[PMID: 22239738] 
[56] Johansen, M.J.; Satterfield, W.C.; Baze, W.B.; Hildebrand, K.R.; 
Gradert, T.L.; Hassenbusch, S.J. Continuous intrathecal infusion of 
hydromorphone: safety in the sheep model and clinical implications. 
Pain Med., 2004, 5(1), 14-25. [http://dx.doi.org/10.1111/j.1526-
4637.2004.04010.x] [PMID: 14996233] 
[57] Deer, T. R.; Prager, J.; Levy, R.; Rathmell, J.; Buchser, E.; Burton, 
A.; Caraway, D.; Cousins, M.; De Andres, J.; Diwan, S.; Erdek, 
M.; Grigsby, E.; Huntoon, M.; Jacobs, M. S.; Kim, P.; Kumar, K.; 
Leong, M.; Liem, L.; McDowell, G. C., 2nd; Panchal, S.; Rauck, 
R.; Saulino, M.; Sitzman, B. T.; Staats, P.; Stanton-Hicks, M.; 
Stearns, L.; Wallace, M.; Willis, K. D.; Witt, W.; Yaksh, T.; 
Mekhail, N. Polyanalgesic Consensus Conference--2012: consensus 
on diagnosis, detection, and treatment of catheter-tip granulomas 
(inflammatory masses). Neuromodulation, 2012, 15(5), 483-495. 
[58] Law, P.Y.; Reggio, P.H.; Loh, H.H. Opioid receptors: toward 
separation of analgesic from undesirable effects. Trends Biochem. 
Sci., 2013, 38(6), 275-282. [http://dx.doi.org/10.1016/j.tibs.2013. 
03.003] [PMID: 23598157] 
[59] Pasternak, G.W. Opioids and their receptors: Are we there yet? 
Neuropharmacology, 2014, 76(Pt B), 198-203. [http://dx.doi.org/ 
10.1016/j.neuropharm.2013.03.039] [PMID: 23624289] 
[60] Lamberts, J.T.; Traynor, J.R. Opioid receptor interacting proteins and 
the control of opioid signaling. Curr. Pharm. Des., 2013, 19(42), 
7333-7347. [http://dx.doi.org/10.2174/138161281942140105160625] 
[PMID: 23448476] 
[61] Raehal, K.M.; Bohn, L.M. β -arrestins: regulatory role and 
therapeutic potential in opioid and cannabinoid receptor-mediated 
analgesia. Handbook Exp. Pharmacol., 2014, 219, 427-443. [http:// 
dx.doi.org/10.1007/978-3-642-41199-1_22] [PMID: 24292843] 
[62] Violin, J.D.; Crombie, A.L.; Soergel, D.G.; Lark, M.W. Biased 
ligands at G protein-coupled receptors: promise and progress (vol 
35, pg 308, 2014). Trends Pharmacol. Sci., 2014, 35(9), 489-489. 
[http://dx.doi.org/10.1016/j.tips.2014.07.005] 
[63] Alfaras-Melainis, K.; Gomes, I.; Rozenfeld, R.; Zachariou, V.; 
Devi, L. Modulation of opioid receptor function by protein-protein 
interactions. Front. Biosci. (Landmark Ed.), 2009, 14, 3594-3607. 
[http://dx.doi.org/10.2741/3474] [PMID: 19273296] 
[64] Fujita, W.; Gomes, I.; Devi, L.A. Heteromers of μ-δ opioid 
receptors: new pharmacology and novel therapeutic possibilities. 
Br. J. Pharmacol., 2015, 172(2), 375-387. [http://dx.doi.org/10. 
1111/bph.12663] [PMID: 24571499] 
[65] Bird, M.F.; Lambert, D.G. Simultaneous targeting of multiple 
opioid receptor types. Curr. Opin. Support. Palliat. Care, 2015, 
9(2), 98-102. [http://dx.doi.org/10.1097/SPC.0000000000000129] 
[PMID: 25872121] 
[66] Le Naour, M.; Akgün, E.; Yekkirala, A.; Lunzer, M.M.; Powers, 
M.D.; Kalyuzhny, A.E.; Portoghese, P.S. Bivalent ligands that 
target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent 
analgesics devoid of tolerance. J. Med. Chem., 2013, 56(13), 5505-
5513. [http://dx.doi.org/10.1021/jm4005219] [PMID: 23734559] 
[67] Smeester, B.A.; Lunzer, M.M.; Akgün, E.; Beitz, A.J.; Portoghese, 
P.S. Targeting putative mu opioid/metabotropic glutamate receptor-
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    247 
5 heteromers produces potent antinociception in a chronic murine 
bone cancer model. Eur. J. Pharmacol., 2014, 743, 48-52. [http:// 
dx.doi.org/10.1016/j.ejphar.2014.09.008] [PMID: 25239072] 
[68] Akgün, E.; Javed, M.I.; Lunzer, M.M.; Smeester, B.A.; Beitz, A.J.; 
Portoghese, P.S. Ligands that interact with putative MOR-mGluR5 
heteromer in mice with inflammatory pain produce potent anti- 
nociception. Proc. Natl. Acad. Sci. USA, 2013, 110(28), 11595-11599. 
[http://dx.doi.org/10.1073/pnas.1305461110] [PMID: 23798416] 
[69] Normandin, A.; Luccarini, P.; Molat, J.L.; Gendron, L.; Dallel, R. 
Spinal μ and δ opioids inhibit both thermal and mechanical pain in 
rats. J. Neurosci., 2013, 33(28), 11703-11714. [http://dx.doi.org/ 
10.1523/JNEUROSCI.1631-13.2013] [PMID: 23843537] 
[70] Tung, A.S.; Yaksh, T.L. In vivo evidence for multiple opiate 
receptors mediating analgesia in the rat spinal cord. Brain Res., 
1982, 247(1), 75-83. [http://dx.doi.org/10.1016/0006-8993(82)91029-
0] [PMID: 6127147] 
[71] Porreca, F.; Heyman, J.S.; Mosberg, H.I.; Omnaas, J.R.; Vaught, 
J.L. Role of mu and delta receptors in the supraspinal and spinal 
analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse. J. 
Pharmacol. Exp. Ther., 1987, 241(2), 393-400. [PMID: 3033214] 
[72] Stewart, P.E.; Hammond, D.L. Activation of spinal delta-1 or delta-
2 opioid receptors reduces carrageenan-induced hyperalgesia in the 
rat. J. Pharmacol. Exp. Ther., 1994, 268(2), 701-708. [PMID: 
8113981] 
[73] Nagasaka, H.; Yaksh, T.L. Effects of intrathecal mu, delta, and 
kappa agonists on thermally evoked cardiovascular and nociceptive 
reflexes in halothane-anesthetized rats. Anesth. Analg., 1995, 80(3), 
437-443. [PMID: 7864404] 
[74] Kouchek, M.; Takasusuki, T.; Terashima, T.; Yaksh, T.L.; Xu, Q. 
Effects of intrathecal SNC80, a delta receptor ligand, on nociceptive 
threshold and dorsal horn substance p release. J. Pharmacol. Exp. 
Ther., 2013, 347(2), 258-264. [http://dx.doi.org/10.1124/jpet.113. 
206573] [PMID: 23978562] 
[75] Russell, R.D.; Leslie, J.B.; Su, Y.F.; Watkins, W.D.; Chang, K.J. 
Continuous intrathecal opioid analgesia: tolerance and cross-
tolerance of mu and delta spinal opioid receptors. J. Pharmacol. 
Exp. Ther., 1987, 240(1), 150-158. [PMID: 3027302] 
[76] Stevens, C.W.; Yaksh, T.L. Studies of morphine and D-ala2- 
D-leu5-enkephalin (DADLE) cross-tolerance after continuous 
intrathecal infusion in the rat. Anesthesiology, 1992, 76(4), 596-
603. [http://dx.doi.org/10.1097/00000542-199204000-00017] [PMID: 
1550284] 
[77] Joseph, E.K.; Levine, J.D. Mu and delta opioid receptors on 
nociceptors attenuate mechanical hyperalgesia in rat. Neuroscience, 
2010, 171(1), 344-350. [http://dx.doi.org/10.1016/j.neuroscience. 
2010.08.035] [PMID: 20736053] 
[78] Scherrer, G.; Imamachi, N.; Cao, Y.Q.; Contet, C.; Mennicken, F.; 
ODonnell, D.; Kieffer, B.L.; Basbaum, A.I. Dissociation of the 
opioid receptor mechanisms that control mechanical and heat pain. 
Cell, 2009, 137(6), 1148-1159. [http://dx.doi.org/10.1016/j.cell. 
2009.04.019] [PMID: 19524516] 
[79] Bardoni, R.; Tawfik, V.L.; Wang, D.; François, A.; Solorzano, C.; 
Shuster, S.A.; Choudhury, P.; Betelli, C.; Cassidy, C.; Smith, K.; 
de Nooij, J.C.; Mennicken, F.; ODonnell, D.; Kieffer, B.L.; 
Woodbury, C.J.; Basbaum, A.I.; MacDermott, A.B.; Scherrer,  
G. Delta opioid receptors presynaptically regulate cutaneous 
mechanosensory neuron input to the spinal cord dorsal horn. 
Neuron, 2014, 81(6), 1312-1327. [http://dx.doi.org/10.1016/j. 
neuron.2014.01.044] [PMID: 24583022] 
[80] Yaksh, T.L. Substance P release from knee joint afferent terminals: 
modulation by opioids. Brain Res., 1988, 458(2), 319-324. [http:// 
dx.doi.org/10.1016/0006-8993(88)90474-X] [PMID: 2463049] 
[81] Aimone, L.D.; Yaksh, T.L. Opioid modulation of capsaicin-evoked 
release of substance P from rat spinal cord in vivo. Peptides, 1989, 
10(6), 1127-1131. [http://dx.doi.org/10.1016/0196-9781(89)90003-
X] [PMID: 2482963] 
[82] Beaudry, H.; Dubois, D.; Gendron, L. Activation of spinal mu-  
and delta-opioid receptors potently inhibits substance P release 
induced by peripheral noxious stimuli. J. Neurosci., 2011, 31(37), 
13068-13077. [http://dx.doi.org/10.1523/JNEUROSCI.1817-11.2011] 
[PMID: 21917790] 
[83] Onofrio, B.M.; Yaksh, T.L. Intrathecal delta-receptor ligand produces 
analgesia in man. Lancet, 1983, 1(8338), 1386-1387. [http://dx.doi. 
org/10.1016/S0140-6736(83)92170-0] [PMID: 6134164] 
[84] Moulin, D.E.; Max, M.B.; Kaiko, R.F.; Inturrisi, C.E.; Maggard, J.; 
Yaksh, T.L.; Foley, K.M. The analgesic efficacy of intrathecal D-
Ala2-D-Leu5-enkephalin in cancer patients with chronic pain. 
Pain, 1985, 23(3), 213-221. [http://dx.doi.org/10.1016/0304-
3959(85)90099-5] [PMID: 3906516] 
[85] Shimoyama, M.; Shimoyama, N.; Zhao, G.M.; Schiller, P.W.; 
Szeto, H.H. Antinociceptive and respiratory effects of intrathecal 
H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA. J. 
Pharmacol. Exp. Ther., 2001, 297(1), 364-371. [PMID: 11259564] 
[86] Svensson, C.I.; Rew, Y.; Malkmus, S.; Schiller, P.W.; Taulane, 
J.P.; Goodman, M.; Yaksh, T.L. Systemic and spinal analgesic 
activity of a delta-opioid-selective lanthionine enkephalin analog. 
J. Pharmacol. Exp. Ther., 2003, 304(2), 827-832. [http://dx.doi. 
org/10.1124/jpet.102.039750] [PMID: 12538839] 
[87] Yaksh, T.L. Pharmacology of spinal adrenergic systems which 
modulate spinal nociceptive processing. Pharmacol. Biochem. 
Behav., 1985, 22(5), 845-858. [http://dx.doi.org/10.1016/0091-
3057(85)90537-4] [PMID: 2861606] 
[88] Pertovaara, A. The noradrenergic pain regulation system:  
a potential target for pain therapy. Eur. J. Pharmacol., 2013,  
716(1-3), 2-7. [http://dx.doi.org/10.1016/j.ejphar.2013.01.067] [PMID: 
23500194] 
[89] Ruffolo, R.R., Jr; Hieble, J.P. Alpha-adrenoceptors. Pharmacol. 
Ther., 1994, 61(1-2), 1-64. [http://dx.doi.org/10.1016/0163-7258 
(94)90058-2] [PMID: 7938167] 
[90] Nicholson, R.; Dixon, A.K.; Spanswick, D.; Lee, K. Noradrenergic 
receptor mRNA expression in adult rat superficial dorsal horn and 
dorsal root ganglion neurons. Neurosci. Lett., 2005, 380(3), 316-321. 
[http://dx.doi.org/10.1016/j.neulet.2005.01.079] [PMID: 15862909] 
[91] Stone, L.S.; Broberger, C.; Vulchanova, L.; Wilcox, G.L.; Hökfelt, 
T.; Riedl, M.S.; Elde, R. Differential distribution of alpha2A and 
alpha2C adrenergic receptor immunoreactivity in the rat spinal 
cord. J. Neurosci., 1998, 18(15), 5928-5937. [PMID: 9671679] 
[92] Pan, Y.Z.; Li, D.P.; Pan, H.L. Inhibition of glutamatergic synaptic 
input to spinal lamina II(o) neurons by presynaptic alpha(2)-
adrenergic receptors. J. Neurophysiol., 2002, 87(4), 1938-1947. 
[http://dx.doi.org/10.1152/jn.00575.2001] [PMID: 11929913] 
[93] Kawasaki, Y.; Kumamoto, E.; Furue, H.; Yoshimura, M. Alpha 2 
adrenoceptor-mediated presynaptic inhibition of primary afferent 
glutamatergic transmission in rat substantia gelatinosa neurons. 
Anesthesiology, 2003, 98(3), 682-689. [http://dx.doi.org/10.1097/ 
00000542-200303000-00016] [PMID: 12606912] 
[94] Sonohata, M.; Furue, H.; Katafuchi, T.; Yasaka, T.; Doi, A.; 
Kumamoto, E.; Yoshimura, M. Actions of noradrenaline on 
substantia gelatinosa neurones in the rat spinal cord revealed by in 
vivo patch recording. J. Physiol., 2004, 555(Pt 2), 515-526. [http:// 
dx.doi.org/10.1113/jphysiol.2003.054932] [PMID: 14673188] 
[95] Millan, M.J. Descending control of pain. Prog. Neurobiol., 2002, 
66(6), 355-474. [http://dx.doi.org/10.1016/S0301-0082(02)00009-
6] [PMID: 12034378] 
[96] Nazarian, A.; Christianson, C.A.; Hua, X.Y.; Yaksh, T.L. 
Dexmedetomidine and ST-91 analgesia in the formalin model is 
mediated by alpha2A-adrenoceptors: a mechanism of action 
distinct from morphine. Br. J. Pharmacol., 2008, 155(7), 1117-
1126. [http://dx.doi.org/10.1038/bjp.2008.341] [PMID: 18846040] 
[97] Yaksh, T.L.; Pogrel, J.W.; Lee, Y.W.; Chaplan, S.R. Reversal of 
nerve ligation-induced allodynia by spinal alpha-2 adrenoceptor 
agonists. J. Pharmacol. Exp. Ther., 1995, 272(1), 207-214. [PMID: 
7815335] 
[98] Takano, Y.; Yaksh, T.L. Characterization of the pharmacology of 
intrathecally administered alpha-2 agonists and antagonists in rats. J. 
Pharmacol. Exp. Ther., 1992, 261(2), 764-772. [PMID: 1349648] 
[99] Yaksh, T.L.; Hua, X.Y.; Kalcheva, I.; Nozaki-Taguchi, N.; Marsala, 
M. The spinal biology in humans and animals of pain states 
generated by persistent small afferent input. Proc. Natl. Acad. Sci. 
USA, 1999, 96(14), 7680-7686. [http://dx.doi.org/10.1073/pnas.96. 
14.7680] [PMID: 10393880] 
[100] Levy, R.; Leiphart, J.; Dills, C. Analgesic action of acute and 
chronic intraspinally administered opiate and alpha 2-adrenergic 
agonists in chronic neuropathic pain. Stereotact. Funct. Neurosurg., 
1994, 62(1-4), 279-289. [http://dx.doi.org/10.1159/000098633] 
[PMID: 7631082] 
[101] Stevens, C.W.; Monasky, M.S.; Yaksh, T.L. Spinal infusion of 
opiate and alpha-2 agonists in rats: tolerance and cross-tolerance 
248    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
studies. J. Pharmacol. Exp. Ther., 1988, 244(1), 63-70. [PMID: 
2891846] 
[102] Capogna, G.; Celleno, D.; Zangrillo, A.; Costantino, P.; Foresta, S. 
Addition of clonidine to epidural morphine enhances postoperative 
analgesia after cesarean delivery. Reg. Anesth., 1995, 20(1), 57-61. 
[PMID: 7727330] 
[103] Engelman, E.; Marsala, C. Efficacy of adding clonidine to 
intrathecal morphine in acute postoperative pain: meta-analysis. Br. 
J. Anaesth., 2013, 110(1), 21-27. [http://dx.doi.org/10.1093/bja/ 
aes344] [PMID: 23002167] 
[104] Yaksh, T.L.; Rathbun, M.; Jage, J.; Mirzai, T.; Grafe, M.;  
Hiles, R.A. Pharmacology and toxicology of chronically infused 
epidural clonidine. HCl in dogs. Fundam. App. Toxicol., 1994, 
23(3), 319-335. 
[105] Dowlatshahi, P.; Yaksh, T.L. Differential effects of two intra- 
ventricularly injected alpha 2 agonists, ST-91 and dexmedetomidine, 
on electroencephalogram, feeding, and electromyogram. Anesth. 
Analg., 1997, 84(1), 133-138. [http://dx.doi.org/10.1213/00000539-
199701000-00025] [PMID: 8989014] 
[106] Buerkle, H.; Boschin, M.; Marcus, M.A.; Brodner, G.; Wüsten, R.; 
Van Aken, H. Central and peripheral analgesia mediated by the 
acetylcholinesterase-inhibitor neostigmine in the rat inflamed knee 
joint model. Anesth. Analg., 1998, 86(5), 1027-1032. [http://dx. 
doi.org/10.1213/00000539-199805000-00023] [PMID: 9585291] 
[107] Knaus, A.E.; Muthig, V.; Schickinger, S.; Moura, E.; Beetz, N.; 
Gilsbach, R.; Hein, L. Alpha2-adrenoceptor subtypesunexpected 
functions for receptors and ligands derived from gene-targeted 
mouse models. Neurochem. Int., 2007, 51(5), 277-281. [http://dx. 
doi.org/10.1016/j.neuint.2007.06.036] [PMID: 17664025] 
[108] Bier, A. Experiments regarding the cocainization of the spinal cord. 
Dtsch Z Chir, 1899, 51, 361-369. [http://dx.doi.org/10.1007/ 
BF02792160] 
[109] Matas, R. Local and regional anesthesiawith cocaine and other 
analgesic drugs, including the subarachnoid method, as applied in 
the general surgical practice. Phil. Med. J., 1900, 6, 820-843. 
[110] Vandam, L.D. On the origins of intrathecal anesthesia. Reg. Anesth. 
Pain Med., 1998, 23(4), 335-339. [PMID: 9690581] 
[111] Akerman, B.; Arweström, E.; Post, C. Local anesthetics potentiate 
spinal morphine antinociception. Anesth. Analg., 1988, 67(10), 
943-948. [PMID: 3421498] 
[112] Penning, J.P.; Yaksh, T.L. Interaction of intrathecal morphine with 
bupivacaine and lidocaine in the rat. Anesthesiology, 1992, 77(6), 
1186-2000. [http://dx.doi.org/10.1097/00000542-199212000-00021] 
[PMID: 1466469] 
[113] Saito, Y.; Kaneko, M.; Kirihara, Y.; Sakura, S.; Kosaka, Y. 
Interaction of intrathecally infused morphine and lidocaine in rats 
(part I): synergistic antinociceptive effects. Anesthesiology, 1998, 
89(6), 1455-1463. [http://dx.doi.org/10.1097/00000542-199812000-
00023] [PMID: 9856720] 
[114] Wu, H.H.; Yin, J.B.; Zhang, T.; Cui, Y.Y.; Dong, Y.L.; Chen, G.Z.; 
Wang, W. Inhibiting spinal neuron-astrocytic activation correlates 
with synergistic analgesia of dexmedetomidine and ropivacaine. 
PLoS One, 2014, 9(3), e92374. [http://dx.doi.org/10.1371/journal. 
pone.0092374] [PMID: 24658263] 
[115] Stocks, G.M.; Hallworth, S.P.; Fernando, R.; England, A.J.; 
Columb, M.O.; Lyons, G. Minimum local analgesic dose of 
intrathecal bupivacaine in labor and the effect of intrathecal 
fentanyl. Anesthesiology, 2001, 94(4), 593-598. [http://dx.doi.org/ 
10.1097/00000542-200104000-00011] 
[116] Deer, T.; Krames, E.S.; Hassenbusch, S.J.; Burton, A.; Caraway, 
D.; Dupen, S.; Eisenach, J.; Erdek, M.; Grigsby, E.; Kim, P.; Levy, 
R.; McDowell, G.; Mekhail, N.; Panchal, S.; Prager, J.; Rauck, R.; 
Saulino, M.; Sitzman, T.; Staats, P.; Stanton-Hicks, M.; Stearns, L.; 
Willis, K.D.; Witt, W.; Follett, K.; Huntoon, M.; Liem, L.; 
Rathmell, J.; Wallace, M.; Buchser, E.; Cousins, M. Polyanalgesic 
consensus conference 2007: recommendations for the management 
of pain by intrathecal (intraspinal) drug delivery: report of an inter- 
disciplinary expert panel. Neuromodulation, 2007, 10(4), 300-328. 
[117] Veizi, I.E.; Hayek, S.M.; Narouze, S.; Pope, J.E.; Mekhail, N. 
Combination of intrathecal opioids with bupivacaine attenuates 
opioid dose escalation in chronic noncancer pain patients. Pain 
Med., 2011, 12(10), 1481-1489. [http://dx.doi.org/10.1111/j.1526-
4637.2011.01232.x] [PMID: 21943351] 
[118] Mercadante, S.; Villari, P.; Ferrera, P.; Arcuri, E. Local anesthetic 
switching for intrathecal tachyphylaxis in cancer patients with pain. 
Anesth. Analg., 2003, 97(1), 187-189. [http://dx.doi.org/10.1213/ 
01.ANE.0000067403.15926.BD] [PMID: 12818964] 
[119] Kongsgaard, U.E.; Werner, M.U. Tachyphylaxis to local anaesthetics. 
What is the clinical evidence? A systematic review. Acta Anaesthesiol. 
Scand., 2015. [PMID: 26358179] 
[120] Strichartz, G.R. Neural Physiology and Local Anesthetic Action. 
In: Neural Blockade in Clinical Anesthesia and Management of 
Pain, CMaB, P.; Lippincot-Raven: Philadelphia, PA, 1998.  
[121] Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International Union 
of Pharmacology. XLVII. Nomenclature and structure-function 
relationships of voltage-gated sodium channels. Pharmacol. Rev., 
2005, 57(4), 397-409. [http://dx.doi.org/10.1124/pr.57.4.4] [PMID: 
16382098] 
[122] Gokin, A.P.; Philip, B.; Strichartz, G.R. Preferential block of small 
myelinated sensory and motor fibers by lidocaine: in vivo 
electrophysiology in the rat sciatic nerve. Anesthesiology, 2001, 
95(6), 1441-1454. [http://dx.doi.org/10.1097/00000542-200112000-
00025] [PMID: 11748404] 
[123] Scholz, A. Mechanisms of (local) anaesthetics on voltage-gated 
sodium and other ion channels. Br. J. Anaesth., 2002, 89(1), 52-61. 
[http://dx.doi.org/10.1093/bja/aef163] [PMID: 12173241] 
[124] Docherty, R.J.; Farmer, C.E. The pharmacology of voltage-gated 
sodium channels in sensory neurones. Handbook Exp. Pharmacol., 
2009, 194(194), 519-561. [http://dx.doi.org/10.1007/978-3-540-79090-
7_15] [PMID: 19655117] 
[125] Stoney, S.D., Jr Limitations on impulse conduction at the  
branch point of afferent axons in frog dorsal root ganglion.  
Exp. Brain Res., 1990, 80(3), 512-524. [http://dx.doi.org/10.1007/ 
BF00227992] [PMID: 2387351] 
[126] Theile, J.W.; Cummins, T.R. Recent developments regarding 
voltage-gated sodium channel blockers for the treatment of 
inherited and acquired neuropathic pain syndromes. Front. 
Pharmacol., 2011, 2, 54. [http://dx.doi.org/10.3389/fphar.2011. 
00054] [PMID: 22007172] 
[127] Wang, W.; Gu, J.; Li, Y.Q.; Tao, Y.X. Are voltage-gated sodium 
channels on the dorsal root ganglion involved in the development 
of neuropathic pain? Mol. Pain, 2011, 7, 16. [http://dx.doi.org/ 
10.1186/1744-8069-7-16] [PMID: 21345196] 
[128] Nieto, F.R.; Cobos, E.J.; Tejada, M.A.; Sánchez-Fernández, C.; 
González-Cano, R.; Cendán, C.M. Tetrodotoxin (TTX) as a 
therapeutic agent for pain. Mar. Drugs, 2012, 10(2), 281-305. 
[http://dx.doi.org/10.3390/md10020281] [PMID: 22412801] 
[129] Aurilio, C.; Pota, V.; Pace, M.C.; Passavanti, M.B.; Barbarisi, M. 
Ionic channels and neuropathic pain: physiopathology and 
applications. J. Cell. Physiol., 2008, 215(1), 8-14. [http://dx.doi. 
org/10.1002/jcp.21280] [PMID: 18205177] 
[130] Liu, M.; Wood, J.N. The roles of sodium channels in nociception: 
implications for mechanisms of neuropathic pain. Pain Med., 2011, 
12(Suppl. 3), S93-S99. [http://dx.doi.org/10.1111/j.1526-4637. 
2011.01158.x] [PMID: 21752183] 
[131] Kharatmal, S.B.; Singh, J.N.; Sharma, S.S. Voltage-Gated Sodium 
Channels as Therapeutic Targets for Treatment of Painful Diabetic 
Neuropathy. Mini Rev. Med. Chem., 2015, 15(14), 1134-1147. 
[http://dx.doi.org/10.2174/1389557515666150722112621] [PMID: 
26202189] 
[132] Waxman, S.G. Painful Na-channelopathies: an expanding universe. 
Trends Mol. Med., 2013, 19(7), 406-409. [http://dx.doi.org/10. 
1016/j.molmed.2013.04.003] [PMID: 23664154] 
[133] Brouwer, B.A.; Merkies, I.S.; Gerrits, M.M.; Waxman, S.G.; 
Hoeijmakers, J.G.; Faber, C.G. Painful neuropathies: the emerging 
role of sodium channelopathies. J. Peripher. Nerv. Syst., 2014, 19(2), 
53-65. [http://dx.doi.org/10.1111/jns5.12071] [PMID: 25250524] 
[134] Yanagidate, F.; Strichartz, G.R. Local anesthetics. Handbook Exp. 
Pharmacol., 2007, (177), 95-127. [PMID: 17087121] 
[135] Lirk, P.; Picardi, S.; Hollmann, M.W. Local anaesthetics: 10 
essentials. Eur. J. Anaesthesiol., 2014, 31(11), 575-585. [http://dx. 
doi.org/10.1097/EJA.0000000000000137] [PMID: 25192265] 
[136] Zaric, D.; Christiansen, C.; Pace, N.L.; Punjasawadwong, Y. 
Transient neurologic symptoms after spinal anesthesia with 
lidocaine versus other local anesthetics: a systematic review of 
randomized, controlled trials. Anesth. Analg., 2005, 100(6), 1811-
1816. [http://dx.doi.org/10.1213/01.ANE.0000136844.87857.78] 
[PMID: 15920219] 
[137] Yamashita, A.; Matsumoto, M.; Matsumoto, S.; Itoh, M.; Kawai, 
K.; Sakabe, T. A comparison of the neurotoxic effects on the spinal 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    249 
cord of tetracaine, lidocaine, bupivacaine, and ropivacaine 
administered intrathecally in rabbits. Anesth. Analg., 2003, 97(2), 
512-519. [table of contents.]. [http://dx.doi.org/10.1213/01.ANE. 
0000068885.78816.5B] [PMID: 12873946] 
[138] Guo, J.; Lv, N.; Su, Y.; Liu, Y.; Zhang, J.; Yang, D. Effects of 
intrathecal anesthesia with different concentrations and doses on 
spinal cord, nerve roots and cerebrospinal fluid in dogs. Int. J. Clin. 
Exp. Med., 2014, 7(12), 5376-5384. [PMID: 25664046] 
[139] Sakura, S.; Bollen, A.W.; Ciriales, R.; Drasner, K. Local anesthetic 
neurotoxicity does not result from blockade of voltage-gated sodium 
channels. Anesth. Analg., 1995, 81(2), 338-346. [PMID: 7618726] 
[140] Kitagawa, N.; Oda, M.; Nobutaka, I.; Satoh, H.; Totoki, T.; 
Morimoto, M. A proposed mechanism for amitriptyline neurotoxicity 
based on its detergent nature. Toxicol. Appl. Pharmacol., 2006, 
217(1), 100-106. [http://dx.doi.org/10.1016/j.taap.2006.08.003] [PMID: 
16978678] 
[141] Gold, M.S.; Reichling, D.B.; Hampl, K.F.; Drasner, K.; Levine, 
J.D. Lidocaine toxicity in primary afferent neurons from the rat. J. 
Pharmacol. Exp. Ther., 1998, 285(2), 413-421. [PMID: 9580578] 
[142] England, S.; de Groot, M.J. Subtype-selective targeting of voltage-
gated sodium channels. Br. J. Pharmacol., 2009, 158(6), 1413-
1425. [http://dx.doi.org/10.1111/j.1476-5381.2009.00437.x] [PMID: 
19845672] 
[143] Clare, J.J. Targeting voltage-gated sodium channels for pain therapy. 
Expert Opin. Investig. Drugs, 2010, 19(1), 45-62. [http://dx.doi. 
org/10.1517/13543780903435340] [PMID: 20001554] 
[144] Schmalhofer, W.A.; Calhoun, J.; Burrows, R.; Bailey, T.; Kohler, 
M.G.; Weinglass, A.B.; Kaczorowski, G.J.; Garcia, M.L.; 
Koltzenburg, M.; Priest, B.T. ProTx-II, a selective inhibitor of 
NaV1.7 sodium channels, blocks action potential propagation in 
nociceptors. Mol. Pharmacol., 2008, 74(5), 1476-1484. [http://dx. 
doi.org/10.1124/mol.108.047670] [PMID: 18728100] 
[145] Moon, J.Y.; Song, S.; Yoon, S.Y.; Roh, D.H.; Kang, S.Y.; Park, 
J.H.; Beitz, A.J.; Lee, J.H. The differential effect of intrathecal 
Nav1.8 blockers on the induction and maintenance of capsaicin- 
and peripheral ischemia-induced mechanical allodynia and thermal 
hyperalgesia. Anesth. Analg., 2012, 114(1), 215-223. [http://dx.doi. 
org/10.1213/ANE.0b013e318238002e] [PMID: 22127815] 
[146] Iwamoto, T.; Takasugi, Y.; Higashino, H.; Ito, H.; Koga, Y.; 
Nakao, S. Antinociceptive action of carbamazepine on thermal 
hypersensitive pain at spinal level in a rat model of adjuvant-
induced chronic inflammation. J. Anesth., 2011, 25(1), 78-86. 
[http://dx.doi.org/10.1007/s00540-010-1046-7] [PMID: 21113631] 
[147] Tan, A.M.; Samad, O.A.; Dib-Hajj, S.D.; Waxman, S.G. Virus-
mediated knockdown of Nav1.3 in dorsal root ganglia of STZ-
induced diabetic rats alleviates tactile allodynia. Mol. Med., 2015, 
21, 544-552. [http://dx.doi.org/10.2119/molmed.2015.00063] [PMID: 
26101954] 
[148] Pan, J.; Lin, X.J.; Ling, Z.H.; Cai, Y.Z. Effect of down-regulation 
of voltage-gated sodium channel Nav1.7 on activation of astrocytes 
and microglia in DRG in rats with cancer pain. Asian Pac. J. Trop. 
Med., 2015, 8(5), 405-411. [http://dx.doi.org/10.1016/S1995-
7645(14)60352-7] [PMID: 26003602] 
[149] Yin, R.; Liu, D.; Chhoa, M.; Li, C.M.; Luo, Y.; Zhang, M.; Lehto, 
S.G.; Immke, D.C.; Moyer, B.D. Voltage-gated sodium channel 
function and expression in injured and uninjured rat dorsal root 
ganglia neurons. Int. J. Neurosci., 2015. [PMID: 25562420] 
[150] Roberson, D.P.; Binshtok, A.M.; Blasl, F.; Bean, B.P.; Woolf, C.J. 
Targeting of sodium channel blockers into nociceptors to produce 
long-duration analgesia: a systematic study and review. Br. J. 
Pharmacol., 2011, 164(1), 48-58. [http://dx.doi.org/10.1111/j. 
1476-5381.2011.01391.x] [PMID: 21457220] 
[151] Schwarz, S.K.; Cheung, H.M.; Ries, C.R.; Lee, S.M.; Wang, J.T.; 
MacLeod, B.A. Lumbar intrathecal administration of the 
quaternary lidocaine derivative, QX-314, produces irritation and 
death in mice. Anesthesiology, 2010, 113(2), 438-444. [http://dx. 
doi.org/10.1097/ALN.0b013e3181dfd31b] [PMID: 20613478] 
[152] Takeda, M.; Tsuboi, Y.; Kitagawa, J.; Nakagawa, K.; Iwata, K.; 
Matsumoto, S. Potassium channels as a potential therapeutic target 
for trigeminal neuropathic and inflammatory pain. Mol. Pain, 2011, 
7, 5. [http://dx.doi.org/10.1186/1744-8069-7-5] [PMID: 21219657] 
[153] Du, X.; Gamper, N. Potassium channels in peripheral pain 
pathways: expression, function and therapeutic potential. Curr. 
Neuropharmacol., 2013, 11(6), 621-640. [http://dx.doi.org/10.2174/ 
1570159X113119990042] [PMID: 24396338] 
[154] Tsantoulas, C.; McMahon, S.B. Opening paths to novel analgesics: 
the role of potassium channels in chronic pain. Trends Neurosci., 
2014, 37(3), 146-158. [http://dx.doi.org/10.1016/j.tins.2013.12.002] 
[PMID: 24461875] 
[155] Olivera, B.M.; Miljanich, G.P.; Ramachandran, J.; Adams, M.E. 
Calcium channel diversity and neurotransmitter release: the omega-
conotoxins and omega-agatoxins. Annu. Rev. Biochem., 1994, 63, 
823-867. [http://dx.doi.org/10.1146/annurev.bi.63.070194.004135] 
[PMID: 7979255] 
[156] Chaplan, S.R.; Pogrel, J.W.; Yaksh, T.L. Role of voltage-
dependent calcium channel subtypes in experimental tactile 
allodynia. J. Pharmacol. Exp. Ther., 1994, 269(3), 1117-1123. [PMID: 
8014856] 
[157] Malmberg, A.B.; Yaksh, T.L. Voltage-sensitive calcium channels 
in spinal nociceptive processing: blockade of N- and P-type 
channels inhibits formalin-induced nociception. J. Neurosci., 1994, 
14(8), 4882-4890. [PMID: 8046458] 
[158] Scott, D.A.; Wright, C.E.; Angus, J.A. Actions of intrathecal 
omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute 
and neuropathic pain in the rat. Eur. J. Pharmacol., 2002, 451(3), 
279-286. [http://dx.doi.org/10.1016/S0014-2999(02)02247-1] [PMID: 
12242089] 
[159] Snutch, T.P. Targeting chronic and neuropathic pain: the N-type 
calcium channel comes of age. NeuroRx: J. Am. Soc. Exper. 
NeuroTherapeutics, 2005, 2(4), 662-670. 
[160] Adams, D.J.; Callaghan, B.; Berecki, G. Analgesic conotoxins: 
block and G protein-coupled receptor modulation of N-type (Ca(V) 
2.2) calcium channels. Br. J. Pharmacol., 2012, 166(2), 486-500. 
[http://dx.doi.org/10.1111/j.1476-5381.2011.01781.x] [PMID: 
22091786] 
[161] Murali, S.S.; Napier, I.A.; Mohammadi, S.A.; Alewood, P.F.; 
Lewis, R.J.; Christie, M.J. High-voltage-activated calcium current 
subtypes in mouse DRG neurons adapt in a subpopulation-specific 
manner after nerve injury. J. Neurophysiol., 2015, 113(5), 1511-1519. 
[http://dx.doi.org/10.1152/jn.00608.2014] [PMID: 25505111] 
[162] Schroeder, C.I.; Doering, C.J.; Zamponi, G.W.; Lewis, R.J. N-type 
calcium channel blockers: novel therapeutics for the treatment of 
pain. Med. Chem., 2006, 2(5), 535-543. [http://dx.doi.org/10.2174/ 
157340606778250216] [PMID: 17017994] 
[163] Malmberg, A.B.; Yaksh, T.L. Effect of continuous intrathecal 
infusion of omega-conopeptides, N-type calcium-channel blockers, 
on behavior and antinociception in the formalin and hot-plate tests 
in rats. Pain, 1995, 60(1), 83-90. [http://dx.doi.org/10.1016/0304-
3959(94)00094-U] [PMID: 7715945] 
[164] Hama, A.; Sagen, J. Antinociceptive effects of the marine snail 
peptides conantokin-G and conotoxin MVIIA alone and in 
combination in rat models of pain. Neuropharmacology, 2009, 
56(2), 556-563. [http://dx.doi.org/10.1016/j.neuropharm.2008.10. 
008] [PMID: 19010337] 
[165] Chen, S.R.; Wess, J.; Pan, H.L. Functional activity of the M2 and 
M4 receptor subtypes in the spinal cord studied with muscarinic 
acetylcholine receptor knockout mice. J. Pharmacol. Exp. Ther., 
2005, 313(2), 765-770. [http://dx.doi.org/10.1124/jpet.104.082537] 
[PMID: 15665136] 
[166] Skov, M.J.; Beck, J.C.; de Kater, A.W.; Shopp, G.M. Nonclinical 
safety of ziconotide: an intrathecal analgesic of a new pharmaceutical 
class. Int. J. Toxicol., 2007, 26(5), 411-421. [http://dx.doi.org/ 
10.1080/10915810701582970] [PMID: 17963128] 
[167] Chu, Y.X.; Zhang, Y.; Zhang, Y.Q.; Zhao, Z.Q. Involvement of 
microglial P2X7 receptors and downstream signaling pathways in 
long-term potentiation of spinal nociceptive responses. Brain 
Behav. Immun., 2010, 24(7), 1176-1189. [http://dx.doi.org/10.1016/ 
j.bbi.2010.06.001] [PMID: 20554014] 
[168] Feldman, P.; Khanna, R. Challenging the catechism of therapeutics 
for chronic neuropathic pain: Targeting CaV2.2 interactions with 
CRMP2 peptides. Neurosci. Lett., 2013, 557 Pt A, 27-36. 
[169] Bourinet, E.; Altier, C.; Hildebrand, M.E.; Trang, T.; Salter, M.W.; 
Zamponi, G.W. Calcium-permeable ion channels in pain signaling. 
Physiol. Rev., 2014, 94(1), 81-140. [http://dx.doi.org/10.1152/ 
physrev.00023.2013] [PMID: 24382884] 
[170] Terashima, T.; Xu, Q.; Yamaguchi, S.; Yaksh, T.L. Intrathecal 
P/Q- and R-type calcium channel blockade of spinal substance  
P release and c-Fos expression. Neuropharmacology, 2013, 75,  
1-8. [http://dx.doi.org/10.1016/j.neuropharm.2013.06.018] [PMID: 
23810829] 
250    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
[171] Cheng, J.K.; Lin, C.S.; Chen, C.C.; Yang, J.R.; Chiou, L.C. Effects 
of intrathecal injection of T-type calcium channel blockers in the 
rat formalin test. Behav. Pharmacol., 2007, 18(1), 1-8. [http://dx. 
doi.org/10.1097/FBP.0b013e3280141375] [PMID: 17218792] 
[172] Takasusuki, T.; Yaksh, T.L. Regulation of spinal substance p 
release by intrathecal calcium channel blockade. Anesthesiology, 
2011, 115(1), 153-164. [http://dx.doi.org/10.1097/ALN.0b013 
e31821950c2] [PMID: 21577088] 
[173] Dalmolin, G.D.; Silva, C.R.; Rigo, F.K.; Gomes, G.M.; Cordeiro, 
Mdo.N.; Richardson, M.; Silva, M.A.; Prado, M.A.; Gomez, M.V.; 
Ferreira, J. Antinociceptive effect of Brazilian armed spider venom 
toxin Tx33 in animal models of neuropathic pain. Pain, 2011, 
152(10), 2224-2232. [http://dx.doi.org/10.1016/j.pain.2011.04.015] 
[PMID: 21570770] 
[174] Dogrul, A.; Gardell, L.R.; Ossipov, M.H.; Tulunay, F.C.; Lai, J.; 
Porreca, F. Reversal of experimental neuropathic pain by T-type 
calcium channel blockers. Pain, 2003, 105(1-2), 159-168. [http:// 
dx.doi.org/10.1016/S0304-3959(03)00177-5] [PMID: 14499432] 
[175] Partridge, B.J.; Chaplan, S.R.; Sakamoto, E.; Yaksh, T.L. 
Characterization of the effects of gabapentin and 3-isobutyl-
gamma-aminobutyric acid on substance P-induced thermal hyper- 
algesia. Anesthesiology, 1998, 88(1), 196-205. [http://dx.doi.org/ 
10.1097/00000542-199801000-00028] [PMID: 9447873] 
[176] Jun, J.H.; Yaksh, T.L. The effect of intrathecal gabapentin and 3-
isobutyl gamma-aminobutyric acid on the hyperalgesia observed 
after thermal injury in the rat. Anesth. Analg., 1998, 86(2), 348-
354. [PMID: 9459247] 
[177] Chu, L.C.; Tsaur, M.L.; Lin, C.S.; Hung, Y.C.; Wang, T.Y.; Chen, 
C.C.; Cheng, J.K. Chronic intrathecal infusion of gabapentin 
prevents nerve ligation-induced pain in rats. Br. J. Anaesth., 2011, 
106(5), 699-705. [http://dx.doi.org/10.1093/bja/aer063] [PMID: 
21441243] 
[178] Dong, L.; Crosby, N.D.; Winkelstein, B.A. Gabapentin alleviates 
facet-mediated pain in the rat through reduced neuronal 
hyperexcitability and astrocytic activation in the spinal cord. J. 
Pain, 2013, 14(12), 1564-1572. [http://dx.doi.org/10.1016/j.jpain. 
2013.07.016] [PMID: 24094695] 
[179] Rauck, R.; Coffey, R.J.; Schultz, D.M.; Wallace, M.S.; Webster, 
L.R.; McCarville, S.E.; Grigsby, E.J.; Page, L.M. Intrathecal gabapentin 
to treat chronic intractable noncancer pain. Anesthesiology, 2013, 
119(3), 675-686. [http://dx.doi.org/10.1097/ALN.0b013e3182a10fbf] 
[PMID: 23835590] 
[180] Sluka, K.A. Pain mechanisms involved in musculoskeletal disorders. 
J. Orthop. Sports Phys. Ther., 1996, 24(4), 240-254. [http://dx.doi. 
org/10.2519/jospt.1996.24.4.240] [PMID: 8892139] 
[181] Zhou, H.Y.; Chen, S.R.; Pan, H.L. Targeting N-methyl-D-aspartate 
receptors for treatment of neuropathic pain. Expert Rev. Clin. 
Pharmacol., 2011, 4(3), 379-388. [http://dx.doi.org/10.1586/ecp. 
11.17] [PMID: 21686074] 
[182] Benrath, J.; Scharbert, G.; Gustorff, B.; Adams, H.A.; Kress, H.G. 
Long-term intrathecal S(+)-ketamine in a patient with cancer-
related neuropathic pain. Br. J. Anaesth., 2005, 95(2), 247-249. 
[http://dx.doi.org/10.1093/bja/aei158] [PMID: 15951328] 
[183] Glasgow, N.G.; Siegler Retchless, B.; Johnson, J.W. Molecular 
bases of NMDA receptor subtype-dependent properties. J. Physiol., 
2015, 593(1), 83-95. [http://dx.doi.org/10.1113/jphysiol.2014.273763] 
[PMID: 25556790] 
[184] Mendell, L.M. Physiological properties of unmyelinated fiber 
projection to the spinal cord. Exp. Neurol., 1966, 16(3), 316-332. 
[http://dx.doi.org/10.1016/0014-4886(66)90068-9] [PMID: 5928985] 
[185] Davies, S.N.; Lodge, D. Evidence for involvement of N-
methylaspartate receptors in wind-up of class 2 neurones in the 
dorsal horn of the rat. Brain Res., 1987, 424(2), 402-406. [http://dx. 
doi.org/10.1016/0006-8993(87)91487-9] [PMID: 2823998] 
[186] Dickenson, A.H.; Sullivan, A.F. Evidence for a role of the NMDA 
receptor in the frequency dependent potentiation of deep rat dorsal 
horn nociceptive neurones following C fibre stimulation. Neuro- 
pharmacology, 1987, 26(8), 1235-1238. [http://dx.doi.org/ 
10.1016/0028-3908(87)90275-9] [PMID: 2821443] 
[187] Price, T.J.; Ghosh, S. ZIPping to pain relief: the role (or not) of 
PKMζ in chronic pain. Mol. Pain, 2013, 9, 6. [http://dx.doi.org/ 
10.1186/1744-8069-9-6] [PMID: 23433248] 
[188] Edelmayer, R.M.; Brederson, J.D.; Jarvis, M.F.; Bitner, R.S. 
Biochemical and pharmacological assessment of MAP-kinase 
signaling along pain pathways in experimental rodent models: a 
potential tool for the discovery of novel antinociceptive therapeutics. 
Biochem. Pharmacol., 2014, 87(3), 390-398. [http://dx.doi.org/ 
10.1016/j.bcp.2013.11.019] [PMID: 24300134] 
[189] Chahine, M.; OLeary, M.E. Regulation/modulation of sensory 
neuron sodium channels. Handbook Exp. Pharmacol., 2014, 221, 
111-135. [http://dx.doi.org/10.1007/978-3-642-41588-3_6] [PMID: 
24737234] 
[190] Luo, X.Q.; Cai, Q.Y.; Chen, Y.; Guo, L.X.; Chen, A.Q.; Wu, Z.Q.; 
Lin, C. Tyrosine phosphorylation of the NR2B subunit of the 
NMDA receptor in the spinal cord contributes to chronic visceral 
pain in rats. Brain Res., 2014, 1542, 167-175. [http://dx.doi.org/ 
10.1016/j.brainres.2013.10.008] [PMID: 24125810] 
[191] Chaplan, S.R.; Malmberg, A.B.; Yaksh, T.L. Efficacy of spinal 
NMDA receptor antagonism in formalin hyperalgesia and nerve 
injury evoked allodynia in the rat. J. Pharmacol. Exp. Ther., 1997, 
280(2), 829-838. [PMID: 9023297] 
[192] Yamamoto, T.; Yaksh, T.L. Spinal pharmacology of thermal 
hyperesthesia induced by constriction injury of sciatic nerve. 
Excitatory amino acid antagonists. Pain, 1992, 49(1), 121-128. 
[http://dx.doi.org/10.1016/0304-3959(92)90198-K] [PMID: 1594273] 
[193] Coderre, T.J. Potent analgesia induced in rats by combined action 
at PCP and polyamine recognition sites of the NMDA receptor 
complex. Eur. J. Neurosci., 1993, 5(4), 390-393. [http://dx.doi.org/ 
10.1111/j.1460-9568.1993.tb00506.x] [PMID: 7903188] 
[194] Coderre, T.J.; Vanempel, I. (Eaa) Antagonists as Analgesic Agents. 
2. Assessment of the Antinociceptive Activity of Combinations of 
Competitive and Noncompetitive NMDA Antagonists with Agents 
Acting at Allosteric-Glycine and Polyamine Receptor-Sites. Pain, 
1994, 59(3), 353-359. [http://dx.doi.org/10.1016/0304-3959(94)90021-
3] [PMID: 7708409] 
[195] Rojas, A.C.; Alves, J.G.; Moreira, E.; Lima, R.; Esther Alencar 
Marques, M.; Moreira de Barros, G.A.; Fukushima, F.B.; Modolo, 
N.S.; Ganem, E.M. The effects of subarachnoid administration of 
preservative-free S(+)-ketamine on spinal cord and meninges in 
dogs. Anesth. Analg., 2012, 114(2), 450-455. [http://dx.doi.org/ 
10.1213/ANE.0b013e31823a5d1b] [PMID: 22167772] 
[196] Walker, S.M.; Westin, B.D.; Deumens, R.; Grafe, M.; Yaksh, T.L. 
Effects of intrathecal ketamine in the neonatal rat: evaluation of 
apoptosis and long-term functional outcome. Anesthesiology, 2010, 
113(1), 147-159. [http://dx.doi.org/10.1097/ALN.0b013e3181dcd71c] 
[PMID: 20526188] 
[197] Vranken, J.H.; Troost, D.; de Haan, P.; Pennings, F.A.; van der 
Vegt, M.H.; Dijkgraaf, M.G.; Hollmann, M.W. Severe toxic 
damage to the rabbit spinal cord after intrathecal administration of 
preservative-free S(+)-ketamine. Anesthesiology, 2006, 105(4), 
813-818. [http://dx.doi.org/10.1097/00000542-200610000-00028] 
[PMID: 17006081] 
[198] Yaksh, T.L.; Tozier, N.; Horais, K.A.; Malkmus, S.; Rathbun, M.; 
Lafranco, L.; Eisenach, J. Toxicology profile of N-methyl-D-
aspartate antagonists delivered by intrathecal infusion in the canine 
model. Anesthesiology, 2008, 108(5), 938-949. [http://dx.doi.org/ 
10.1097/ALN.0b013e31816c902a] [PMID: 18431131] 
[199] Hassenbusch, S.J.; Satterfield, W.C.; Gradert, T.L.; Binhazim, 
A.W.; Ahad, G.; Mokhtarzadeh, M.; Schapiro, S.J.; Payne, R. 
Preclinical toxicity study of intrathecal administration of the  
pain relievers dextrorphan, dextromethorphan, and memantine  
in the sheep model. Neuromodulation: J. Int. Soc., 1999, 2(4),  
230-240. 
[200] Paoletti, P. Molecular basis of NMDA receptor functional 
diversity. Eur. J. Neurosci., 2011, 33(8), 1351-1365. [http://dx.doi. 
org/10.1111/j.1460-9568.2011.07628.x] [PMID: 21395862] 
[201] Santangelo, R.M.; Acker, T.M.; Zimmerman, S.S.; Katzman, B.M.; 
Strong, K.L.; Traynelis, S.F.; Liotta, D.C. Novel NMDA receptor 
modulators: an update. Expert Opin. Ther. Pat., 2012, 22(11), 
1337-1352. [http://dx.doi.org/10.1517/13543776.2012.728587] [PMID: 
23009122] 
[202] Kim, Y.; Cho, H.Y.; Ahn, Y.J.; Kim, J.; Yoon, Y.W. Effect of 
NMDA NR2B antagonist on neuropathic pain in two spinal cord 
injury models. Pain, 2012, 153(5), 1022-1029. [http://dx.doi.org/ 
10.1016/j.pain.2012.02.003] [PMID: 22424878] 
[203] Pedersen, L.M.; Gjerstad, J. Spinal cord long-term potentiation is 
attenuated by the NMDA-2B receptor antagonist Ro 256981. Acta 
Physiol. (Oxf.), 2008, 192(3), 421-427. [http://dx.doi.org/10.1111/ 
j.1748-1716.2007.01756.x] [PMID: 17970830] 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    251 
[204] Malmberg, A.B.; Gilbert, H.; McCabe, R.T.; Basbaum, A.I. 
Powerful antinociceptive effects of the cone snail venom-derived 
subtype-selective NMDA receptor antagonists conantokins G and 
T. Pain, 2003, 101(1-2), 109-116. [http://dx.doi.org/10.1016/S0304-
3959(02)00303-2] [PMID: 12507705] 
[205] Kolhekar, R.; Meller, S.T.; Gebhart, G.F. N-methyl-D-aspartate 
receptor-mediated changes in thermal nociception: allosteric 
modulation at glycine and polyamine recognition sites. Neuro- 
science, 1994, 63(4), 925-936. [http://dx.doi.org/10.1016/0306-
4522(94)90560-6] [PMID: 7535397] 
[206] Wallace, M.S.; Lam, V.; Schettler, J. NGX426, an oral AMPA-
kainate antagonist, is effective in human capsaicin-induced pain 
and hyperalgesia. Pain Med., 2012, 13(12), 1601-1610. [http://dx. 
doi.org/10.1111/j.1526-4637.2012.01509.x] [PMID: 23110368] 
[207] Takano, Y.; Sato, E.; Kaneko, T.; Sato, I. Antihyperalgesic effects 
of intrathecally administered magnesium sulfate in rats. Pain, 2000, 
84(2-3), 175-179. [http://dx.doi.org/10.1016/S0304-3959(99)00207-
9] [PMID: 10666522] 
[208] Chanimov, M.; Cohen, M.L.; Grinspun, Y.; Herbert, M.; Reif, R.; 
Kaufman, I.; Bahar, M. Neurotoxicity after spinal anaesthesia 
induced by serial intrathecal injections of magnesium sulphate.  
An experimental study in a rat model. Anaesthesia, 1997, 52(3), 
223-228. [http://dx.doi.org/10.1111/j.1365-2044.1997.034-az0057.x] 
[PMID: 9124662] 
[209] Mebazaa, M.S.; Ouerghi, S.; Frikha, N.; Moncer, K.; Mestiri, T.; 
James, M.F.; Ben Ammar, M.S. Is magnesium sulfate by the 
intrathecal route efficient and safe? Ann. Fr. Anesth. Reanim., 
2011, 30(1), 47-50. [http://dx.doi.org/10.1016/j.annfar.2010.12.005] 
[PMID: 21236623] 
[210] Roberts, J.C.; Grocholski, B.M.; Kitto, K.F.; Fairbanks, C.A. 
Pharmacodynamic and pharmacokinetic studies of agmatine after 
spinal administration in the mouse. J. Pharmacol. Exp. Ther., 2005, 
314(3), 1226-1233. [http://dx.doi.org/10.1124/jpet.105.086173] [PMID: 
15933157] 
[211] Tong, C.K.; MacDermott, A.B. Both Ca2+-permeable and -
impermeable AMPA receptors contribute to primary synaptic drive 
onto rat dorsal horn neurons. (vol 575, pg 133, 2006). J. Physiol., 
2006, 575(2), 685-685. 
[212] Jin, H.C.; Keller, A.J.; Jung, J.K.; Subieta, A.; Brennan, T.J. 
Epidural tezampanel, an AMPA/kainate receptor antagonist, 
produces postoperative analgesia in rats. Anesth. Analg., 2007, 
105(4), 1152-1159. [http://dx.doi.org/10.1213/01.ane.0000281435. 
58012.e3] [PMID: 17898404] 
[213] Oshiro, M.; Hefferan, M.P.; Kakinohana, O.; Lukacova, N.; 
Sugahara, K.; Yaksh, T.L.; Marsala, M. Suppression of stretch 
reflex activity after spinal or systemic treatment with AMPA 
receptor antagonist NGX424 in rats with developed baclofen tolerance. 
Br. J. Pharmacol., 2010, 161(5), 976-985. [http://dx.doi.org/ 
10.1111/j.1476-5381.2010.00954.x] [PMID: 20977450] 
[214] Sang, C.N.; Hostetter, M.P.; Gracely, R.H.; Chappell, A.S.; 
Schoepp, D.D.; Lee, G.; Whitcup, S.; Caruso, R.; Max, M.B. AMPA/ 
kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia 
but not pain in normal skin in humans. Anesthesiology, 1998, 89(5), 
1060-1067. [http://dx.doi.org/10.1097/00000542-199811000-00005] 
[PMID: 9821993] 
[215] Sorkin, L.S.; Yaksh, T.L.; Doom, C.M. Mechanical allodynia in 
rats is blocked by a Ca2+ permeable AMPA receptor antagonist. 
Neuroreport, 1999, 10(17), 3523-3526. [http://dx.doi.org/10.1097/ 
00001756-199911260-00011] [PMID: 10619637] 
[216] Jones, T.L.; Sorkin, L.S. Calcium-permeable alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid/kainate receptors mediate 
development, but not maintenance, of secondary allodynia evoked by 
first-degree burn in the rat. J. Pharmacol. Exp. Ther., 2004, 310(1), 
223-229. [http://dx.doi.org/10.1124/jpet.103.064741] [PMID: 15007101] 
[217] Dirig, D.M.; Yaksh, T.L. Intrathecal baclofen and muscimol, but 
not midazolam, are antinociceptive using the rat-formalin model. J. 
Pharmacol. Exp. Ther., 1995, 275(1), 219-227. [PMID: 7562553] 
[218] Nadeson, R.; Guo, Z.; Porter, V.; Gent, J.P.; Goodchild, C.S. 
gamma-Aminobutyric acidA receptors and spinally mediated 
antinociception in rats. J. Pharmacol. Exp. Ther., 1996, 278(2), 
620-626. [PMID: 8768712] 
[219] Hwang, J.H.; Yaksh, T.L. The effect of spinal GABA receptor 
agonists on tactile allodynia in a surgically-induced neuropathic 
pain model in the rat. Pain, 1997, 70(1), 15-22. [http://dx.doi.org/ 
10.1016/S0304-3959(96)03249-6] [PMID: 9106805] 
[220] Malan, T.P.; Mata, H.P.; Porreca, F. Spinal GABA(A) and 
GABA(B) receptor pharmacology in a rat model of neuropathic 
pain. Anesthesiology, 2002, 96(5), 1161-1167. [http://dx.doi.org/ 
10.1097/00000542-200205000-00020] [PMID: 11981157] 
[221] Gwak, Y.S.; Tan, H.Y.; Nam, T.S.; Paik, K.S.; Hulsebosch, C.E.; 
Leem, J.W. Activation of spinal GABA receptors attenuates 
chronic central neuropathic pain after spinal cord injury. J. Neuro- 
trauma, 2006, 23(7), 1111-1124. [http://dx.doi.org/10.1089/neu. 
2006.23.1111] [PMID: 16866624] 
[222] Roberts, L.A.; Beyer, C.; Komisaruk, B.R. Nociceptive responses 
to altered GABAergic activity at the spinal cord. Life Sci., 1986, 
39(18), 1667-1674. [http://dx.doi.org/10.1016/0024-3205(86)90164-
5] [PMID: 3022091] 
[223] Di Lio, A.; Benke, D.; Besson, M.; Desmeules, J.; Daali, Y.; Wang, 
Z.J.; Edwankar, R.; Cook, J.M.; Zeilhofer, H.U. HZ166, a novel 
GABAA receptor subtype-selective benzodiazepine site ligand, is 
antihyperalgesic in mouse models of inflammatory and neuropathic 
pain. Neuropharmacology, 2011, 60(4), 626-632. [http://dx.doi.org/ 
10.1016/j.neuropharm.2010.11.026] [PMID: 21145329] 
[224] Reichl, S.; Augustin, M.; Zahn, P.K.; Pogatzki-Zahn, E.M. Peripheral 
and spinal GABAergic regulation of incisional pain in rats. Pain, 
2012, 153(1), 129-141. [http://dx.doi.org/10.1016/j.pain.2011.09.028] 
[PMID: 22054599] 
[225] Svensson, E.; Persson, J.; Fitzsimmons, B.; Yaksh, T.L. Intrathecal 
neurosteroids and a neurosteroid antagonist: effects on 
inflammation-evoked thermal hyperalgesia and tactile allodynia. 
Neurosci. Lett., 2013, 548, 27-32. [http://dx.doi.org/10.1016/ 
j.neulet.2013.05.027] [PMID: 23707652] 
[226] Juif, P.E.; Melchior, M.; Poisbeau, P. Characterization of the fast 
GABAergic inhibitory action of etifoxine during spinal nociceptive 
processing in male rats. Neuropharmacology, 2015, 91, 117-122. 
[http://dx.doi.org/10.1016/j.neuropharm.2014.12.022] [PMID: 
25545681] 
[227] Whitwam, J.G.; Niv, D.; Loh, L.; Jack, R.D. Depression of 
nociceptive reflexes by intrathecal benzodiazepine in dogs. Lancet, 
1982, 2(8313), 1465. [http://dx.doi.org/10.1016/S0140-6736(82) 
91368-X] [PMID: 6129540] 
[228] Serrao, J.M.; Marks, R.L.; Morley, S.J.; Goodchild, C.S. Intrathecal 
midazolam for the treatment of chronic mechanical low back pain: 
a controlled comparison with epidural steroid in a pilot study. Pain, 
1992, 48(1), 5-12. [http://dx.doi.org/10.1016/0304-3959(92)90125-
U] [PMID: 1531383] 
[229] Tucker, A.P.; Lai, C.; Nadeson, R.; Goodchild, C.S. Intrathecal 
midazolam I: a cohort study investigating safety. Anesth. Analg., 
2004, 98(6), 1512-1520. [http://dx.doi.org/10.1213/01.ANE.0000087075. 
14589.F5] [PMID: 15155299] 
[230] Tucker, A.P.; Mezzatesta, J.; Nadeson, R.; Goodchild, C.S. 
Intrathecal midazolam II: combination with intrathecal fentanyl  
for labor pain. Anesth. Analg., 2004, 98(6), 1521-1527. [table of 
contents.]. [http://dx.doi.org/10.1213/01.ANE.0000112434.68702.E4] 
[PMID: 15155300] 
[231] Ho, K.M.; Ismail, H. Use of intrathecal midazolam to improve 
perioperative analgesia: a meta-analysis. Anaesth. Intens. Care, 
2008, 36(3), 365-373. [PMID: 18564797] 
[232] Olsen, R.W.; Sieghart, W. International Union of Pharmacology. 
LXX. Subtypes of γ-aminobutyric acid(A) receptors: classification 
on the basis of subunit composition, pharmacology, and function. 
Update. Pharmacol. Rev., 2008, 60(3), 243-260. [http://dx.doi. 
org/10.1124/pr.108.00505] [PMID: 18790874] 
[233] Sieghart, W.; Ramerstorfer, J.; Sarto-Jackson, I.; Varagic, Z.; Ernst, 
M. A novel GABA(A) receptor pharmacology: drugs interacting 
with the α(+) β(-) interface. Br. J. Pharmacol., 2012, 166(2), 476-
485. [http://dx.doi.org/10.1111/j.1476-5381.2011.01779.x] [PMID: 
22074382] 
[234] Sigel, E.; Lüscher, B.P. A closer look at the high affinity 
benzodiazepine binding site on GABAA receptors. Curr. Top.  
Med. Chem., 2011, 11(2), 241-246. [http://dx.doi.org/10.2174/ 
156802611794863562] [PMID: 21189125] 
[235] Wang, M. Neurosteroids and GABA-A Receptor Function. Front. 
Endocrinol. (Lausanne), 2011, 2, 44. [http://dx.doi.org/10.3389/ 
fendo.2011.00044] [PMID: 22654809] 
[236] Carver, C.M.; Reddy, D.S. Neurosteroid interactions with synaptic 
and extrasynaptic GABA(A) receptors: regulation of subunit 
plasticity, phasic and tonic inhibition, and neuronal network 
252    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
excitability. Psychopharmacology (Berl.), 2013, 230(2), 151-188. 
[http://dx.doi.org/10.1007/s00213-013-3276-5] [PMID: 24071826] 
[237] Bohlhalter, S.; Weinmann, O.; Mohler, H.; Fritschy, J.M. Laminar 
compartmentalization of GABAA-receptor subtypes in the spinal 
cord: an immunohistochemical study. J. Neurosci., 1996, 16(1), 
283-297. [PMID: 8613794] 
[238] Enna, S.J.; McCarson, K.E. The role of GABA in the mediation 
and perception of pain. Adv. Pharmacol., 2006, 54, 1-27. [http:// 
dx.doi.org/10.1016/S1054-3589(06)54001-3] [PMID: 17175808] 
[239] Labrakakis, C.; Tong, C.K.; Weissman, T.; Torsney, C.; 
MacDermott, A.B. Localization and function of ATP and GABAA 
receptors expressed by nociceptors and other postnatal sensory 
neurons in rat. J. Physiol., 2003, 549(Pt 1), 131-142. [http://dx.doi. 
org/10.1113/jphysiol.2002.031963] [PMID: 12665615] 
[240] Witschi, R.; Punnakkal, P.; Paul, J.; Walczak, J.S.; Cervero, F.; 
Fritschy, J.M.; Kuner, R.; Keist, R.; Rudolph, U.; Zeilhofer, H.U. 
Presynaptic alpha2-GABAA receptors in primary afferent 
depolarization and spinal pain control. J. Neurosci., 2011, 31(22), 
8134-8142. [http://dx.doi.org/10.1523/JNEUROSCI.6328-10.2011] 
[PMID: 21632935] 
[241] Hevers, W.; Lüddens, H. The diversity of GABAA receptors. 
Pharmacological and electrophysiological properties of GABAA 
channel subtypes. Mol. Neurobiol., 1998, 18(1), 35-86. [http://dx. 
doi.org/10.1007/BF02741459] [PMID: 9824848] 
[242] Krall, J.; Balle, T.; Krogsgaard-Larsen, N.; Sørensen, T.E.; 
Krogsgaard-Larsen, P.; Kristiansen, U.; Frølund, B. GABAA 
receptor partial agonists and antagonists: structure, binding mode, 
and pharmacology. Adv. Pharmacol., 2015, 72, 201-227. [http:// 
dx.doi.org/10.1016/bs.apha.2014.10.003] [PMID: 25600372] 
[243] Yaksh, T.L.; Allen, J.W. The use of intrathecal midazolam in humans: a 
case study of process. Anesth. Analg., 2004, 98(6), 1536-1545. 
[http://dx.doi.org/10.1213/01.ANE.0000122638.41130.BF] [PMID: 
15155302] 
[244] Yaksh, T.L.; Allen, J.W. Preclinical insights into the implementation 
of intrathecal midazolam: a cautionary tale. Anesth. Analg., 2004, 
98(6), 1509-1511. [http://dx.doi.org/10.1213/01.ANE.0000121768. 
79904.7F] [PMID: 15155298] 
[245] Malinovsky, J.M.; Cozian, A.; Lepage, J.Y.; Mussini, J.M.; Pinaud, 
M.; Souron, R. Ketamine and midazolam neurotoxicity in the 
rabbit. Anesthesiology, 1991, 75(1), 91-97. [http://dx.doi.org/10. 
1097/00000542-199107000-00015] [PMID: 2064066] 
[246] Erdine, S.; Yücel, A.; Ozyalçin, S.; Ozyuvaci, E.; Talu, G.K.; 
Ahiskali, B.; Apak, H.; Savci, N. Neurotoxicity of midazolam in 
the rabbit. Pain, 1999, 80(1-2), 419-423. [http://dx.doi.org/10.1016/ 
S0304-3959(98)00240-1] [PMID: 10204757] 
[247] Abedini, M.; Parish, M.; Mahmoodpoor, A.; Vazifehshenas, H. 
Cauda equina syndrome as a result of inadvertent intrathecal 
injection of sodium thiopentone. Anaesth. Intens. Care, 2015, 
43(1), 131-132. [PMID: 25579301] 
[248] Wafford, K.A.; van Niel, M.B.; Ma, Q.P.; Horridge, E.; Herd, 
M.B.; Peden, D.R.; Belelli, D.; Lambert, J.J. Novel compounds 
selectively enhance delta subunit containing GABA A receptors 
and increase tonic currents in thalamus. Neuropharmacology, 2009, 
56(1), 182-189. [http://dx.doi.org/10.1016/j.neuropharm.2008.08. 
004] [PMID: 18762200] 
[249] Ferando, I.; Mody, I. Interneuronal GABAA receptors inside and 
outside of synapses. Curr. Opin. Neurobiol., 2014, 26, 57-63. 
[http://dx.doi.org/10.1016/j.conb.2013.12.001] [PMID: 24650505] 
[250] Petersen, J.G.; Bergmann, R.; Krogsgaard-Larsen, P.; Balle, T.; 
Frølund, B. Probing the orthosteric binding site of GABAA 
receptors with heterocyclic GABA carboxylic acid bioisosteres. 
Neurochem. Res., 2014, 39(6), 1005-1015. [http://dx.doi.org/10. 
1007/s11064-013-1226-6] [PMID: 24362592] 
[251] Aouad, M.; Petit-Demoulière, N.; Goumon, Y.; Poisbeau, P. 
Etifoxine stimulates allopregnanolone synthesis in the spinal cord 
to produce analgesia in experimental mononeuropathy. Eur. J. 
Pain, 2014, 18(2), 258-268. [http://dx.doi.org/10.1002/j.1532-
2149.2013.00367.x] [PMID: 23881562] 
[252] Hoestgaard-Jensen, K.; Dalby, N.O.; Krall, J.; Hammer, H.; 
Krogsgaard-Larsen, P.; Frølund, B.; Jensen, A.A. Probing α4βδ 
GABAA receptor heterogeneity: differential regional effects  
of a functionally selective α4β1δ/α4β3δ receptor agonist on  
tonic and phasic inhibition in rat brain. J. Neurosci., 2014, 34 
(49), 16256-16272. [http://dx.doi.org/10.1523/JNEUROSCI.1495-
14.2014] [PMID: 25471566] 
[253] Wilson, P.R.; Yaksh, T.L. Baclofen is antinociceptive in the spinal 
intrathecal space of animals. Eur. J. Pharmacol., 1978, 51(4), 323-
330. [http://dx.doi.org/10.1016/0014-2999(78)90423-5] [PMID: 
581376] 
[254] Mathur, S.N.; Chu, S.K.; McCormick, Z.; Chang Chien, G.C.; 
Marciniak, C.M. Long-term intrathecal baclofen: outcomes after 
more than 10 years of treatment. PM R, 2014, 6(6), 506-513.e1. 
[http://dx.doi.org/10.1016/j.pmrj.2013.12.005] [PMID: 24355547] 
[255] Guillaume, D.; Van Havenbergh, A.; Vloeberghs, M.; Vidal,  
J.; Roeste, G. A clinical study of intrathecal baclofen using a 
programmable pump for intractable spasticity. Arch. Phys. Med. 
Rehabil., 2005, 86(11), 2165-2171. [http://dx.doi.org/10.1016/j. 
apmr.2005.05.018] [PMID: 16271565] 
[256] Furr-Stimming, E.; Boyle, A.M.; Schiess, M.C. Spasticity and 
intrathecal baclofen. Semin. Neurol., 2014, 34(5), 591-596. [http:// 
dx.doi.org/10.1055/s-0034-1396012] [PMID: 25520030] 
[257] Patel, S.; Naeem, S.; Kesingland, A.; Froestl, W.; Capogna, M.; 
Urban, L.; Fox, A. The effects of GABA(B) agonists and 
gabapentin on mechanical hyperalgesia in models of neuropathic 
and inflammatory pain in the rat. Pain, 2001, 90(3), 217-226. [http:// 
dx.doi.org/10.1016/S0304-3959(00)00404-8] [PMID: 11207393] 
[258] Hama, A.; Sagen, J. Combinations of intrathecal gamma-amino-
butyrate receptor agonists and N-methyl-d-aspartate receptor 
antagonists in rats with neuropathic spinal cord injury pain. Eur. J. 
Pharmacol., 2012, 683(1-3), 101-108. [http://dx.doi.org/10.1016/ 
j.ejphar.2012.03.015] [PMID: 22449374] 
[259] Liu, P.; Guo, W.Y.; Zhao, X.N.; Bai, H.P.; Wang, Q.; Wang, X.L.; 
Zhang, Y.Z. Intrathecal baclofen, a GABAB receptor agonist, 
inhibits the expression of p-CREB and NR2B in the spinal dorsal 
horn in rats with diabetic neuropathic pain. Can. J. Physiol. 
Pharmacol., 2014, 92(8), 655-660. [http://dx.doi.org/10.1139/cjpp-
2013-0463] [PMID: 24988216] 
[260] van Rijn, M.A.; Munts, A.G.; Marinus, J.; Voormolen, J.H.; de 
Boer, K.S.; Teepe-Twiss, I.M.; van Dasselaar, N.T.; Delhaas, E.M.; 
van Hilten, J.J. Intrathecal baclofen for dystonia of complex regional 
pain syndrome. Pain, 2009, 143(1-2), 41-47. [http://dx.doi.org/10. 
1016/j.pain.2009.01.014] [PMID: 19232828] 
[261] Brown, D.C.; Agnello, K. Intrathecal substance P-saporin in the 
dog: efficacy in bone cancer pain. Anesthesiology, 2013, 119(5), 
1178-1185. [http://dx.doi.org/10.1097/ALN.0b013e3182a95188] 
[PMID: 24195949] 
[262] Kornau, H.C. GABA(B) receptors and synaptic modulation. Cell 
Tissue Res., 2006, 326(2), 517-533. [http://dx.doi.org/10.1007/ 
s00441-006-0264-7] [PMID: 16932937] 
[263] Yang, K.; Wang, D.; Li, Y.Q. Distribution and depression of the 
GABA(B) receptor in the spinal dorsal horn of adult rat. Brain Res. 
Bull., 2001, 55(4), 479-485. [http://dx.doi.org/10.1016/S0361-9230 
(01)00546-9] [PMID: 11543948] 
[264] Thomas, D.A.; Navarrete, I.M.; Graham, B.A.; McGowan, M.K.; 
Hammond, D.L. Antinociception produced by systemic R(+)-
baclofen hydrochloride is attenuated by CGP 35348 administered 
to the spinal cord or ventromedial medulla of rats. Brain Res., 
1996, 718(1-2), 129-137. [http://dx.doi.org/10.1016/0006-8993(96) 
00100-X] [PMID: 8773775] 
[265] Aran, S.; Hammond, D.L. Antagonism of baclofen-induced 
antinociception by intrathecal administration of phaclofen or 2-
hydroxy-saclofen, but not delta-aminovaleric acid in the rat. J. 
Pharmacol. Exp. Ther., 1991, 257(1), 360-368. [PMID: 1850472] 
[266] Sabbe, M.B.; Grafe, M.R.; Pfeifer, B.L.; Mirzai, T.H.; Yaksh, T.L. 
Toxicology of baclofen continuously infused into the spinal 
intrathecal space of the dog. Neurotoxicology, 1993, 14(4), 397-
410. [PMID: 8164885] 
[267] Deer, T.R.; Raso, L.J.; Coffey, R.J.; Allen, J.W. Intrathecal 
baclofen and catheter tip inflammatory mass lesions (granulomas): 
a reevaluation of case reports and imaging findings in light of 
experimental, clinicopathological, and radiological evidence. Pain 
Med., 2008, 9(4), 391-395. [http://dx.doi.org/10.1111/j.1526-4637. 
2008.00468.x] [PMID: 18489628] 
[268] Murphy, P.M.; Skouvaklis, D.E.; Amadeo, R.J.; Haberman, C.; 
Brazier, D.H.; Cousins, M.J. Intrathecal catheter granuloma associated 
with isolated baclofen infusion. Anesth. Analg., 2006, 102(3), 848-
852. [http://dx.doi.org/10.1213/01.ane.0000196523.06573.10] [PMID: 
16492839] 
[269] Enna, S.J.; Harstad, E.B.; McCarson, K.E. Regulation of 
neurokinin-1 receptor expression by GABA(B) receptor agonists. 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    253 
Life Sci., 1998, 62(17-18), 1525-1530. [http://dx.doi.org/10.1016/ 
S0024-3205(98)00101-5] [PMID: 9585130] 
[270] Brusberg, M.; Ravnefjord, A.; Martinsson, R.; Larsson, H.; 
Martinez, V.; Lindström, E. The GABA(B) receptor agonist, 
baclofen, and the positive allosteric modulator, CGP7930, inhibit 
visceral pain-related responses to colorectal distension in rats. 
Neuropharmacology, 2009, 56(2), 362-367. [http://dx.doi.org/ 
10.1016/j.neuropharm.2008.09.006] [PMID: 18824012] 
[271] Prado, W. A.; Goncalves, A. S. Antinociceptive effect of 
intrathecal neostigmine evaluated in rats by two different pain 
models. Braz. J. Med. Biol. Res., 1997, 30(10), 1225-1231. 
[272] Hwang, J.H.; Hwang, K.S.; Leem, J.K.; Park, P.H.; Han, S.M.; Lee, 
D.M. The antiallodynic effects of intrathecal cholinesterase 
inhibitors in a rat model of neuropathic pain. Anesthesiology, 1999, 
90(2), 492-499. [http://dx.doi.org/10.1097/00000542-199902000-
00025] [PMID: 9952157] 
[273] Hartvig, P.; Gillberg, P.G.; Gordh, T., Jr; Post, C. Cholinergic 
mechanisms in pain and analgesia. Trends Pharmacol. Sci., 
1989(Suppl.), 75-79. [PMID: 2694528] 
[274] Lavandhomme, P.; Pan, H.L.; Eisenach, J.C. Intrathecal 
neostigmine, but not sympathectomy, relieves mechanical allodynia 
in a rat model of neuropathic pain. Anesthesiology, 1998, 89(2), 493-
499. [http://dx.doi.org/10.1097/00000542-199808000-00027] [PMID: 
9710409] 
[275] Park, P.; Schachter, S.; Yaksh, T. Intrathecal huperzine A increases 
thermal escape latency and decreases flinching behavior in the 
formalin test in rats. Neurosci. Lett., 2010, 470(1), 6-9. [http:// 
dx.doi.org/10.1016/j.neulet.2009.12.033] [PMID: 20026382] 
[276] Bouaziz, H.; Tong, C.; Eisenach, J.C. Postoperative analgesia from 
intrathecal neostigmine in sheep. Anesth. Analg., 1995, 80(6), 1140-
1144. [PMID: 7762841] 
[277] Lauretti, G.R.; Hood, D.D.; Eisenach, J.C.; Pfeifer, B.L. A multi-
center study of intrathecal neostigmine for analgesia following 
vaginal hysterectomy. Anesthesiology, 1998, 89(4), 913-918. [http:// 
dx.doi.org/10.1097/00000542-199810000-00016] [PMID: 9778009] 
[278] Ho, K.M.; Ismail, H.; Lee, K.C.; Branch, R. Use of intrathecal 
neostigmine as an adjunct to other spinal medications in 
perioperative and peripartum analgesia: a meta-analysis. Anaesth. 
Intens. Care, 2005, 33(1), 41-53. [PMID: 15957690] 
[279] Habib, A.S.; Gan, T.J. Use of neostigmine in the management of 
acute postoperative pain and labour pain: a review. CNS Drugs, 2006, 
20(10), 821-839. [http://dx.doi.org/10.2165/00023210-200620100-
00004] [PMID: 16999453] 
[280] Naguib, M.; Yaksh, T.L. Characterization of muscarinic receptor 
subtypes that mediate antinociception in the rat spinal cord. Anesth. 
Analg., 1997, 85(4), 847-853. [http://dx.doi.org/10.1213/00000539-
199710000-00025] [PMID: 9322468] 
[281] Iwamoto, E.T.; Marion, L. Characterization of the antinociception 
produced by intrathecally administered muscarinic agonists in rats. J. 
Pharmacol. Exp. Ther., 1993, 266(1), 329-338. [PMID: 8101218] 
[282] Yamamura, H.I.; Wamsley, J.K.; Deshmukh, P.; Roeske, W.R. 
Differential light microscopic autoradiographic localization of 
muscarinic cholinergic receptors in the brainstem and spinal cord 
of the rat using [3H]pirenzepine. Eur. J. Pharmacol., 1983, 91(1), 
147-149. [http://dx.doi.org/10.1016/0014-2999(83)90379-5] [PMID: 
6688587] 
[283] Bonner, T.I. New subtypes of muscarinic acetylcholine receptors. 
Trends Pharmacol. Sci., 1989(Suppl.), 11-15. [PMID: 2694516] 
[284] Caulfield, M.P.; Birdsall, N.J. International Union of Phar- 
macology. XVII. Classification of muscarinic acetylcholine receptors. 
Pharmacol. Rev., 1998, 50(2), 279-290. [PMID: 9647869] 
[285] Halliwell, J.V. Physiological mechanisms of cholinergic action in 
the hippocampus. Prog. Brain Res., 1990, 84, 255-272. [http://dx. 
doi.org/10.1016/S0079-6123(08)60910-3] [PMID: 2176300] 
[286] Fisahn, A.; Yamada, M.; Duttaroy, A.; Gan, J.W.; Deng, C.X.; 
McBain, C.J.; Wess, J. Muscarinic induction of hippocampal 
gamma oscillations requires coupling of the M1 receptor to two 
mixed cation currents. Neuron, 2002, 33(4), 615-624. [http:// 
dx.doi.org/10.1016/S0896-6273(02)00587-1] [PMID: 11856534] 
[287] Brown, D.A. Muscarinic acetylcholine receptors (mAChRs) in the 
nervous system: some functions and mechanisms. J. Mol. 
Neurosci., 2010, 41(3), 340-346. [http://dx.doi.org/10.1007/s12031-
010-9377-2] [PMID: 20446119] 
[288] Cai, Y-Q.; Chen, S-R.; Han, H-D.; Sood, A.K.; Lopez-Berestein, 
G.; Pan, H-L. Role of M2, M3, and M4 muscarinic receptor 
subtypes in the spinal cholinergic control of nociception  
revealed using siRNA in rats. J. Neurochem., 2009, 111(4), 1000-
1010. [http://dx.doi.org/10.1111/j.1471-4159.2009.06396.x] [PMID: 
19780895] 
[289] Chen, S.R.; Chen, H.; Yuan, W.X.; Wess, J.; Pan, H.L. Differential 
regulation of primary afferent input to spinal cord by muscarinic 
receptor subtypes delineated using knockout mice. J. Biol. Chem., 
2014, 289(20), 14321-14330. [http://dx.doi.org/10.1074/jbc.M114. 
550384] [PMID: 24695732] 
[290] Zhang, H.M.; Zhou, H.Y.; Chen, S.R.; Gautam, D.; Wess, J.; Pan, 
H.L. Control of glycinergic input to spinal dorsal horn neurons by 
distinct muscarinic receptor subtypes revealed using knockout mice. 
J. Pharmacol. Exp. Ther., 2007, 323(3), 963-971. [http://dx.doi. 
org/10.1124/jpet.107.127795] [PMID: 17878406] 
[291] Baba, H.; Kohno, T.; Okamoto, M.; Goldstein, P.A.; Shimoji, K.; 
Yoshimura, M. Muscarinic facilitation of GABA release in 
substantia gelatinosa of the rat spinal dorsal horn. J. Physiol., 1998, 
508(Pt 1), 83-93. [http://dx.doi.org/10.1111/j.1469-7793.1998.083br. 
x] [PMID: 9490821] 
[292] Yaksh, T.L.; Grafe, M.R.; Malkmus, S.; Rathbun, M.L.; Eisenach, 
J.C. Studies on the safety of chronically administered intrathecal 
neostigmine methylsulfate in rats and dogs. Anesthesiology, 1995, 
82(2), 412-427. [http://dx.doi.org/10.1097/00000542-199502000-
00012] [PMID: 7856900] 
[293] Greig, N.H.; Reale, M.; Tata, A.M. New pharmacological 
approaches to the cholinergic system: an overview on muscarinic 
receptor ligands and cholinesterase inhibitors. Recent Patents CNS 
Drug Discov., 2013, 8(2), 123-141. [http://dx.doi.org/10.2174/ 
1574889811308020003] [PMID: 23597304] 
[294] Sosnowski, M.; Stevens, C.W.; Yaksh, T.L. Assessment of the role 
of A1/A2 adenosine receptors mediating the purine antinociception, 
motor and autonomic function in the rat spinal cord. J. Pharmacol. 
Exp. Ther., 1989, 250(3), 915-922. [PMID: 2778719] 
[295] Lee, Y.W.; Yaksh, T.L. Pharmacology of the spinal adenosine 
receptor which mediates the antiallodynic action of intrathecal 
adenosine agonists. J. Pharmacol. Exp. Ther., 1996, 277(3), 1642-
1648. [PMID: 8667233] 
[296] Cui, J.G.; Sollevi, A.; Linderoth, B.; Meyerson, B.A. Adenosine 
receptor activation suppresses tactile hypersensitivity and potentiates 
spinal cord stimulation in mononeuropathic rats. Neurosci. Lett., 
1997, 223(3), 173-176. [http://dx.doi.org/10.1016/S0304-3940(97) 
13435-8] [PMID: 9080460] 
[297] Yamaguchi, D.; Terayama, R.; Omura, S.; Tsuchiya, H.; Sato, T.; 
Ichikawa, H.; Sugimoto, T. Effect of adenosine A1 receptor agonist 
on the enhanced excitability of spinal dorsal horn neurons after 
peripheral nerve injury. Int. J. Neurosci., 2014, 124(3), 213-222. [http:// 
dx.doi.org/10.3109/00207454.2013.842566] [PMID: 24016034] 
[298] Katz, N.K.; Ryals, J.M.; Wright, D.E. Central or peripheral delivery 
of an adenosine A1 receptor agonist improves mechanical allodynia 
in a mouse model of painful diabetic neuropathy. Neuroscience, 
2015, 285, 312-323. [http://dx.doi.org/10.1016/j.neuroscience.2014. 
10.065] [PMID: 25451280] 
[299] Zahn, P.K.; Straub, H.; Wenk, M.; Pogatzki-Zahn, E.M. Adenosine 
A1 but not A2a receptor agonist reduces hyperalgesia caused by a 
surgical incision in rats: a pertussis toxin-sensitive G protein-
dependent process. Anesthesiology, 2007, 107(5), 797-806. [http:// 
dx.doi.org/10.1097/01.anes.0000286982.36342.3f] [PMID: 18073555] 
[300] Rane, K.; Karlsten, R.; Sollevi, A.; Gordh, T., Jr; Svensson, B.A. 
Spinal cord morphology after chronic intrathecal administration of 
adenosine in the rat. Acta Anaesthesiol. Scand., 1999, 43(10), 
1035-1040. [http://dx.doi.org/10.1034/j.1399-6576.1999.431011.x] 
[PMID: 10593467] 
[301] Eisenach, J.C.; Curry, R.; Hood, D.D. Dose response of intrathecal 
adenosine in experimental pain and allodynia. Anesthesiology, 
2002, 97(4), 938-942. [http://dx.doi.org/10.1097/00000542-200210000-
00028] [PMID: 12357162] 
[302] Belfrage, M.; Segerdahl, M.; Arnér, S.; Sollevi, A. The safety and 
efficacy of intrathecal adenosine in patients with chronic 
neuropathic pain. Anesth. Analg., 1999, 89(1), 136-142. [PMID: 
10389791] 
[303] Eisenach, J.C.; Rauck, R.L.; Curry, R. Intrathecal, but not 
intravenous adenosine reduces allodynia in patients with neuropathic 
pain. Pain, 2003, 105(1-2), 65-70. [http://dx.doi.org/10.1016/S0304-
3959(03)00158-1] [PMID: 14499421] 
254    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
[304] Sharma, M.; Mohta, M.; Chawla, R. Efficacy of intrathecal 
adenosine for postoperative pain relief. Eur. J. Anaesthesiol.,  
2006, 23(6), 449-453. [http://dx.doi.org/10.1017/S0265021506000342] 
[PMID: 16507193] 
[305] Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; 
Linden, J. International Union of Pharmacology. XXV. Nomenclature 
and classification of adenosine receptors. Pharmacol. Rev., 2001, 
53(4), 527-552. [PMID: 11734617] 
[306] Choca, J.I.; Green, R.D.; Proudfit, H.K. Adenosine A1 and A2 
receptors of the substantia gelatinosa are located predominantly on 
intrinsic neurons: an autoradiography study. J. Pharmacol. Exp. 
Ther., 1988, 247(2), 757-764. [PMID: 3183969] 
[307] Sawynok, J.; Liu, X.J. Adenosine in the spinal cord and periphery: 
release and regulation of pain. Prog. Neurobiol., 2003, 69(5),  
313-340. [http://dx.doi.org/10.1016/S0301-0082(03)00050-9] [PMID: 
12787573] 
[308] Schulte, G.; Robertson, B.; Fredholm, B.B.; DeLander, G.E.; 
Shortland, P.; Molander, C. Distribution of antinociceptive adenosine 
A1 receptors in the spinal cord dorsal horn, and relationship to 
primary afferents and neuronal subpopulations. Neuroscience, 
2003, 121(4), 907-916. [http://dx.doi.org/10.1016/S0306-4522(03) 
00480-9] [PMID: 14580941] 
[309] Sawynok, J. Adenosine receptor activation and nociception. Eur. J. 
Pharmacol., 1998, 347(1), 1-11. [http://dx.doi.org/10.1016/S0014-
2999(97)01605-1] [PMID: 9650842] 
[310] Li, J.; Perl, E.R. Adenosine inhibition of synaptic transmission in 
the substantia gelatinosa. J. Neurophysiol., 1994, 72(4), 1611-1621. 
[PMID: 7823090] 
[311] Sosnowski, M.; Yaksh, T.L. The role of spinal and brainstem 
adenosine receptors in the modulation of the volume-evoked 
micturition reflex in the unanesthetized rat. Brain Res., 1990, 515 
(1-2), 207-213. [http://dx.doi.org/10.1016/0006-8993(90)90597-5] 
[PMID: 2357559] 
[312] Kitta, T.; Chancellor, M.B.; de Groat, W.C.; Kuno, S.; Nonomura, 
K.; Yoshimura, N. Suppression of bladder overactivity by adenosine 
A2A receptor antagonist in a rat model of Parkinson disease. J. 
Urol., 2012, 187(5), 1890-1897. [http://dx.doi.org/10.1016/j.juro. 
2011.12.062] [PMID: 22425056] 
[313] Martin, T.J.; Eisenach, J.C.; Misler, J.; Childers, S.R. Chronic 
activation of spinal adenosine A1 receptors results in hypersensitivity. 
Neuroreport, 2006, 17(15), 1619-1622. [http://dx.doi.org/10.1097/ 
01.wnr.0000239949.37825.e9] [PMID: 17001280] 
[314] Chiari, A.; Yaksh, T.L.; Myers, R.R.; Provencher, J.; Moore, L.; 
Lee, C.S.; Eisenach, J.C. Preclinical toxicity screening of 
intrathecal adenosine in rats and dogs. Anesthesiology, 1999, 91(3), 
824-832. [http://dx.doi.org/10.1097/00000542-199909000-00035] 
[PMID: 10485794] 
[315] Karlsten, R.; Gordh, T., Jr; Svensson, B.A. A neurotoxicologic 
evaluation of the spinal cord after chronic intrathecal injection of 
R-phenylisopropyl adenosine (R-PIA) in the rat. Anesth. Analg., 
1993, 77(4), 731-736. [http://dx.doi.org/10.1213/00000539-199310000-
00013] [PMID: 8214657] 
[316] Loram, L.C.; Harrison, J.A.; Sloane, E.M.; Hutchinson, M.R.; 
Sholar, P.; Taylor, F.R.; Berkelhammer, D.; Coats, B.D.; Poole, S.; 
Milligan, E.D.; Maier, S.F.; Rieger, J.; Watkins, L.R. Enduring 
reversal of neuropathic pain by a single intrathecal injection of 
adenosine 2A receptor agonists: a novel therapy for neuropathic 
pain. J. Neurosci., 2009, 29(44), 14015-14025. [http://dx.doi.org/ 
10.1523/JNEUROSCI.3447-09.2009] [PMID: 19890011] 
[317] Dai, S.S.; Zhou, Y.G. Adenosine 2A receptor: a crucial neuro- 
modulator with bidirectional effect in neuroinflammation and brain 
injury. Rev. Neurosci., 2011, 22(2), 231-239. [http://dx.doi.org/ 
10.1515/rns.2011.020] [PMID: 21476942] 
[318] Yaksh, T.L.; Dirig, D.M.; Conway, C.M.; Svensson, C.; Luo, Z.D.; 
Isakson, P.C. The acute antihyperalgesic action of nonsteroidal, 
anti-inflammatory drugs and release of spinal prostaglandin E2 is 
mediated by the inhibition of constitutive spinal cyclooxygenase-2 
(COX-2) but not COX-1. J. Neurosci., 2001, 21(16), 5847-5853. 
[PMID: 11487607] 
[319] Malmberg, A.B.; Yaksh, T.L. Cyclooxygenase inhibition and the 
spinal release of prostaglandin E2 and amino acids evoked by paw 
formalin injection: a microdialysis study in unanesthetized rats. J. 
Neurosci., 1995, 15(4), 2768-2776. [PMID: 7722627] 
[320] Yang, L.C.; Marsala, M.; Yaksh, T.L. Characterization of time 
course of spinal amino acids, citrulline and PGE2 release after 
carrageenan/kaolin-induced knee joint inflammation: a chronic 
microdialysis study. Pain, 1996, 67(2-3), 345-354. [http://dx.doi. 
org/10.1016/0304-3959(96)03106-5] [PMID: 8951928] 
[321] Lau, Y.M.; Wong, S.C.; Tsang, S.W.; Lau, W.K.; Lu, A.P.; Zhang, 
H. Cellular sources of cyclooxygenase-1 and -2 up-regulation in the 
spinal dorsal horn after spinal nerve ligation. Neuropathol. Appl. 
Neurobiol., 2014, 40(4), 452-463. [http://dx.doi.org/10.1111/nan. 
12078] [PMID: 23899306] 
[322] Meves, H. The action of prostaglandins on ion channels. Curr. 
Neuropharmacol., 2006, 4(1), 41-57. [http://dx.doi.org/10.2174/ 
157015906775203048] [PMID: 18615137] 
[323] Harvey, R.J.; Depner, U.B.; Wässle, H.; Ahmadi, S.; Heindl, C.; 
Reinold, H.; Smart, T.G.; Harvey, K.; Schütz, B.; Abo-Salem, 
O.M.; Zimmer, A.; Poisbeau, P.; Welzl, H.; Wolfer, D.P.; Betz, H.; 
Zeilhofer, H.U.; Müller, U.; Gly, R. GlyR alpha3: an essential 
target for spinal PGE2-mediated inflammatory pain sensitization. 
Science, 2004, 304(5672), 884-887. [http://dx.doi.org/10.1126/ 
science.1094925] [PMID: 15131310] 
[324] Parris, W. C.; Janicki, P. K.; Johnson, B., Jr; Horn, J. L. Intrathecal 
ketorolac tromethamine produces analgesia after chronic constriction 
injury of sciatic nerve in rat. Can. J. Anaesth., 1996, 43(8), 867-
870. 
[325] Lee, I.O.; Seo, Y. The effects of intrathecal cyclooxygenase-1, 
cyclooxygenase-2, or nonselective inhibitors on pain behavior and 
spinal Fos-like immunoreactivity. Anesth. Analg., 2008, 106(3), 
972-977. [http://dx.doi.org/10.1213/ane.0b013e318163f602] [PMID: 
18292448] 
[326] Malmberg, A.B.; Yaksh, T.L. Antinociceptive actions of spinal 
nonsteroidal anti-inflammatory agents on the formalin test in the rat. 
J. Pharmacol. Exp. Ther., 1992, 263(1), 136-146. [PMID: 1403779] 
[327] Zhu, X.; Conklin, D.R.; Eisenach, J.C. Preoperative inhibition of 
cyclooxygenase-1 in the spinal cord reduces postoperative pain. 
Anesth. Analg., 2005, 100(5), 1390-1393. [http://dx.doi.org/10. 
1213/01.ANE.0000148127.53832.8E] [PMID: 15845692] 
[328] Yaksh, T. L.; Horais, K. A.; Tozier, N.; Rathbun, M.; Richter, P.; 
Rossi, S.; Grafe, M.; Tong, C.; Meschter, C.; Cline, J. M.; 
Eisenach, J. Intrathecal ketorolac in dogs and rats. Toxicol. Sci., 
2004, 80(2), 322-334. 
[329] Korkmaz, H.A.; Maltepe, F.; Erbayraktar, S.; Yilmaz, O.; Güray, 
M.; Canda, M.S.; Günerli, A.; Gökmen, N. Antinociceptive and 
neurotoxicologic screening of chronic intrathecal administration  
of ketorolac tromethamine in the rat. Anesth. Analg., 2004, 98(1), 
148-152. [http://dx.doi.org/10.1213/01.ANE.0000093226.75543.90] 
[PMID: 14693610] 
[330] Eisenach, J.C.; Curry, R.; Hood, D.D.; Yaksh, T.L. Phase I safety 
assessment of intrathecal ketorolac. Pain, 2002, 99(3), 599-604. 
[http://dx.doi.org/10.1016/S0304-3959(02)00208-7] [PMID: 12406536] 
[331] Eisenach, J.C.; Curry, R.; Tong, C.; Houle, T.T.; Yaksh, T.L. 
Effects of intrathecal ketorolac on human experimental pain. 
Anesthesiology, 2010, 112(5), 1216-1224. [http://dx.doi.org/10. 
1097/ALN.0b013e3181d94d8b] [PMID: 20395821] 
[332] Lauretti, G.R.; Righeti, C.C.; Mattos, A.L. Intrathecal ketorolac 
enhances intrathecal morphine analgesia following total knee 
arthroplasty. J. Anaesthesiol. Clin. Pharmacol., 2013, 29(4), 503-508. 
[http://dx.doi.org/10.4103/0970-9185.119155] [PMID: 24249988] 
[333] Eisenach, J.C.; Curry, R.; Rauck, R.; Pan, P.; Yaksh, T.L. Role of 
spinal cyclooxygenase in human postoperative and chronic pain. 
Anesthesiology, 2010, 112(5), 1225-1233. [http://dx.doi.org/10. 
1097/ALN.0b013e3181d94dc0] [PMID: 20395820] 
[334] Wang, L.; Bauer, M.; Curry, R.; Larsson, A.; Sessler, D.I.; 
Eisenach, J.C. Intrathecal ketorolac does not improve acute or 
chronic pain after hip arthroplasty: a randomized controlled trial. J. 
Anesth., 2014, 28(5), 790-793. [http://dx.doi.org/10.1007/s00540-
014-1798-6] [PMID: 24535482] 
[335] Ferraguti, F.; Shigemoto, R. Metabotropic glutamate receptors. Cell 
Tissue Res., 2006, 326(2), 483-504. [http://dx.doi.org/10.1007/ 
s00441-006-0266-5] [PMID: 16847639] 
[336] Ritter, S.L.; Hall, R.A. Fine-tuning of GPCR activity by receptor-
interacting proteins. Nat. Rev. Mol. Cell Biol., 2009, 10(12), 819-
830. [http://dx.doi.org/10.1038/nrm2803] [PMID: 19935667] 
[337] Osikowicz, M.; Mika, J.; Przewlocka, B. The glutamatergic system 
as a target for neuropathic pain relief. Exp. Physiol., 2013, 98(2), 
372-384. [http://dx.doi.org/10.1113/expphysiol.2012.069922] [PMID: 
23002244] 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    255 
[338] Boye, L.D.; Ingemann, K.G.; Panchalingam, V.; Laursen, J.C.; 
Nørgaard, P.J.; Skallerup, A.M.; Kandiah, A.; Gazerani, P. 
Investigating the expression of metabotropic glutamate receptors in 
trigeminal ganglion neurons and satellite glial cells: implications 
for craniofacial pain. J. Recept. Signal Transduct. Res., 2014, 
34(4), 261-269. [http://dx.doi.org/10.3109/10799893.2014.885049] 
[PMID: 24495291] 
[339] Shigemoto, R.; Kinoshita, A.; Wada, E.; Nomura, S.; Ohishi, H.; 
Takada, M.; Flor, P.J.; Neki, A.; Abe, T.; Nakanishi, S.; Mizuno, 
N. Differential presynaptic localization of metabotropic glutamate 
receptor subtypes in the rat hippocampus. J. Neurosci., 1997, 
17(19), 7503-7522. [PMID: 9295396] 
[340] Palazzo, E.; Marabese, I.; de Novellis, V.; Rossi, F.; Maione, S. 
Supraspinal metabotropic glutamate receptors: a target for pain 
relief and beyond. Eur. J. Neurosci., 2014, 39(3), 444-454. 
[http://dx.doi.org/10.1111/ejn.12398] [PMID: 24494684] 
[341] Mills, C.D.; Johnson, K.M.; Hulsebosch, C.E. Group I meta- 
botropic glutamate receptors in spinal cord injury: roles in neuro- 
protection and the development of chronic central pain. J. 
Neurotrauma, 2002, 19(1), 23-42. [http://dx.doi.org/10.1089/ 
089771502753460213] [PMID: 11852976] 
[342] Mills, C.D.; Johnson, K.M.; Hulsebosch, C.E. Role of group II and 
group III metabotropic glutamate receptors in spinal cord injury. 
Exp. Neurol., 2002, 173(1), 153-167. [http://dx.doi.org/10.1006/ 
exnr.2001.7828] [PMID: 11771948] 
[343] Osikowicz, M.; Mika, J.; Makuch, W.; Przewlocka, B. Glutamate 
receptor ligands attenuate allodynia and hyperalgesia and potentiate 
morphine effects in a mouse model of neuropathic pain. Pain, 
2008, 139(1), 117-126. [http://dx.doi.org/10.1016/j.pain.2008.03. 
017] [PMID: 18442882] 
[344] Fisher, K.; Coderre, T.J. Comparison of nociceptive effects 
produced by intrathecal administration of mGluR agonists. Neuro- 
report, 1996, 7(15-17), 2743-2747. [http://dx.doi.org/10.1097/ 
00001756-199611040-00067] [PMID: 8981459] 
[345] Fisher, K.; Coderre, T.J. The contribution of metabotropic 
glutamate receptors (mGluRs) to formalin-induced nociception. 
Pain, 1996, 68(2-3), 255-263. [http://dx.doi.org/10.1016/S0304-
3959(96)03212-5] [PMID: 9121812] 
[346] Zeilhofer, H.U. Loss of glycinergic and GABAergic inhibition in 
chronic paincontributions of inflammation and microglia. Int. 
Immunopharmacol., 2008, 8(2), 182-187. [http://dx.doi.org/10. 
1016/j.intimp.2007.07.009] [PMID: 18182224] 
[347] Goudet, C.; Chapuy, E.; Alloui, A.; Acher, F.; Pin, J.P.; Eschalier, 
A. Group III metabotropic glutamate receptors inhibit hyperalgesia 
in animal models of inflammation and neuropathic pain. Pain, 
2008, 137(1), 112-124. [http://dx.doi.org/10.1016/j.pain.2007.08. 
020] [PMID: 17900808] 
[348] Ren, B.X.; Gu, X.P.; Zheng, Y.G.; Liu, C.L.; Wang, D.; Sun, Y.E.; 
Ma, Z.L. Intrathecal injection of metabotropic glutamate receptor 
subtype 3 and 5 agonist/antagonist attenuates bone cancer pain by 
inhibition of spinal astrocyte activation in a mouse model. 
Anesthesiology, 2012, 116(1), 122-132. [http://dx.doi.org/10.1097/ 
ALN.0b013e31823de68d] [PMID: 22123524] 
[349] Acher, F.; Goudet, C. Therapeutic potential of group III 
metabotropic glutamate receptor ligands in pain. Curr. Opin. 
Pharmacol., 2015, 20, 64-72. [http://dx.doi.org/10.1016/j.coph. 
2014.11.007] [PMID: 25498980] 
[350] Montana, M.C.; Gereau, R.W. Metabotropic glutamate receptors as 
targets for analgesia: antagonism, activation, and allosteric modulation. 
Curr. Pharm. Biotechnol., 2011, 12(10), 1681-1688. [http://dx. 
doi.org/10.2174/138920111798357438] [PMID: 21466446] 
[351] Saito, O.; Svensson, C.I.; Buczynski, M.W.; Wegner, K.; Hua, 
X.Y.; Codeluppi, S.; Schaloske, R.H.; Deems, R.A.; Dennis, E.A.; 
Yaksh, T.L. Spinal glial TLR4-mediated nociception and 
production of prostaglandin E(2) and TNF. Br. J. Pharmacol., 
2010, 160(7), 1754-1764. [http://dx.doi.org/10.1111/j.1476-5381. 
2010.00811.x] [PMID: 20649577] 
[352] Liu, T.; Gao, Y.J.; Ji, R.R. Emerging role of Toll-like receptors in 
the control of pain and itch. Neurosci. Bull., 2012, 28(2), 131-144. 
[http://dx.doi.org/10.1007/s12264-012-1219-5] [PMID: 22466124] 
[353] Watkins, L.R.; Hutchinson, M.R.; Rice, K.C.; Maier, S.F. The toll 
of opioid-induced glial activation: improving the clinical efficacy 
of opioids by targeting glia. Trends Pharmacol. Sci., 2009, 30(11), 
581-591. [http://dx.doi.org/10.1016/j.tips.2009.08.002] [PMID: 
19762094] 
[354] Jacobsen, J.H.; Watkins, L.R.; Hutchinson, M.R. Discovery of a 
novel site of opioid action at the innate immune pattern-recognition 
receptor TLR4 and its role in addiction. Int. Rev. Neurobiol.,  
2014, 118, 129-163. [http://dx.doi.org/10.1016/B978-0-12-801284-
0.00006-3] [PMID: 25175864] 
[355] Connolly, D.J.; ONeill, L.A. New developments in Toll-like 
receptor targeted therapeutics. Curr. Opin. Pharmacol., 2012, 
12(4), 510-518. [http://dx.doi.org/10.1016/j.coph.2012.06.002] [PMID: 
22748800] 
[356] Lucas, K.; Maes, M. Role of the Toll Like receptor (TLR) radical 
cycle in chronic inflammation: possible treatments targeting the 
TLR4 pathway. Mol. Neurobiol., 2013, 48(1), 190-204. [http:// 
dx.doi.org/10.1007/s12035-013-8425-7] [PMID: 23436141] 
[357] Wang, X.; Smith, C.; Yin, H. Targeting Toll-like receptors with 
small molecule agents. Chem. Soc. Rev., 2013, 42(12), 4859-4866. 
[http://dx.doi.org/10.1039/c3cs60039d] [PMID: 23503527] 
[358] Vasileiou, I.; Fotopoulou, G.; Matzourani, M.; Patsouris, E.; 
Theocharis, S. Evidence for the involvement of cannabinoid 
receptors polymorphisms in the pathophysiology of human diseases. 
Expert Opin. Ther. Targets, 2013, 17(4), 363-377. [http://dx.doi. 
org/10.1517/14728222.2013.754426] [PMID: 23293857] 
[359] Anand, P.; Whiteside, G.; Fowler, C.J.; Hohmann, A.G. Targeting 
CB2 receptors and the endocannabinoid system for the treatment of 
pain. Brain Res. Brain Res. Rev., 2009, 60(1), 255-266. [http://dx. 
doi.org/10.1016/j.brainresrev.2008.12.003] [PMID: 19150370] 
[360] Starowicz, K.; Przewlocka, B. Modulation of neuropathic-pain-
related behaviour by the spinal endocannabinoid/endovanilloid 
system. Philos. Trans. Royal Soc. Lond., 2012, 367(1607), 3286-
3299. 
[361] Cui, J.H.; Kim, W.M.; Lee, H.G.; Kim, Y.O.; Kim, C.M.; Yoon, 
M.H. Antinociceptive effect of intrathecal cannabinoid receptor 
agonist WIN 55,2122 in a rat bone tumor pain model. Neurosci. 
Lett., 2011, 493(3), 67-71. [http://dx.doi.org/10.1016/j.neulet.2010. 
12.052] [PMID: 21195743] 
[362] Cui, J.H.; Ju, J.; Yoon, M.H. Pharmacology of cannabinoid receptor 
agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain. 
Pharmacology, 2013, 92(3-4), 150-157. [http://dx.doi.org/10.1159/ 
000354296] [PMID: 24008428] 
[363] Wilkerson, J.L.; Gentry, K.R.; Dengler, E.C.; Wallace, J.A.; 
Kerwin, A.A.; Kuhn, M.N.; Zvonok, A.M.; Thakur, G.A.; 
Makriyannis, A.; Milligan, E.D. Immunofluorescent spectral 
analysis reveals the intrathecal cannabinoid agonist, AM1241, 
produces spinal anti-inflammatory cytokine responses in neuro- 
pathic rats exhibiting relief from allodynia. Brain Behav., 2012, 
2(2), 155-177. [http://dx.doi.org/10.1002/brb3.44] [PMID: 22574283] 
[364] Burnstock, G. Physiology and pathophysiology of purinergic 
neurotransmission. Physiol. Rev., 2007, 87(2), 659-797. [http://dx. 
doi.org/10.1152/physrev.00043.2006] [PMID: 17429044] 
[365] Abbracchio, M.P.; Burnstock, G.; Verkhratsky, A.; Zimmermann, 
H. Purinergic signalling in the nervous system: an overview. 
Trends Neurosci., 2009, 32(1), 19-29. [http://dx.doi.org/10.1016/ 
j.tins.2008.10.001] [PMID: 19008000] 
[366] Kobayashi, K.; Yamanaka, H.; Noguchi, K. Expression of ATP 
receptors in the rat dorsal root ganglion and spinal cord. Anat. Sci. 
Int., 2013, 88(1), 10-16. [http://dx.doi.org/10.1007/s12565-012-
0163-9] [PMID: 23179910] 
[367] Bianco, F.; Fumagalli, M.; Pravettoni, E.; DAmbrosi, N.;  
Volonte, C.; Matteoli, M.; Abbracchio, M.P.; Verderio, C. Patho- 
physiological roles of extracellular nucleotides in glial cells: 
differential expression of purinergic receptors in resting and 
activated microglia. Brain Res. Brain Res. Rev., 2005, 48(2), 144-
156. [http://dx.doi.org/10.1016/j.brainresrev.2004.12.004] [PMID: 
15850653] 
[368] Inoue, K.; Tsuda, M. The role of microglia and ATP receptors in a 
mechanism of neuropathic pain. Nihon yakurigaku zasshi. Folia 
Pharmacologica Japonica, 2006, 127(1), 14-17. 
[369] Jarvis, M.F. The neural-glial purinergic receptor ensemble in 
chronic pain states. Trends Neurosci., 2010, 33(1), 48-57. 
[http://dx.doi.org/10.1016/j.tins.2009.10.003] [PMID: 19914722] 
[370] Clark, A.K.; Wodarski, R.; Guida, F.; Sasso, O.; Malcangio, M.; 
Cathepsin, S. Cathepsin S release from primary cultured microglia 
is regulated by the P2X7 receptor. Glia, 2010, 58(14), 1710-1726. 
[http://dx.doi.org/10.1002/glia.21042] [PMID: 20629190] 
[371] Donnelly-Roberts, D.; McGaraughty, S.; Shieh, C.C.; Honore, P.; 
Jarvis, M.F. Painful purinergic receptors. J. Pharmacol. Exp. Ther., 
256    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
2008, 324(2), 409-415. [http://dx.doi.org/10.1124/jpet.106.105890] 
[PMID: 18042830] 
[372] Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; 
Kohsaka, S.; Salter, M.W.; Inoue, K. P2X4 receptors induced in 
spinal microglia gate tactile allodynia after nerve injury. Nature, 
2003, 424(6950), 778-783. [http://dx.doi.org/10.1038/nature01786] 
[PMID: 12917686] 
[373] Chessell, I.P.; Hatcher, J.P.; Bountra, C.; Michel, A.D.; Hughes, 
J.P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W.L.; 
Grahames, C.B.; Casula, M.A.; Yiangou, Y.; Birch, R.; Anand, P.; 
Buell, G.N. Disruption of the P2X7 purinoceptor gene abolishes 
chronic inflammatory and neuropathic pain. Pain, 2005, 114(3), 
386-396. [http://dx.doi.org/10.1016/j.pain.2005.01.002] [PMID: 
15777864] 
[374] Kobayashi, K.; Yamanaka, H.; Yanamoto, F.; Okubo, M.; Noguchi, 
K. Multiple P2Y subtypes in spinal microglia are involved in neuro-
pathic pain after peripheral nerve injury. Glia, 2012, 60(10), 1529-
1539. [http://dx.doi.org/10.1002/glia.22373] [PMID: 22736439] 
[375] Tozaki-Saitoh, H.; Tsuda, M.; Miyata, H.; Ueda, K.; Kohsaka, S.; 
Inoue, K. P2Y12 receptors in spinal microglia are required for 
neuropathic pain after peripheral nerve injury. J. Neurosci., 2008, 
28(19), 4949-4956. [http://dx.doi.org/10.1523/JNEUROSCI.0323-
08.2008] [PMID: 18463248] 
[376] Trang, T.; Salter, M.W. P2X4 purinoceptor signaling in chronic 
pain. Purinergic Signal., 2012, 8(3), 621-628. [http://dx.doi.org/ 
10.1007/s11302-012-9306-7] [PMID: 22528681] 
[377] Sacerdote, P.; Franchi, S.; Moretti, S.; Castelli, M.; Procacci, P.; 
Magnaghi, V.; Panerai, A.E. Cytokine modulation is necessary for 
efficacious treatment of experimental neuropathic pain. J. Neuro- 
immune Pharmacol., 2013, 8(1), 202-211. [http://dx.doi.org/ 
10.1007/s11481-012-9428-2] [PMID: 23242694] 
[378] Opal, S.M.; DePalo, V.A. Anti-inflammatory cytokines. Chest, 
2000, 117(4), 1162-1172. [http://dx.doi.org/10.1378/chest.117.4. 
1162] [PMID: 10767254] 
[379] Tayal, V.; Kalra, B.S. Cytokines and anti-cytokines as 
therapeuticsan update. Eur. J. Pharmacol., 2008, 579(1-3), 1-12. 
[http://dx.doi.org/10.1016/j.ejphar.2007.10.049] [PMID: 18021769] 
[380] Milligan, E. D.; Penzkover, K. R.; Soderquist, R. G.; Mahoney, M. 
J. Spinal interleukin-10 therapy to treat peripheral neuropathic pain. 
Neuromodulation, 2012, 15(6), 520-526. 
[381] Yaksh, T.L.; Farb, D.H.; Leeman, S.E.; Jessell, T.M. Intrathecal 
capsaicin depletes substance P in the rat spinal cord and produces 
prolonged thermal analgesia. Science, 1979, 206(4417), 481-483. 
[http://dx.doi.org/10.1126/science.228392] [PMID: 228392] 
[382] Jhamandas, K.; Yaksh, T.L.; Harty, G.; Szolcsanyi, J.; Go, V.L. 
Action of intrathecal capsaicin and its structural analogues on  
the content and release of spinal substance P: selectivity of  
action and relationship to analgesia. Brain Res., 1984, 306(1-2), 
215-225. [http://dx.doi.org/10.1016/0006-8993(84)90371-8] [PMID: 
6205719] 
[383] Szolcsanyi, J. Capsaicin and sensory neurones: a historical perspective. 
Prog. Drug Res. Fortschritte der Arzneimittelforschung. Progres 
des recherches pharmaceutiques, 2014, 68, 1-37. 
[384] Brown, D.C.; Agnello, K.; Iadarola, M.J. Intrathecal resiniferatoxin 
in a dog model: efficacy in bone cancer pain. Pain, 2015, 156(6), 
1018-1024. [PMID: 25659068] 
[385] Binshtok, A.M.; Bean, B.P.; Woolf, C.J. Inhibition of nociceptors 
by TRPV1-mediated entry of impermeant sodium channel blockers. 
Nature, 2007, 449(7162), 607-610. [http://dx.doi.org/10.1038/ 
nature06191] [PMID: 17914397] 
[386] Latapy, C.; Beaulieu, J.M. β -Arrestins in the central nervous 
system. Prog. Mol. Biol. Transl. Sci., 2013, 118, 267-295. [http://dx. 
doi.org/10.1016/B978-0-12-394440-5.00011-5] [PMID: 23764058] 
[387] Wiley, R.G.; Lappi, D.A. Targeted toxins in pain. Adv. Drug Deliv. 
Rev., 2003, 55(8), 1043-1054. [http://dx.doi.org/10.1016/S0169-
409X(03)00102-9] [PMID: 12935943] 
[388] Todd, A.J. Anatomy of primary afferents and projection neurones 
in the rat spinal dorsal horn with particular emphasis on substance 
P and the neurokinin 1 receptor. Exp. Physiol., 2002, 87(2), 245-
249. [http://dx.doi.org/10.1113/eph8702351] [PMID: 11856970] 
[389] Khasabov, S.G.; Rogers, S.D.; Ghilardi, J.R.; Peters, C.M.; 
Mantyh, P.W.; Simone, D.A. Spinal neurons that possess the 
substance P receptor are required for the development of central 
sensitization. J. Neurosci., 2002, 22(20), 9086-9098. [PMID: 
12388616] 
[390] Wiese, A.J.; Rathbun, M.; Butt, M.T.; Malkmus, S.A.; Richter, 
P.J.; Osborn, K.G.; Xu, Q.; Veesart, S.L.; Steinauer, J.J.; Higgins, 
D.; Lappi, D.A.; Russell, B.; Yaksh, T.L. Intrathecal substance P-
saporin in the dog: distribution, safety, and spinal neurokinin-1 
receptor ablation. Anesthesiology, 2013, 119(5), 1163-1177. [http:// 
dx.doi.org/10.1097/ALN.0b013e3182a95164] [PMID: 24051388] 
[391] Pellett, S. Learning from the past: historical aspects of bacterial 
toxins as pharmaceuticals. Curr. Opin. Microbiol., 2012, 15(3), 
292-299. [http://dx.doi.org/10.1016/j.mib.2012.05.005] [PMID: 
22651975] 
[392] Kakegawa, W.; Yuzaki, M. A mechanism underlying AMPA 
receptor trafficking during cerebellar long-term potentiation. Proc. 
Natl. Acad. Sci. USA, 2005, 102(49), 17846-17851. [http://dx.doi. 
org/10.1073/pnas.0508910102] [PMID: 16303868] 
[393] Marinelli, S.; Luvisetto, S.; Cobianchi, S.; Makuch, W.; Obara, I.; 
Mezzaroma, E.; Caruso, M.; Straface, E.; Przewlocka, B.; Pavone, 
F. Botulinum neurotoxin type A counteracts neuropathic pain and 
facilitates functional recovery after peripheral nerve injury in animal 
models. Neuroscience, 2010, 171(1), 316-328. [http://dx.doi.org/ 
10.1016/j.neuroscience.2010.08.067] [PMID: 20826198] 
[394] Huang, P.P.; Khan, I.; Suhail, M.S.; Malkmus, S.; Yaksh, T.L. 
Spinal botulinum neurotoxin B: effects on afferent transmitter 
release and nociceptive processing. PLoS One, 2011, 6(4),  
e19126. [http://dx.doi.org/10.1371/journal.pone.0019126] [PMID: 
21559464] 
[395] Lee, W.H.; Shin, T.J.; Kim, H.J.; Lee, J.K.; Suh, H.W.; Lee, S.C.; 
Seo, K. Intrathecal administration of botulinum neurotoxin type A 
attenuates formalin-induced nociceptive responses in mice. Anesth. 
Analg., 2011, 112(1), 228-235. [http://dx.doi.org/10.1213/ANE. 
0b013e3181ffa1d7] [PMID: 21081780] 
[396] Coelho, A.; Oliveira, R.; Rossetto, O.; Cruz, C.D.; Cruz, F.; 
Avelino, A. Intrathecal administration of botulinum toxin type A 
improves urinary bladder function and reduces pain in rats with 
cystitis. Eur. J. Pain, 2014, 18(10), 1480-1489. [http://dx.doi.org/ 
10.1002/ejp.513] [PMID: 24756904] 
[397] Ramachandran, R.; Yaksh, T.L. Therapeutic use of botulinum toxin 
in migraine: mechanisms of action. Br. J. Pharmacol., 2014, 
171(18), 4177-4192. [http://dx.doi.org/10.1111/bph.12763] [PMID: 
24819339] 
[398] Matak, I.; Lacković, Z. Botulinum toxin A, brain and pain. Prog. 
Neurobiol., 2014, 119-120, 39-59. [http://dx.doi.org/10.1016/ 
j.pneurobio.2014.06.001] [PMID: 24915026] 
[399] Carroll, I.; Fischbein, N.; Barad, M.; Mackey, S. Human response 
to unintended intrathecal injection of botulinum toxin. Pain Med., 
2011, 12(7), 1094-1097. [http://dx.doi.org/10.1111/j.1526-4637. 
2011.01135.x] [PMID: 21627762] 
[400] Mustafa, G.; Anderson, E.M.; Bokrand-Donatelli, Y.; Neubert, 
J.K.; Caudle, R.M. Anti-nociceptive effect of a conjugate of 
substance P and light chain of botulinum neurotoxin type A. Pain, 
2013, 154(11), 2547-2553. [http://dx.doi.org/10.1016/j.pain.2013. 
07.041] [PMID: 23933181] 
[401] Röhl, T.; Kurreck, J. RNA interference in pain research. J. 
Neurochem., 2006, 99(2), 371-380. [http://dx.doi.org/10.1111/ 
j.1471-4159.2006.04082.x] [PMID: 17029593] 
[402] Dominguez, E.; Meunier, A.; Pohl, M. Gene-based approaches in 
the study of pathological pain. Methods Mol. Biol., 2010, 617, 297-308. 
[http://dx.doi.org/10.1007/978-1-60327-323-7_22] [PMID: 20336430] 
[403] Molet, J.; Pohl, M. Gene-based approaches in pain research and 
exploration of new therapeutic targets and strategies. Eur. J. 
Pharmacol., 2013, 716(1-3), 129-141. [http://dx.doi.org/10.1016/ 
j.ejphar.2013.01.073] [PMID: 23500201] 
[404] Kim, D.S.; Li, K.W.; Boroujerdi, A.; Peter Yu, Y.; Zhou, C.Y.; 
Deng, P.; Park, J.; Zhang, X.; Lee, J.; Corpe, M.; Sharp, K.; 
Steward, O.; Eroglu, C.; Barres, B.; Zaucke, F.; Xu, Z.C.; Luo, 
Z.D. Thrombospondin-4 contributes to spinal sensitization and 
neuropathic pain states. J. Neurosci., 2012, 32(26), 8977-8987. 
[http://dx.doi.org/10.1523/JNEUROSCI.6494-11.2012] [PMID: 
22745497] 
[405] Hua, X.Y.; Chen, P.; Polgar, E.; Nagy, I.; Marsala, M.; Phillips, E.; 
Wollaston, L.; Urban, L.; Yaksh, T.L.; Webb, M. Spinal neurokinin 
NK1 receptor down-regulation and antinociception: effects of 
spinal NK1 receptor antisense oligonucleotides and NK1 receptor 
occupancy. J. Neurochem., 1998, 70(2), 688-698. [http://dx.doi. 
org/10.1046/j.1471-4159.1998.70020688.x] [PMID: 9453563] 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    257 
[406] Alvarez, P.; Chen, X.; Bogen, O.; Green, P.G.; Levine, J.D. IB4(+) 
nociceptors mediate persistent muscle pain induced by GDNF. J. 
Neurophysiol., 2012, 108(9), 2545-2553. [http://dx.doi.org/10. 
1152/jn.00576.2012] [PMID: 22914655] 
[407] Tan, P.H.; Yang, L.C.; Shih, H.C.; Lan, K.C.; Cheng, J.T. Gene 
knockdown with intrathecal siRNA of NMDA receptor NR2B 
subunit reduces formalin-induced nociception in the rat. Gene 
Ther., 2005, 12(1), 59-66. [http://dx.doi.org/10.1038/sj.gt.3302376] 
[PMID: 15470478] 
[408] Fundytus, M.E.; Yashpal, K.; Chabot, J.G.; Osborne, M.G.; 
Lefebvre, C.D.; Dray, A.; Henry, J.L.; Coderre, T.J. Knockdown of 
spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates 
pain and restores opioid efficacy after nerve injury in rats. Br. J. 
Pharmacol., 2001, 132(1), 354-367. [http://dx.doi.org/10.1038/sj. 
bjp.0703810] [PMID: 11156596] 
[409] Fundytus, M.E.; Osborne, M.G.; Henry, J.L.; Coderre, T.J.; Dray, 
A. Antisense oligonucleotide knockdown of mGluR1 alleviates 
hyperalgesia and allodynia associated with chronic inflammation. 
Pharmacol. Biochem. Behav., 2002, 73(2), 401-410. [http://dx. 
doi.org/10.1016/S0091-3057(02)00831-6] [PMID: 12117595] 
[410] Chen, M.; Zhang, X.; Xu, H.; Ma, X.; Jiang, W.; Xu, T. Inhibitory 
effect of spinal mGlu(5) receptor antisense oligonucleotide on the 
up-regulated expression of spinal G protein associated with chronic 
morphine treatment. Eur. J. Pharmacol., 2014, 723, 253-258. 
[http://dx.doi.org/10.1016/j.ejphar.2013.11.024] [PMID: 24296320] 
[411] Barclay, J.; Patel, S.; Dorn, G.; Wotherspoon, G.; Moffatt, S.; 
Eunson, L.; Abdelal, S.; Natt, F.; Hall, J.; Winter, J.; Bevan, S.; 
Wishart, W.; Fox, A.; Ganju, P. Functional downregulation of 
P2X3 receptor subunit in rat sensory neurons reveals a significant 
role in chronic neuropathic and inflammatory pain. J. Neurosci., 
2002, 22(18), 8139-8147. [PMID: 12223568] 
[412] Dorn, G.; AbdelAl, S.; Natt, F.J.; Weiler, J.; Hall, J.; Meigel, I.; 
Mosbacher, J.; Wishart, W. Specific inhibition of the rat ligand-
gated ion channel P2X3 function via methoxyethoxy-modified 
phosphorothioated antisense oligonucleotides. Antisense Nucleic 
Acid Drug Dev., 2001, 11(3), 165-174. [http://dx.doi.org/10.1089/ 
108729001300338690] [PMID: 11446592] 
[413] Wu, Z.; Yang, Q.; Crook, R.J.; ONeil, R.G.; Walters, E.T. TRPV1 
channels make major contributions to behavioral hypersensitivity 
and spontaneous activity in nociceptors after spinal cord injury. 
Pain, 2013, 154(10), 2130-2141. [http://dx.doi.org/10.1016/j.pain. 
2013.06.040] [PMID: 23811042] 
[414] Alvarez, P.; Green, P.G.; Levine, J.D. Role for monocyte 
chemoattractant protein-1 in the induction of chronic muscle pain 
in the rat. Pain, 2014, 155(6), 1161-1167. [http://dx.doi.org/10. 
1016/j.pain.2014.03.004] [PMID: 24637038] 
[415] Yao, Y.X.; Jiang, Z.; Zhao, Z.Q. Knockdown of synaptic 
scaffolding protein Homer 1b/c attenuates secondary hyperalgesia 
induced by complete Freunds adjuvant in rats. Anesth. Analg., 
2011, 113(6), 1501-1508. [http://dx.doi.org/10.1213/ANE.0b013 
e31822c0b98] [PMID: 22003220] 
[416] Svensson, C.I.; Lucas, K.K.; Hua, X.Y.; Powell, H.C.; Dennis, 
E.A.; Yaksh, T.L. Spinal phospholipase A2 in inflammatory 
hyperalgesia: role of the small, secretory phospholipase A2. 
Neuroscience, 2005, 133(2), 543-553. [http://dx.doi.org/10.1016/j. 
neuroscience.2005.01.024] [PMID: 15885922] 
[417] Fitzsimmons, B.L.; Zattoni, M.; Svensson, C.I.; Steinauer, J.; Hua, 
X.Y.; Yaksh, T.L. Role of spinal p38alpha and beta MAPK in 
inflammatory hyperalgesia and spinal COX-2 expression. 
Neuroreport, 2010, 21(4), 313-317. [http://dx.doi.org/10.1097/ 
WNR.0b013e32833774bf] [PMID: 20134354] 
[418] Kim, D.H.; Fitzsimmons, B.; Hefferan, M.P.; Svensson, C.I.; 
Wancewicz, E.; Monia, B.P.; Hung, G.; Butler, M.; Marsala, M.; 
Hua, X.Y.; Yaksh, T.L. Inhibition of spinal cytosolic phospholipase 
A(2) expression by an antisense oligonucleotide attenuates tissue 
injury-induced hyperalgesia. Neuroscience, 2008, 154(3), 1077-
1087. [http://dx.doi.org/10.1016/j.neuroscience.2008.04.033] [PMID: 
18511207] 
[419] Lai, J.; Gold, M.S.; Kim, C.S.; Bian, D.; Ossipov, M.H.; Hunter, 
J.C.; Porreca, F. Inhibition of neuropathic pain by decreased 
expression of the tetrodotoxin-resistant sodium channel, NaV1.8. 
Pain, 2002, 95(1-2), 143-152. [http://dx.doi.org/10.1016/S0304-
3959(01)00391-8] [PMID: 11790477] 
[420] Parada, C.A.; Vivancos, G.G.; Tambeli, C.H.; Cunha, F.Q.; 
Ferreira, S.H. Activation of presynaptic NMDA receptors coupled 
to NaV1.8-resistant sodium channel C-fibers causes retrograde 
mechanical nociceptor sensitization. Proc. Natl. Acad. Sci. USA, 
2003, 100(5), 2923-2928. [http://dx.doi.org/10.1073/pnas.252777799] 
[PMID: 12589028] 
[421] Bourinet, E.; Alloui, A.; Monteil, A.; Barrère, C.; Couette, B.; 
Poirot, O.; Pages, A.; McRory, J.; Snutch, T.P.; Eschalier, A.; 
Nargeot, J. Silencing of the Cav3.2 T-type calcium channel gene  
in sensory neurons demonstrates its major role in nociception.  
EMBO J., 2005, 24(2), 315-324. [http://dx.doi.org/10.1038/sj.emboj. 
7600515] [PMID: 15616581] 
[422] Wen, X.J.; Li, Z.J.; Chen, Z.X.; Fang, Z.Y.; Yang, C.X.; Li, H.; 
Zeng, Y.M. Intrathecal administration of Cav3.2 and Cav3.3 
antisense oligonucleotide reverses tactile allodynia and thermal 
hyperalgesia in rats following chronic compression of dorsal root of 
ganglion. Acta Pharmacol. Sin., 2006, 27(12), 1547-1552. [http:// 
dx.doi.org/10.1111/j.1745-7254.2006.00461.x] [PMID: 17112407] 
[423] Mamet, J.; Klukinov, M.; Yaksh, T.L.; Malkmus, S.A.; Williams, 
S.; Harris, S.; Manning, D.C.; Taylor, B.K.; Donahue, R.R.; 
Porreca, F.; Xie, J.Y.; Oyarzo, J.; Brennan, T.J.; Subieta, A.; 
Schmidt, W.K.; Yeomans, D.C. Single intrathecal administration of 
the transcription factor decoy AYX1 prevents acute and chronic 
pain after incisional, inflammatory, or neuropathic injury. Pain, 
2014, 155(2), 322-333. [http://dx.doi.org/10.1016/j.pain.2013.10.015] 
[PMID: 24145208] 
[424] Storek, B.; Reinhardt, M.; Wang, C.; Janssen, W.G.; Harder, N.M.; 
Banck, M.S.; Morrison, J.H.; Beutler, A.S. Sensory neuron 
targeting by self-complementary AAV8 via lumbar puncture for 
chronic pain. Proc. Natl. Acad. Sci. USA, 2008, 105(3), 1055-1060. 
[http://dx.doi.org/10.1073/pnas.0708003105] [PMID: 18215993] 
[425] Tzabazis, A.Z.; Klukinov, M.; Feliciano, D.P.; Wilson, S.P.; 
Yeomans, D.C. Gene therapy for trigeminal pain in mice. Gene 
Ther., 2014, 21(4), 422-426. [http://dx.doi.org/10.1038/gt.2014.14] 
[PMID: 24572785] 
[426] Wu, F.; Xu, X.; Miao, X.; Chen, J.; Sun, Y.; Yu, W. Effect of 
recombinant adenovirus coding for endomorphin-2 on neuropathic 
pain in rats. Int. J. Clin. Exp. Pathol., 2012, 5(9), 914-923. [PMID: 
23119108] 
[427] Goss, J.R.; Mata, M.; Goins, W.F.; Wu, H.H.; Glorioso, J.C.; Fink, 
D.J. Antinociceptive effect of a genomic herpes simplex virus-
based vector expressing human proenkephalin in rat dorsal root 
ganglion. Gene Ther., 2001, 8(7), 551-556. [http://dx.doi.org/ 
10.1038/sj.gt.3301430] [PMID: 11319622] 
[428] Wu, C.M.; Lin, M.W.; Cheng, J.T.; Wang, Y.M.; Huang, Y.W.; 
Sun, W.Z.; Lin, C.R. Regulated, electroporation-mediated delivery 
of pro-opiomelanocortin gene suppresses chronic constriction 
injury-induced neuropathic pain in rats. Gene Ther., 2004, 11(11), 933-
940. [http://dx.doi.org/10.1038/sj.gt.3302244] [PMID: 15116065] 
[429] Milligan, E.D.; Sloane, E.M.; Langer, S.J.; Cruz, P.E.; Chacur, M.; 
Spataro, L.; Wieseler-Frank, J.; Hammack, S.E.; Maier, S.F.; 
Flotte, T.R.; Forsayeth, J.R.; Leinwand, L.A.; Chavez, R.; Watkins, 
L.R. Controlling neuropathic pain by adeno-associated virus driven 
production of the anti-inflammatory cytokine, interleukin-10. Mol. 
Pain, 2005, 1, 9. [http://dx.doi.org/10.1186/1744-8069-1-9] [PMID: 
15813997] 
[430] Soderquist, R.G.; Sloane, E.M.; Loram, L.C.; Harrison, J.A.; 
Dengler, E.C.; Johnson, S.M.; Amer, L.D.; Young, C.S.; Lewis, 
M.T.; Poole, S.; Frank, M.G.; Watkins, L.R.; Milligan, E.D.; 
Mahoney, M.J. Release of plasmid DNA-encoding IL-10 from 
PLGA microparticles facilitates long-term reversal of neuropathic 
pain following a single intrathecal administration. Pharm. Res., 
2010, 27(5), 841-854. [http://dx.doi.org/10.1007/s11095-010-0077-
y] [PMID: 20224990] 
[431] Pleticha, J.; Malkmus, S.A.; Heilmann, L.F.; Veesart, S.L.; Rezek, 
R.; Xu, Q.; Yaksh, T.L.; Beutler, A.S. High cerebrospinal fluid 
levels of interleukin-10 attained by AAV in dogs. Gene Ther., 
2015, 22(2), 202-208. [http://dx.doi.org/10.1038/gt.2014.96] [PMID: 
25354684] 
[432] Ndong, C.; Landry, R.P.; DeLeo, J.A.; Romero-Sandoval, E.A. 
Mitogen activated protein kinase phosphatase-1 prevents the 
development of tactile sensitivity in a rodent model of neuropathic 
pain. Mol. Pain, 2012, 8, 34. [http://dx.doi.org/10.1186/1744-8069-
8-34] [PMID: 22540262] 
[433] Fischer, G.; Pan, B.; Vilceanu, D.; Hogan, Q.H.; Yu, H. Sustained 
relief of neuropathic pain by AAV-targeted expression of CBD3 
258    Current Neuropharmacology, 2017, Vol. 15, No. 2 Yaksh et al. 
peptide in rat dorsal root ganglion. Gene Ther., 2014, 21(1), 44-51. 
[http://dx.doi.org/10.1038/gt.2013.56] [PMID: 24152582] 
[434] Fan, L.; Guan, X.; Wang, W.; Zhao, J.Y.; Zhang, H.; Tiwari, V.; 
Hoffman, P.N.; Li, M.; Tao, Y.X. Impaired neuropathic pain and 
preserved acute pain in rats overexpressing voltage-gated 
potassium channel subunit Kv1.2 in primary afferent neurons. Mol. 
Pain, 2014, 10(1), 8. [http://dx.doi.org/10.1186/1744-8069-10-8] 
[PMID: 24472174] 
[435] Chattopadhyay, M.; Zhou, Z.; Hao, S.; Mata, M.; Fink, D.J. 
Reduction of voltage gated sodium channel protein in DRG by 
vector mediated miRNA reduces pain in rats with painful diabetic 
neuropathy. Mol. Pain, 2012, 8, 17. [http://dx.doi.org/10.1186/ 
1744-8069-8-17] [PMID: 22439790] 
[436] Xu, Q.; Chou, B.; Fitzsimmons, B.; Miyanohara, A.; Shubayev,  
V.; Santucci, C.; Hefferan, M.; Marsala, M.; Hua, X.Y. In vivo 
gene knockdown in rat dorsal root ganglia mediated by self-
complementary adeno-associated virus serotype 5 following intra- 
thecal delivery. PLoS One, 2012, 7(3), e32581. [http://dx.doi.org/ 
10.1371/journal.pone.0032581] [PMID: 22403675] 
[437] Beutler, A.S.; Banck, M.S.; Walsh, C.E.; Milligan, E.D. Intrathecal 
gene transfer by adeno-associated virus for pain. Curr. Opin. Mol. 
Ther., 2005, 7(5), 431-439. [PMID: 16248278] 
[438] Hutchings, M.; Weller, R.O. Anatomical relationships of the pia 
mater to cerebral blood vessels in man. J. Neurosurg., 1986, 65(3), 
316-325. [http://dx.doi.org/10.3171/jns.1986.65.3.0316] [PMID: 
3734882] 
[439] Cloyd, M.W.; Low, F.N. Scanning electron microscopy of the 
subarachnoid space in the dog. I. Spinal cord levels. J. Comp. 
Neurol., 1974, 153(4), 325-368. [http://dx.doi.org/10.1002/cne. 
901530402] [PMID: 4816519] 
[440] Filippidis, A. S.; Zarogiannis, S. G.; Ioannou, M.; Gourgoulianis, K.; 
Molyvdas, P. A.; Hatzoglou, C. Permeability of the arachnoid and pia 
mater. Child's Nervous System, 2012, 28(4), 533-540. 
[441] Vulchanova, L.; Schuster, D.J.; Belur, L.R.; Riedl, M.S.; Podetz-
Pedersen, K.M.; Kitto, K.F.; Wilcox, G.L.; McIvor, R.S.; 
Fairbanks, C.A. Differential adeno-associated virus mediated gene 
transfer to sensory neurons following intrathecal delivery by direct 
lumbar puncture. Mol. Pain, 2010, 6, 31. [http://dx.doi.org/10. 
1186/1744-8069-6-31] [PMID: 20509925] 
[442] Wall, P.D.; Shortland, P. Long-range afferents in the rat spinal 
cord. 1. Numbers, distances and conduction velocities. Philos. 
Trans. R. Soc. Lond. B Biol. Sci., 1991, 334(1269), 85-93. [http:// 
dx.doi.org/10.1098/rstb.1991.0098] [PMID: 1684674] 
[443] Shortland, P.; Wall, P.D. Long-range afferents in the rat spinal 
cord. II. Arborizations that penetrate grey matter. Philos. Trans. R. 
Soc. Lond. B Biol. Sci., 1992, 337(1282), 445-455. [http://dx.doi. 
org/10.1098/rstb.1992.0120] [PMID: 1279734] 
[444] Hylden, J.L.; Wilcox, G.L. Intrathecal opioids block a spinal action 
of substance P in mice: functional importance of both mu- and 
delta-receptors. Eur. J. Pharmacol., 1982, 86(1), 95-98. [http://dx. 
doi.org/10.1016/0014-2999(82)90403-4] [PMID: 6186500] 
[445] Yaksh, T.L. Analgetic actions of intrathecal opiates in cat and 
primate. Brain Res., 1978, 153(1), 205-210. [http://dx.doi.org/ 
10.1016/0006-8993(78)91146-0] [PMID: 98219] 
[446] Yaksh, T.L.; Noueihed, R.Y.; Durant, P.A. Studies of the 
pharmacology and pathology of intrathecally administered 4-
anilinopiperidine analogues and morphine in the rat and cat. 
Anesthesiology, 1986, 64(1), 54-66. [http://dx.doi.org/10.1097/ 
00000542-198601000-00009] [PMID: 2867722] 
[447] Sabbe, M.B.; Grafe, M.R.; Mjanger, E.; Tiseo, P.J.; Hill, H.F.; 
Yaksh, T.L. Spinal delivery of sufentanil, alfentanil, and morphine in 
dogs. Physiologic and toxicologic investigations. Anesthesiology, 
1994, 81(4), 899-920. [http://dx.doi.org/10.1097/00000542-199410000-
00017] [PMID: 7943841] 
[448] Nordberg, G.; Hedner, T.; Mellstrand, T.; Dahlström, B. 
Pharmacokinetic aspects of intrathecal morphine analgesia. 
Anesthesiology, 1984, 60(5), 448-454. [http://dx.doi.org/10.1097/ 
00000542-198405000-00010] [PMID: 6546839] 
[449] Lipman, J.J.; Blumenkopf, B. Comparison of subjective and 
objective analgesic effects of intravenous and intrathecal morphine 
in chronic pain patients by heat beam dolorimetry. Pain, 1989, 
39(3), 249-256. [http://dx.doi.org/10.1016/0304-3959(89)90037-7] 
[PMID: 2616177] 
[450] Suzukawa, M.; Matsumoto, M.; Collins, J.G.; Kitahata, L.M.; 
Yuge, O. Dose-response suppression of noxiously evoked activity of 
WDR neurons by spinally administered fentanyl. Anesthesiology, 
1983, 58(6), 510-513. [http://dx.doi.org/10.1097/00000542-198306000-
00005] [PMID: 6859581] 
[451] Homma, E.; Collins, J.G.; Kitahata, L.M.; Matsumoto, M.; 
Kawahara, M. Suppression of noxiously evoked WDR dorsal horn 
neuronal activity by spinally administered morphine. Anesthesiology, 
1983, 58(3), 232-236. [http://dx.doi.org/10.1097/00000542-198303000-
00005] [PMID: 6829958] 
[452] Bujedo, B.M.; Santos, S.G.; Azpiazu, A.U. A review of epidural 
and intrathecal opioids used in the management of postoperative 
pain. J. Opioid Manag., 2012, 8(3), 177-192. [http://dx.doi.org/ 
10.5055/jom.2012.0114] [PMID: 22798178] 
[453] Syková, E.; Nicholson, C. Diffusion in brain extracellular space. 
Physiol. Rev., 2008, 88(4), 1277-1340. [http://dx.doi.org/10.1152/ 
physrev.00027.2007] [PMID: 18923183] 
[454] Wolak, D.J.; Thorne, R.G. Diffusion of macromolecules in the 
brain: implications for drug delivery. Mol. Pharm., 2013, 10(5), 1492-
1504. [http://dx.doi.org/10.1021/mp300495e] [PMID: 23298378] 
[455] Schroth, G.; Klose, U. Cerebrospinal fluid flow. I. Physiology of 
cardiac-related pulsation. Neuroradiology, 1992, 35(1), 1-9. 
[http://dx.doi.org/10.1007/BF00588270] [PMID: 1289731] 
[456] Schroth, G.; Klose, U. Cerebrospinal fluid flow. II. Physiology of 
respiration-related pulsations. Neuroradiology, 1992, 35(1), 10-15. 
[http://dx.doi.org/10.1007/BF00588271] [PMID: 1289732] 
[457] Bernards, C.M. Cerebrospinal fluid and spinal cord distribution of 
baclofen and bupivacaine during slow intrathecal infusion in pigs. 
Anesthesiology, 2006, 105(1), 169-178. [http://dx.doi.org/10.1097/ 
00000542-200607000-00027] [PMID: 16810009] 
[458] Flack, S.H.; Anderson, C.M.; Bernards, C. Morphine distribution in 
the spinal cord after chronic infusion in pigs. Anesth. Analg., 2011, 
112(2), 460-464. [http://dx.doi.org/10.1213/ANE.0b013e318203b7c0] 
[PMID: 21212256] 
[459] Flack, S.H.; Bernards, C.M. Cerebrospinal fluid and spinal cord 
distribution of hyperbaric bupivacaine and baclofen during  
slow intrathecal infusion in pigs. Anesthesiology, 2010, 112(1), 
165-173. [http://dx.doi.org/10.1097/ALN.0b013e3181c38da5] [PMID: 
19996952] 
[460] Wallace, M.; Yaksh, T.L. Characteristics of distribution  
of morphine and metabolites in cerebrospinal fluid and plasma  
with chronic intrathecal morphine infusion in humans. Anesth. 
Analg., 2012, 115(4), 797-804. [http://dx.doi.org/10.1213/ANE.0b013 
e3182645dfd] [PMID: 22822192] 
[461] Yaksh, T.L.; Hassenbusch, S.; Burchiel, K.; Hildebrand, K.R.; 
Page, L.M.; Coffey, R.J. Inflammatory masses associated with 
intrathecal drug infusion: a review of preclinical evidence and 
human data. Pain Med., 2002, 3(4), 300-312. [http://dx.doi.org/ 
10.1046/j.1526-4637.2002.02048.x] [PMID: 15099235] 
[462] Yaksh, T.L. Spinal Delivery and Assessment of Drug Safety. In: 
Fundamental Neuropathology for Pathologists and Toxicologists; 
Principles and Techniques, 2011; pp. 451-462. [http://dx.doi.org/ 
10.1002/9780470939956.ch27] 
[463] Bhatia, G.; Lau, M.E.; Koury, K.M.; Gulur, P. Intrathecal Drug 
Delivery (ITDD) systems for cancer pain. F1000 Res., 2013, 2, 96. 
[PMID: 24555051] 
[464] Deer, T.R.; Raso, L.J.; Garten, T.G. Inflammatory mass of an 
intrathecal catheter in patients receiving baclofen as a sole agent: a 
report of two cases and a review of the identification and treatment 
of the complication. Pain Med., 2007, 8(3), 259-262. [http://dx.doi. 
org/10.1111/j.1526-4637.2006.00150.x] [PMID: 17371413] 
[465] Grouls, R.J.; Korsten, E.H.; Yaksh, T.L. General considerations for 
the formulation of drugs for spinal delivery. In: Spinal Drug 
Delivery; Yaksh, T.L., Ed.; Elsevier Science B.V.: Amsterdam, 
1999; pp. 371-393. 
[466] Lagarce, F.; Benoit, J.P. Sustained release formulations for spinal 
drug delivery. J. Drug Deliv. Sci. Technol., 2004, 14(5), 331-343. 
[http://dx.doi.org/10.1016/S1773-2247(04)50061-8] 
[467] Yaksh, T.L.; Jang, J.D.; Nishiuchi, Y.; Braun, K.P.; Ro, S.G.; 
Goodman, M. The utility of 2-hydroxypropyl-beta-cyclodextrin as 
a vehicle for the intracerebral and intrathecal administration of 
drugs. Life Sci., 1991, 48(7), 623-633. [http://dx.doi.org/10.1016/ 
0024-3205(91)90537-L] [PMID: 1703620] 
[468] Jang, J.; Yaksh, T.L.; Hill, H.F. Use of 2-hydroxypropyl-beta-
cyclodextrin as an intrathecal drug vehicle with opioids. J. 
Pharmacol. Exp. Ther., 1992, 261(2), 592-600. [PMID: 1349642] 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    259 
[469] Meert, T.F.; Mesens, J.; Verheyen, P.; Noorduin, H. Hydroxypropyl-
beta-cyclodextrin can modulate the activity of spinally administered 
sufentanil. Eur. J. Anaesthesiol., 1992, 9(5), 399-409. [PMID: 
1396627] 
[470] Yaksh, T.L.; Malmberg, A.B.; Ro, S.; Schiller, P.; Goodman, M. 
Characterization of the spinal antinociceptive activity of 
constrained peptidomimetic opioids. J. Pharmacol. Exp. Ther., 
1995, 275(1), 63-72. [PMID: 7562596] 
[471] Lagarce, F.; Faisant, N.; Desfontis, J.C.; Marescaux, L.; Gautier, 
F.; Holopherne, D.; Rousselet, M.C.; Menei, P.; Benoit, J.P. 
Biopharmaceutics of intrathecal baclofen-loaded microparticles in a 
goat model. Int. J. Pharm., 2005, 298(1), 68-79. [http://dx.doi.org/ 
10.1016/j.ijpharm.2005.03.025] [PMID: 15919163] 
[472] Lagarce, F.; Faisant, N.; Desfontis, J. C.; Marescaux, L.; Gautier, 
F.; Richard, J.; Menei, P.; Benoit, J. P. Baclofen-loaded 
microspheres in gel suspensions for intrathecal drug delivery: in 
vitro and in vivo evaluation. Eur. J. Pharm. Biopharm., 2005, 
61(3), 171-180. 
[473] Hildebrand, K.R.; Elsberry, D.D.; Hassenbusch, S.J. Stability and 
compatibility of morphine-clonidine admixtures in an implantable 
infusion system. J. Pain Symptom Manage., 2003, 25(5), 464-471. 
[http://dx.doi.org/10.1016/S0885-3924(03)00041-1] [PMID: 12727045] 
[474] Classen, A.M.; Wimbish, G.H.; Kupiec, T.C. Stability of admixture 
containing morphine sulfate, bupivacaine hydrochloride, and 
clonidine hydrochloride in an implantable infusion system. J. Pain 
Symptom Manage., 2004, 28(6), 603-611. [http://dx.doi.org/ 
10.1016/j.jpainsymman.2004.04.011] [PMID: 15589086] 
[475] Ward, K. W.; Nagilla, R.; Jolivette, L. J. Comparative evaluation of 
oral systemic exposure of 56 xenobiotics in rat, dog, monkey and 
human. Xenobiotica, 2005, 35(2), 191-210. 
[476] Bergadano, A.; Andersen, O.K.; Arendt-Nielsen, L.; Spadavecchia, 
C. Noninvasive assessment of the facilitation of the nociceptive 
withdrawal reflex by repeated electrical stimulations in conscious 
dogs. Am. J. Vet. Res., 2007, 68(8), 899-907. [http://dx.doi.org/ 
10.2460/ajvr.68.8.899] [PMID: 17669031] 
[477] Wegner, K.; Horais, K.A.; Tozier, N.A.; Rathbun, M.L.; 
Shtaerman, Y.; Yaksh, T.L. Development of a canine nociceptive 
thermal escape model. J. Neurosci. Methods, 2008, 168(1), 88-97. 
[http://dx.doi.org/10.1016/j.jneumeth.2007.09.019] [PMID: 18054083] 
[478] Watabiki, T.; Nagakura, Y.; Wegner, K.; Kakimoto, S.; Tozier, 
N.A.; Malkmus, S.A.; Yaksh, T.L. Assessment of canine sensory 
function by using sine-wave electrical stimuli paradigm. Physiol. 
Behav., 2010, 101(3), 327-330. [http://dx.doi.org/10.1016/j. 
physbeh.2010.05.019] [PMID: 20570687] 
[479] Rohrbach, H.; Zeiter, S.; Andersen, O.K.; Wieling, R.; 
Spadavecchia, C. Quantitative assessment of the nociceptive 
withdrawal reflex in healthy, non-medicated experimental sheep. 
Physiol. Behav., 2014, 129, 181-185. [http://dx.doi.org/10.1016/ 
j.physbeh.2014.02.017] [PMID: 24561088] 
[480] Rohrbach, H.; Andersen, O.K.; Zeiter, S.; Wieling, R.; Spadavecchia, 
C. Repeated electrical stimulations as a tool to evoke temporal 
summation of nociceptive inputs in healthy, non-medicated 
experimental sheep. Physiol. Behav., 2015, 142, 85-89. [http://dx. 
doi.org/10.1016/j.physbeh.2015.02.008] [PMID: 25659734] 
[481] Piel, M.J.; Kroin, J.S.; van Wijnen, A.J.; Kc, R.; Im, H.J. Pain 
assessment in animal models of osteoarthritis. Gene, 2014, 537(2), 184-
188. [http://dx.doi.org/10.1016/j.gene.2013.11.091] [PMID: 24333346] 
[482] Brimmo, O.A.; Pfeiffer, F.; Bozynski, C.C.; Kuroki, K.; Cook, C.; 
Stoker, A.; Sherman, S.L.; Monibi, F.; Cook, J.L. Development of 
a Novel Canine Model for Posttraumatic Osteoarthritis of the Knee. 
J. Knee Surg., 2015. [http://dx.doi.org/10.1055/s-0035-1549026] 
[PMID: 25892003] 
[483] McCarty, D.J., Jr; Phelps, P.; Pyenson, J. Crystal-induced 
inflammation in canine joints. I. An experimental model with 
quantification of the host response. J. Exp. Med., 1966, 124(1), 99-
114. [http://dx.doi.org/10.1084/jem.124.1.99] [PMID: 4287616] 
[484] Lopez, M.J.; Kunz, D.; Vanderby, R., Jr; Heisey, D.; Bogdanske, 
J.; Markel, M.D. A comparison of joint stability between anterior 
cruciate intact and deficient knees: a new canine model of anterior 
cruciate ligament disruption. J. Orthop. Res., 2003, 21(2), 224-230. 
[http://dx.doi.org/10.1016/S0736-0266(02)00132-8] [PMID: 12568952] 
[485] Budsberg, S.C. Long-term temporal evaluation of ground reaction 
forces during development of experimentally induced osteoarthritis 
in dogs. Am. J. Vet. Res., 2001, 62(8), 1207-1211. [http://dx.doi. 
org/10.2460/ajvr.2001.62.1207] [PMID: 11497439] 
[486] Marshall, W.; Bockstahler, B.; Hulse, D.; Carmichael, S. A review of 
osteoarthritis and obesity: current understanding of the relationship 
and benefit of obesity treatment and prevention in the dog. Vet. 
Comp. Orthop. Traumatol., 2009, 22(5), 339-345. [PMID: 19750285] 
[487] Ru, G.; Terracini, B.; Glickman, L.T. Host related risk factors for 
canine osteosarcoma. Vet. J., 1998, 156(1), 31-39. [http://dx. 
doi.org/10.1016/S1090-0233(98)80059-2] [PMID: 9691849] 
[488] Brown, D.C.; Bell, M.; Rhodes, L. Power of treatment success 
definitions when the Canine Brief Pain Inventory is used to evaluate 
carprofen treatment for the control of pain and inflammation in 
dogs with osteoarthritis. Am. J. Vet. Res., 2013, 74(12), 1467-1473. 
[http://dx.doi.org/10.2460/ajvr.74.12.1467] [PMID: 24274882] 
[489] Lascelles, B.D.; Knazovicky, D.; Case, B.; Freire, M.; Innes, J.F.; 
Drew, A.C.; Gearing, D.P. A canine-specific anti-nerve growth 
factor antibody alleviates pain and improves mobility and function 
in dogs with degenerative joint disease-associated pain. BMC Vet. 
Res., 2015, 11(1), 101. [http://dx.doi.org/10.1186/s12917-015-
0413-x] [PMID: 25926287] 
[490] Hayashida, K. Substance P-saporin for bone cancer pain in dogs: 
can mans best friend solve the lost in translation problem in analgesic 
development? Anesthesiology, 2013, 119(5), 999-1000. [http://dx. 
doi.org/10.1097/ALN.0b013e3182a951a2] [PMID: 24195943] 
[491] Walker, S.M.; Yaksh, T.L. Neuraxial analgesia in neonates and 
infants: a review of clinical and preclinical strategies for the 
development of safety and efficacy data. Anesth. Analg., 2012, 
115(3), 638-662. [PMID: 22798528] 
[492] Butt, M.T. Evaluation of the Adult Nervous System in Preclinical 
Studies. In: Fundamental Neuropathology for Pathologists and 
Toxicologists: Principles and Techniques; Butt, B.B., Ed.; John 
Wiley & Sons, Inc.: Hoboken, NJ, USA, 2011; pp. 321-338. 
[http://dx.doi.org/10.1002/9780470939956.ch21] 
[493] Westin, B.D.; Walker, S.M.; Deumens, R.; Grafe, M.; Yaksh, T.L. 
Validation of a preclinical spinal safety model: effects of 
intrathecal morphine in the neonatal rat. Anesthesiology, 2010, 
113(1), 183-199. [http://dx.doi.org/10.1097/ALN.0b013e3181dcd6ec] 
[PMID: 20526189] 
[494] Yahalom, B.; Athiraman, U.; Soriano, S.G.; Zurakowski, D.; 
Carpino, E.A.; Corfas, G.; Berde, C.B. Spinal anesthesia in infant 
rats: development of a model and assessment of neurologic 
outcomes. Anesthesiology, 2011, 114(6), 1325-1335. [http://dx.doi. 
org/10.1097/ALN.0b013e31821b5729] [PMID: 21555934] 
[495] Walker, S.M.; Grafe, M.; Yaksh, T.L. Intrathecal clonidine in the 
neonatal rat: dose-dependent analgesia and evaluation of spinal 
apoptosis and toxicity. Anesth. Analg., 2012, 115(2), 450-460. [http:// 
dx.doi.org/10.1213/ANE.0b013e3182501a09] [PMID: 22467896] 
[496] Hamurtekin, E.; Fitzsimmons, B.L.; Shubayev, V.I.; Grafe, M.R.; 
Deumens, R.; Yaksh, T.L.; Walker, S.M. Evaluation of spinal 
toxicity and long-term spinal reflex function after intrathecal 
levobupivaciane in the neonatal rat. Anesthesiology, 2013, 119(1), 
142-155. [http://dx.doi.org/10.1097/ALN.0b013e31828fc7e7] [PMID: 
23514721] 
[497] Yaksh, T.L.; Rudy, T.A. Analgesia mediated by a direct spinal 
action of narcotics. Science, 1976, 192(4246), 1357-1358. [http:// 
dx.doi.org/10.1126/science.1273597] [PMID: 1273597] 
[498] Yaksh, T.L.; Rudy, T.A. Chronic catheterization of the spinal 
subarachnoid space. Physiol. Behav., 1976, 17(6), 1031-1036. [http:// 
dx.doi.org/10.1016/0031-9384(76)90029-9] [PMID: 14677603] 
 
